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Abstract 
Infectious diseases and cancers are the second and third largest causes of death 
worldwide.  UDP-N-acetyl-glucosamine (UNAG) enolpyruvyl transferase (MurA) 
and Cyclin-dependent kinases (CDKs) are proven as antibiotic and anticancer targets, 
respectively. 
MurA belongs to the enolpyruvyl transferase family of enzymes.  MurA catalyzes 
the first committed step in the biosynthesis of cell wall peptidoglycan, and is the 
target of fosfomycin, a naturally occurring broad-spectrum antibiotic.  Ever 
increasing resistance of bacteria to fosfomycin has placed an emphasis on the 
identification and characterization of novel MurA inhibitors. 
Knowledge of the detailed enzymatic mechanism is essential for the discovery of 
potent MurA inhibitors.  The studies on the mutant MurA enzymes Arg91Lys, 
Asp123Ala, Arg120Ala, and Cys115Asp, revealed key catalytic residues and residues 
important for the conformational changes in the enzymatic reaction.  Several new 
inhibitors of MurA were identified by High-Throughput Screening (HTS), and 
kinetically characterized.  It appears that most of these compounds bind to the open 
conformation of MurA, and thus the inhibitor binding site is largely solvent exposed.  
These results suggest that MurA inhibitors need to be designed to induce the open-
closed transformation of the enzyme, like the natural substrate UNAG.  Such 
inhibitors should be much more potent than the inhibitors discovered in this work. 
CDK2 plays a critical role in the G1- to S-phase checkpoint of the cell cycle.  
Only a few drugs targeting CDK2 are in clinical trials, thus there is a need for the 
discovery of novel CDK2 inhibitors.  
Six CDK2 inhibitor scaffolds were identified by HTS, and the molecular modes 
of action of four of them were thoroughly characterized by steady-state kinetics and 
crystallography.  Structure-Activity Relationship (SAR) analysis of the four scaffolds 
gave rise to the design of analogs with excellent potency.  In addition, computational 
studies were performed, and novel CDK2 inhibitor scaffolds were designed.  The 
selectivities and cytotoxic properties of these inhibitors are not known yet.   
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1. Introduction 
1.1. MurA (UDP-N-acetyl-glucosamine enolpyruvyl transferase)  
Since the antibiotic properties of penicillin were first discovered in 1929, many 
antibiotic agents have contributed to the prevention and treatment of infections 
caused by bacteria.  Despite the success of the antibiotics in the market and clinics, 
infections are still the second largest cause of death and remain as a major public 
health problem.  Antibiotic resistance is a serious public health threat and results in 
the return of untreatable infections on a massive scale.  Thus, there is a great need for 
novel antibiotic agents to solve resistance problems of current antibiotics1.  One of the 
best known targets for antibiotic therapy is the peptidoglycan biosynthetic pathway, 
validated in the clinic with fosfomycin, vancomycin, and penicillins. 
The peptidoglycan (murein) in a bacterial cell confers mechanical resistance to 
the higher internal osmotic pressure and provides the cell with structural strength. 
Peptidoglycan is also a structure unique to prokaryotic cells.  Thus drugs targeting the 
biosynthesis of peptidoglycan (i.e. the Mur pathway) would be effective antibiotic 
agents leading to cell death, without affecting the host2.   
Peptidoglycan consists of glycan chains comprised of alternating N-acetyl-
muramic acid and N-acetyl-glucosamine residues, and both residues are cross-linked 
by short peptides.  This cross-linkage joining glycan chains makes peptidoglycan 
structures rigid and tensile2.  The biosynthesis of peptidoglycan is a complex process, 
consisting of a three-step pathway3.  The first stage is the synthesis of the monomeric 
 19
 
 
Figure 1.  Three stages of peptidoglycan biosynthesis9. 
building block, UDP-N-acetyl-glucosamine and UDP-N-acetyl-muramyl pentapeptide 
in the cytoplasm by the enzymes MurA-F4.  The second stage occurs on the inner side 
of the membrane, with synthesis of a lipid-linked intermediate and its subsequent 
translocation to the external face of the cytoplasmic membrane by MraY5 and MurG6.  
Then, a polymerization reaction takes place in the periplasmic space catalyzed by 
transglycosylases7 and transpeptidases8, 9 (Figure 1).  
Mur enzymes are unique to bacteria and are involved in critical functions of 
almost all bacterial organisms10.  In addition, inhibitors of Mur enzymes have 
potential to be bactericidal, leading to cell lysis and bacterial cell death11.  
The first committed step in the pathway is the transfer of an enolpyruvyl group 
from phosphoenol pyruvate (PEP) to UNAG producing enolpyruvyl-UDP-N-acetyl-
glucosamine (EP-UNAG) with the release of inorganic phosphate (Pi).  This step is 
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Figure 2.  The reactions catalyzed by MurA and EPSPS 
catalyzed by UDP-N-acetyl-glucosamine enolpyruvate transferase (MurA, 
EC 2.5.1.7.) (Figure 2)3, 12.  While PEP is used as a phosphoryl transferring agent in 
most PEP-dependent enzymatic reactions, the reaction catalyzed by MurA is unique 
because it involves the attack at the chemically less reactive C-2 position of PEP, 
leading to the cleavage of the C–O bond rather than P–O bond.  MurA is inhibited by 
the naturally occurring antibiotic fosfomycin13, which is the active ingredient of the 
broad spectrum antibiotic Monurol®. 
The only other enzyme known to catalyze a similar reaction is 5-enolpyruvyl-
shikimate-3-phosphate synthase (EPSPS, EC 2.5.1.19) (Figure 2), which uses 
shikimate-3-phosphate (S3P) as its second substrate instead of UNAG.  EPSPS 
catalyzes the sixth step in the biosynthesis of the aromatic amino acids (the shikimate 
pathway) in bacteria, plants, and fungi, and has been extensively studied because it is 
the target of glyphosate14, the active ingredient of the herbicide Roundup®.   
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While Gram-negative bacteria including E. coli have one copy of the murA gene, 
several Gram-positive bacteria have two genes, murA1 and murA2.  Gene knockout 
experiments that removed either, but not both, of the murA genes showed that the 
organism was still viable, suggesting that the two genes encode active enzymes that 
can substitute for each other15.  It is also known that both MurA enzymes are 
inhibited by fosfomycin. 
1.1.1. Reaction Mechanism of MurA 
The unusual reaction catalyzed by MurA has been extensively studied.  
Mechanistic and structural data of MurA show that the reaction follows an ordered 
addition-elimination mechanism, with UNAG interacting with free enzyme prior to 
the binding of PEP or fosfomycin.  However, the detailed enzymatic mechanism of 
MurA has only been clearly identified recently16–20. 
The first step of the MurA reaction is thought to proceed by protonation of PEP 
producing an oxocarbonium ion and deprotonation of the 3'-OH on UNAG.  The oxy-
anion then attacks C-2 of the PEP-oxocarbonium ion, leading to a tetrahedral 
intermediate of both substrates (Figure 3-B).  The detailed mechanism of the 
formation of this tetrahedral intermediate is not certain.  Whether it is a concerted or a 
stepwise mechanism is currently under debate.  The elimination step of the reaction 
may proceed either by the aid of a residue in the MurA active site (Figure 3-C1) or by 
intramolecular-catalysis (Figure 3-C2), i.e. the deprotonation of C-3 of PEP can be 
performed by the phosphate moiety attached to C-2 of PEP or by a basic amino acid 
 22
UN
AG
Enz-X:
Enz-Y-H
A1
UN
AG
B
UN
AG
D
UN
AG
Enz-Z:
C1
UN
AG
C2
+
 
                                                                                                                                 
 
Figure 3.  Addition-elimination mechanism catalyzed by MurA.  
 A proton is added to phosphoenol pyruvate yielding a PEP oxocarbenium ion and the 
target hydroxyl group of UNAG is deprotonated (A1). It is followed by a 
nucleophilic attack of the oxyanion on the C2 atom of the PEP oxocarbenium ion 
leading to a covalent adduct of the two substrates, where the C2 atom of the PEP 
moiety is in a tetrahedral configuration (B). The elimination of phosphate may 
proceed through the action of an enzyme residue (C1) or through self-catalysis (C2). 
Either mechanism results in the formation of the vinyl ether product and Pi (D). 
in the MurA active site, leading to separation of the product, EP-UNAG, and 
releasing of inorganic phosphate (Pi).  
Some early biochemical studies of the enzymatic mechanism of MurA proposed 
the existence of a covalent adduct of PEP and Cys115 in the reaction17, 18.  Since this 
mechanism cannot explain the activity of Cys115Asp mutant MurA, it has been 
suggested that UNAG directly attacks PEP at the first step of the MurA reaction.     
While the existence of the hemi thio-ketal intermediate of Cys115 and PEP is still 
debated, another role of Cys115 in the reaction catalyzed by MurA has been 
identified.  Studies with the Cys115Ser mutant enzyme indicated that the function of 
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Figure 4.  A stereoview of EP-UNAG bound to Cys115Ser MurA20.  The reaction products, 
EP-UNAG and Pi, are shown in green color. The active site residues are in grey. The 
violet colored residues represent polar/charged residues. Water and glycerol 
molecules are shown in transparent cyan color. Dashed lines represent polar or ionic 
interactions. 
Cys115 is to support product release.  Kinetic analysis of Cys115Ser mutant MurA 
showed a single turnover of the reaction.  Structural study in the presence of the 
substrates depicts the product state of the enzyme with EP-UNAG and Pi (Figure 4)20.   
The stereochemical course of the reaction has been studied as well.  Initial studies 
with PEP analogs had led to the conclusion that the addition of UNAG to C-2 of PEP 
proceeds from the 2-si face and with the anti addition and the syn elimination 
steps19, 21, 22.  However, a structural study with Asp305Ala MurA mutant clearly 
demonstrated that the addition step occurs to the 2-re face of PEP suggesting syn 
addition and anti elimination stereochemistry (Figure 5)23.  From the crystal structure 
of Asp305Ala MurA with the TI, it was shown that Asp305 is responsible for the 
final deprotonation reaction required for the elimination of Pi (Enz-Z of Figure 3-C1). 
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The identification of the residues involved in the catalysis of MurA has been 
enhanced by structural information given by crystallographic data.  Crystallization of 
the MurA mutants, Cys115Ser and Asp305Ala, with products and the TI, 
respectively, allowed the identification of a set of charged residues, interacting with 
the PEP moiety of the TI or products.  These charged amino acids in the active site 
are postulated to be critical residues in the reaction mechanism of MurA by serving as 
acid-base catalysts.  These residues are Lys22, Arg120, Arg331, and Arg371, and 
(A) 
 
(B) 
 
 
Figure 5.  Structural study with Asp305Ala MurA23. 
(A) A stereoview of the tetrahedral intermediate bound to MurA active site.  The 
TI is shown in green and the set of charged residues in MurA are shown in magenta. The polar 
and charged interactions are shown as dashed lines. 
(B) Stereochemical course of enolpyruvyl transferase reaction.  Enzyme-X and H-
Y-Enzyme denote residues in the active site involved in proton transfer.  
 25
they are highly conserved through MurA enzymes from various organisms.  
Structural studies of mutant enzymes on these residues would provide a detailed 
catalytic mechanism of MurA. 
1.1.2. Structural Features of MurA 
In recent years, 
the mechanistic 
understanding of 
the enzymatic 
reaction by MurA 
has been given a 
structural basis 
through deter-
mination of a series 
of crystal structures of various forms of the enzyme19, 24–27.  The single polypeptide 
chain of MurA folds into two globular domains, each comprising an inside-out α/β 
barrel, built up by 6-fold repetition of a common βαβαββ motif.  This architecture is 
shared with EPSPS, the only other enolpyruvyl transferase, although the sequence 
identity between MurA and EPSPS is only ~25 %28.  Thus, these two enzymes share 
not only a unique enzymatic reaction, but also distinct structural features.   
 
 
Figure 6.  Conformational changes of MurA upon binding of 
UNAG. The open form of MurA undergoes the 
conformational changes into the closed form after UNAG 
binding. 
Several crystal structures of liganded and un-liganded MurA have been 
determined.  MurA contains a highly flexible loop, which is involved in substrate and 
inhibitor binding.   The conformation of the loop varies in these crystal structures, 
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depending on the presence or absence of ligands and the crystallization conditions, 
i.e. pH and ionic strengths.  Prior to the binding of substrates, free MurA enzyme 
exists in an open state.  Upon binding of UNAG the two domains approach each 
other, establishing the active site in the cleft between the two domains and generating 
the PEP binding site (Figure 6).  One of the notable structural changes during this 
process is the conformation of a loop, composed of the 10 amino acid residues, 
Pro112–Pro121, in the top domain, N-terminal domain.  The loop moves toward to 
the active site and closes the cleft like a lid.  This ‘induced fit’ mechanism is the 
structural evidence of the ordered substrate binding for the MurA enzymatic reaction. 
The conformational change from the open to the closed states of MurA can be 
monitored by the use of the extrinsic fluorophor, 8-anilino-1-naphthalene sulfonate 
(ANS).  The co-crystal structure of MurA with ANS showed that ANS binds to the 
flexible loop, Pro112–Pro121, and restructures it29.  ANS in the open form of MurA 
is released by UNAG binding, thus ANS is used as a detector of the conformational 
 
Figure 7.  Structures of MurA at free stage, ANS binding, and UNAG binding.  ANS binds 
on the loop of the open state, and is released when the MurA undergoes conformation 
changes upon UNAG binding.  The loop of MurA is shown in magenta color, and 
ANS and UNAG are represented in yellow color. 
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change of MurA (Figure 7).  In the closed state of MurA, the loop has moved toward 
the cleft, and the conformation of Arg91 is changed to stabilize the closed loop 
conformation through hydrogen bonds to backbone carbonyl oxygen atoms of Gly113 
and Arg120.  Arg91 is also essential for the ANS binding to un-liganded open-form 
MurA, and the conformational change of this residue will dissociate ANS.  Thus, 
Arg91 is considered as one of the critical residues in the open-closed conformational 
change of the loop.  In addition, there are other conserved residues in the loop and the 
hinge regions, which may be essential for the loop conformational change (Table 130).  
 
Table 1. Conserved amino acids in the loop and hinge region of MurA30.  Conservation is the 
result of comparing 163 MurA sequences. 
 
Residue Asp49 Arg91 Pro112 Gly113 Gly114 Ile117 Gly118 Arg120 Pro121 Asp123 Asp231 
Conservation 100% 100% 95.7% 100% 100% 95.7% 100% 100% 86.5% 87.1% 100% 
Although the large flexible loop of MurA is a unique and interesting feature, it 
often interferes with crystallization due to its flexible character. 
1.1.3. MurA Inhibition of and Resistance to Fosfomycin 
Fosfomycin ((1R, 2S)-epoxy propyl phosphonic acid31) is a naturally occurring 
antibiotic produced by certain Streptomyces species using PEP as a precursor.  It is 
effective against both Gram-positive and Gram-negative bacteria.  Fosfomycin is the 
drug for the treatment of pediatric gastrointestinal infections resulting from Shiga-like 
toxin–producing E. coli in Japan32–34.  It is also predominantly used for the treatment 
of bacterial infections of the urinary tract and is clinically desirable due to its low 
toxicity to humans.  It has been shown that fosfomycin is effective even against 
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bacterial infections resistant to other antibiotics, e.g. vancomycin-resistant 
enterococci35 and quinolone-resistant E. coli36.   
The bactericidal activity of fosfomycin is exerted through inhibition of MurA.  
Inhibition of MurA by fosfomycin is competitive against PEP but becomes 
irreversible by forming a covalent bond with the active Cys115 residue of the enzyme 
via epoxide ring opening (Figure 8)26, 37, 38.  Fosfomycin inhibition of MurA was 
found to be time-dependent as well as UNAG-dependent, which suggests that the 
conformational change of MurA upon UNAG binding prior to fosfomycin is essential 
for inactivation.  
 
 
Figure 8. Inhibition of MurA via a covalent modification of Cys115 by fosfomycin.  
Although resistance of E. coli to fosfomycin is rarely found in the clinic, there is a 
high frequency of development of fosfomycin resistance in many other pathogenic 
organisms causing urinary tract infections such as Serratia marcescens, Klebsiella 
pneumoniae, E. cloacae, and Staphylococcus epidermidis39–43.  Several mechanisms 
of fosfomycin resistance are known: i) decreased uptake of fosfomycin13, 44–46, ii) 
inactivation of fosfomycin by a plasmid-encoded glutathione transferase47–52, and iii) 
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replacement of MurA Cys115 by Asp53.  Detailed descriptions of these mechanisms 
are as follows. 
i) Early instances of resistance to fosfomycin were due to chromosomal mutants 
resulting in decreased uptake44, 45.  Fosfomycin is taken into cells by active 
transporters, L-α-glycerophosphate uptake system and glucose-6-phosphate uptake 
system13.  Most chromosomally changed resistant organisms have impairments in one 
or both of these uptake systems, thus losing the ability to import fosfomycin into the 
cells44.   
ii) A decade after the first use of fosfomycin in the clinic, plasmid-mediated 
resistance was observed, consisting the inactivation of fosfomycin by fosfomycin 
resistance proteins39, 54.  The analysis of the first enzyme (FosA) shown to inactivate 
fosfomycin revealed that the resistance was caused by adduct formation between 
fosfomycin and the sulfhydryl of glutathione, a reaction catalyzed by glutathione S-
transferase47, 48.  This reaction opens the epoxide ring to render fosfomycin inactive 
against MurA. 
iii) Alteration of MurA Cys115 to an Asp residue has been found in 
Mycobacterium and Chlamydiae species, which show an innate resistance to 
fosfomycin53, 55.  Studies of site-directed mutagenesis of Cys115 to Asp revealed 
retention of enzyme activity, but conferred resistance to fosfomycin53.  Since other 
organisms, Actinomycetales, Actinomyces, Nocardia, and Streptomyces, have Asp in 
place of MurA Cys115, it is expected that these organisms are also resistant to 
fosfomycin53, 55. 
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1.1.4. Inhibitors of MurA 
As described in the previous section, fosfomycin is the most well-known inhibitor 
of MurA, also the only one used in the clinic.  A number of novel inhibitors of MurA 
have been discovered through high-throughput screening (HTS) in the pharmaceutical 
industry.  Three new inhibitors of MurA, compound 1, 2, and 3 in Figure 9, were 
identified with a submicromolar range of IC50 values (IC50 = 0.2 – 0.9 μM)56.  They 
showed UNAG-dependent and time-dependent inhibition, which suggests that these 
compounds may have similar modes of action as fosfomycin.  However, they also 
showed nonspecific inhibition of DNA, RNA, and protein biosynthesis.  From a 
whole-cell assay of peptidoglycan biosynthesis, a derivative of diarylmethane 
(compound 4) was identified as an inhibitor of MurA and showed the same pattern of 
MurA inhibition as fosfomycin57.  4-alkyl and 4,4-bis-alkyl pyrazolidinedione 
derivatives (e.g. compound 5) were reported as inhibitors of MurA and MurB58.  
Naphthyl tetronic acids were also identified as inhibitors targeting multiple Mur 
enzymes in the peptidoglycan biosynthetic pathway59. The most potent compound 
(compound 6) in this group was active against both Gram-positive and Gram-negative 
bacteria in cell-based assays.  Sesquiterpene lactones (e.g. compound 7) were shown 
to be irreversible inhibitors of Pseudomonas aeruginosa and E. coli MurA by 
alkylating Cys11560.  The sesquiterpene lactone compounds did not show inhibitory 
activity against Cys115Asp mutant MurA.  A new series of inhibitors of MurA with 
2-aminotetralone motif (compound 8) was recently discovered by screening, and a 
mode of action involving formation of a covalent adduct was proposed61.  
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Figure 9.  Structures of MurA inhibitors described in the literatures56–63. (Amino acid 
sequence is shown for inhibitor 10.) 
Each IC50 value is shown below its structure with species tested on.  Ki value is 
shown for inhibitor 9 (T6362).
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Compound 9 (T6362) discovered in Aventis was co-crystallized with MurA62.  In the 
structure, the inhibitor bound on the loop in the open state of MurA.  From the 
structural study along with kinetic analysis, it was found that the compound inhibits 
MurA by inhibiting the conformational change to the closed state.  In addition to 
small molecule inhibitors, inhibitions of MurA by peptides and proteins have been 
discovered.  A 12-mer peptide inhibitor (PEP 1354 peptide, 8 of Figure 9) of MurA 
was identified by phage display and showed a competitive inhibition to UNAG with 
an IC50 value of 200 μM for Pseudomonas aeruginosa MurA63.  A protein of RNA 
phage Qβ (A2) was reported to cause host cell lysis by inhibiting MurA64.  Although 
fosfomycin has remained the only MurA inhibitor on the market up to date, numerous 
efforts to find novel inhibitors of MurA, using accumulated mechanistic and 
structural information, are currently in progress.  
 
1.2. Cyclin-dependent kinase 2 
1.2.1. Cell Cycle and Cyclin-Dependent Kinase (CDK) 
Many polypeptide chains released from a ribosome after translation often need 
posttranslational modification such as phosphorylation, attachment of fatty acids, or 
glycosylation65, 66.  Reversible protein phosphorylation, principally on serine, 
threonine, or tyrosine residue, is one of the most important posttranslational 
modifications.  The phosphorylation of a protein can change its function, leading to 
the gain or loss of catalytic activity, or increasing binding affinity to other proteins.  
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Thus, phosphorylation plays a critical role in the regulation of many cellular 
processes including cell cycle, growth, apoptosis, and signal transduction pathways67.  
The enzymes catalyzing the phosphorylation are protein kinases.  Protein kinases 
catalyze the transfer of a γ-phosphoryl group from ATP to the side chain hydroxyl 
(OH) of a serine, threonine, or tyrosine residue on a target protein.  From the human 
genome project, genes for 518 protein kinases have been identified68.  These have 
been classified into 8 families based on the sequence of the catalytic domains and 
biological functions. The cyclin-dependent kinases (CDKs, EC 2.7.11.22), which are 
members of serine/threonine protein kinases, are categorized in the CMGC kinase 
family which is named an acronym of CDKs, mitogen-activated kinases, glycogen-
synthase kinases, and CDK-like kinases. 
CDKs are responsible for control of the cell cycle progression in proliferating 
eukaryotic cells.  Currently, eleven CDKs have been identified69, 70.  The CDK 
proteins have similar sizes of 30-40 kDa and share approximately 40% amino acid 
sequence similarity.  The 
activity of CDKs is 
closely associated with 
specific cyclins71, 72.  The 
complexes of CDK and 
cyclin found to date are 
shown in Table 2.  Each 
phase of the cell cycle is 
Table 2. CDK and partner cyclins 
Cyclin-dependent Kinase Cyclin 
CDK1 A, B 
CDK2 A, E 
CDK3 C 
CDK4 D 
CDK5 D 
CDK6 D 
CDK7 H 
CDK8 C 
CDK9 K, T 
CDK11 L 
unknown F, G, I 
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characterized by the expression of different CDK-cyclin complexes70, 73.  Cyclins of 
the D family form complexes with CDK4 and 6 during the G1 phase71, cyclin E with 
CDK2 in late G1, cyclin A with CDK2 in S phase, and cyclin B with CDK1 during 
the transition from G2 to M phase74, 75.  Control of CDK activity in a cell cycle is 
accomplished by a number of mechanisms.  CDKs are regulated by the formation of 
an active hetero-dimer complex with their cyclin partners.  The CDKs are not 
catalytically active unless bound to a cyclin, resulting in a complex with basal 
catalytic activity.  Concentrations of cyclin partners oscillate during the cell cycle and 
M
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Figure 10.  An overview of some essential steps in cell-cycle progression.  CDKs, their 
activators (cyclins, CDK7:cyclinH), and inhibitors (p15, p16, p18, p21, and p27) 
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are regulated by transcription, followed by ubiquitin-mediated degradation.  
Phosphorylation of the CDK at a conserved threonine residue (Thr160 in CDK2) by 
CDK-activating kinase (CAK, also known as CDK7) is required for full activity76.   
In addition to the positive role of cyclins and CAK on CDK activity, endogenous 
CDK inhibitors provide counteracting negative control77–79.  There are two categories 
of CDK inhibitors defined by whether the inhibitor binds to CDK alone or CDK/cylin 
complexes.  The former category is termed the INK family, and p15, p16, p18, and 
p19 belong to this group of CDK inhibitors.  These proteins bind to CDK and prevent 
formation of the complex with cyclins. CDK inhibitors in the latter category include 
p21, p27, and p57, and they bind to CDK/cyclin complexes (Figure 10).  
Uncontrolled cell growth due to abnormal cell cycle progression is the basic 
feature of cancer.  Thus, many of the cell cycle regulatory mechanisms have been 
found to be altered in cancerous tumor cells.  Mutations and over-expression of 
cyclins, loss of the function of CDK inhibitors, and CDK substrate alterations are the 
hallmark of many different kinds of cancer, including lung cancer, colon cancer, 
breast cancer, B-cell and T-cell lymphoma, bladder cancer, and neuroblastoma80.  In 
particular, over-expression of cyclins D1 and E is often found in breast cancer and 
colon cancer81, 82.  Amplification and over-expression of CDK4 are also seen in 
various human cancers83.  One of the strategies for cancer treatment is to control the 
indiscriminate proliferation of tumor cells and arrest the cell cycle at the G1 or S 
phase.  Inhibition of CDK activity with low molecular weight molecules could indeed 
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restore this cell-cycle control, and thus potentially help in combating cancer and its 
proliferation. 
1.2.2. Structural Features of CDK2 
Structural studies of CDKs have provided a detailed understanding of the 
activation of CDK by cyclin, ATP binding and phosphorylation.  Almost 200 crystal 
structures of CDKs have been 
released to date, with and without 
ions, cyclins, ATP, phosphorylated 
residues, or other ligands.  Among 
these structural studies of CDKs, 
studies with CDK2 are the most 
abundant84.  CDK2 adopts a 
typical protein kinase fold.  A 
smaller N-terminal domain 
consists principally of β-strands 
and one helix, and a larger C-
terminal domain is primarily α-
helical85.  The ATP binding site is 
located at the interface of the two domains, and ATP binding to CDK2 induces a 
slight closure of the cleft (Figure 11).  This ATP binding site can be divided into three 
regions: adenine, ribose, and phosphate binding regions, defined with reference to the 
chemical moieties in ATP.  The adenine ring is located between Ala31 and Leu134 
 
Figure 11. Overall structure of CDK2 with ATP. 
(PDB ID: 1HCK).  The ATP binding site is 
located between C- and N-terminal.  The P- and 
T-loops are flexible regions in the CDK2 
structure and become rigid by the complex 
formation with cyclinA. 
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forming hydrophobic pockets by Ile10, Ala31, Val64, Phe80, Glu81, Phe82, Leu83, 
Leu134, and Ala144.  In addition to the hydrophobic interactions, the N6 and N1 
atoms of adenine form hydrogen bonds with the backbone carbonyl of Glu81 and the 
backbone NH of Leu83, respectively.  The ribose ring of ATP has a hydrophobic 
interaction with Val18 while Asp86 and Gln131 make hydrogen bonds with its 
hydroxyl groups.  The triphosphate component forms a hydrogen bond with Lys33 
and contacts Asp145 and Asn132 by the mediation of a magnesium ion (Figure 12)86.  
 
(A)   (B) 
 
 
Figure 12.   (A) Chemical structure of ATP.  
(B) A stereoview of ATP binding site of CDK2-ATP complex structure 
(1HCK) 86.  Green colored molecule is ATP. Blue dashed lines represent hydrogen 
bonds and orange dashed lines show van der Waals interactions.  Purple colored 
sphere denotes magnesium ion. 
 
In all structures of the CDK2 monomer, electron density is weakly and poorly 
defined in two regions, residues 36–47 corresponding to the cyclin recognition part 
(known as the P-loop) and residues 150–164 containing the phosphorylation site (the 
T-loop)86–89.  Binding of cyclin A to CDK2 induces significant structural changes to 
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CDK2, producing an optimized ATP binding site, while there is little structural 
change in cyclin A itself (Figure 13).  This conformational change allows 
catalytically important residues to move into the correct positions in the active site, i.e. 
Glu51 and Lys33 coordinate to the α-phosphate of ATP and Asp145, Phe146, and 
Gly147 induce the correct conformation in the triphosphate moiety of ATP for 
catalytic transfer90, 91. Phosphorylation at Thr160 of CDK2 is required for full activity 
of the CDK2/cyclin A complex.  The crystal structure of the CDK2 (phosphorylated 
Thr160)/cyclin A complex shows that the phosphorylation completes the structural 
changes in the active site by creating a peptide binding site.  Phosphorylated Thr160 
 
 
Figure 13.  Overall structures of CDK2-ATP complex (left with blue color, 1HCK)86 and 
CDK2-cyclinA-ATP complex (right with light blue color, 1FIN)91.  Grey colored 
molecule on each structure is ATP, and red and yellow colored structures denote P-
loop and T-loop, respectively.  Note that a part of P-loop on CDK2-ATP complex is 
invisible in crystal structure because of the flexibility. Orange and green colored α-
helix undergo conformational changes upon making complex with cyclinA.  
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acts as an organizing center by interacting with Arg126, adjacent to the catalytic 
aspartate, Asp12789, 90.  
1.2.3. CDK Inhibitors and Their Modes of Action 
The development of CDK inhibitors has progressed rapidly, aided by the enlarged 
structural information of CDK2-ligand interactions from numerous crystal structure 
studies.  All known CDK2 inhibitors target the ATP binding site.  They compete with 
ATP for inhibition and interact with CDK2 in the same manner as ATP, i.e. by 
making hydrogen bonds with backbone of Glu81 and Leu83, and hydrophobic 
interactions with Ala31 and Leu13488, 92–107.  Several classes of inhibitors based on 
their scaffolds have been developed and successfully modified to improve their 
potency as CDK2 inhibitors (Figures 14 and 15).  Some of them have shown 
moderate selectivity. 
As it will be discussed in detail in the following paragraphs, substantial efforts 
have led to the discovery of several different classes of CDK inhibitors with excellent 
potency.  First-generation CDK inhibitors, UCN-01 and flavopiridol, are in late stages 
of clinical trials for cancer treatment, and several second-generation inhibitors such as 
roscovitin, E7070, and aminothiazole, are also being evaluated in clinical trials and 
showing promising results.  However, inhibitors selective for a single CDK have yet 
to be identified.  This could be due to the conservation of the ATP binding pocket of 
CDKs.  CDK inhibitors can be subdivided into three main classes based on their 
selectivity108, 109: i) compounds that are not selective for any specific CDK (e.g. 
flavopiridol and oxindole (7)), ii) compounds that inhibit CDK1, 2, 5 (e.g. 
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Figure 14.  Small molecule inhibitors of CDK (1).   
The numbers below each structure represent IC50 values for various CDKs. 
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Figure 15.  Small molecule inhibitors of CDK (2).  
The numbers below each structure represent IC50 values for various CDKs. 
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compound (19) compound (20)
CDK1/cyclin B >30 M
CDK2/cyclin E >30 M
CDK4/cyclin D 1.2 M
CDK1/cyclin B >40 M
CDK2/cyclin A 209 nM
CDK2/cyclin E 165 nM
CDK4/cyclin D 8 nM
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Figure 16.   Chemical structures of CDK inhibitors selective to CDK4 and CDK6. 
olomoucine, roscovitine, purvalanol, hymenialdisine, indirubin-5-sulfonate, and 
alsterpaullone), and iii) compounds that are selective for CDK4 and 6 (e.g. 
compounds 19 and 20 in Figure 16). 
Selectivity is a key issue for CDK inhibitors because of the toxicity and inhibition 
of specific cancer types.  The toxicities resulting from targeting specific CDKs 
restrict the use of inhibitors to certain cell types, for example, pituitary or pancreatic β 
cells for CDK4 inhibitors due to reduced proliferation of endocrine or erythroid cells, 
and germ cells for CDK2 inhibitors due to sterility.  Inhibitors targeting specific 
CDKs show inhibition of certain types of tumor cells.  For example, CDK4 inhibition 
is efficient on Her2-positive mammary gland tumors but not on MYC-induced breast 
carcinomas, and CDK1 inhibition by purvalanol shows cytotoxic effects in MYC-
overexpressing cells but not in oncogene-type cells. 
1) The first small molecule inhibitors of CDKs is Staurosporine, a metabolite 
from Streptomyces sp, which has attracted considerable attention since it was 
characterized as a potent inhibitor of protein kinase C (IC50 = 1 nM)110, 111.  It was 
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later found that staurosporine is a nonspecific inhibitor of a number of protein kinases 
with IC50 values of 1 – 100 nM range.  Some staurosporine derivatives are more 
selective protein kinase inhibitors and show anti-tumor activities in various human 
cancer cell lines112, 113.  Among them, UCN-01, also isolated from Streptomyces, is 
currently under–
going clinical 
trials for cancer 
treatment114.  In 
vitro, UCN-01 is 
effective in cell 
cycle regulation 
by inhibiting 
CDK2, CDK4, 
and CDK6 with IC50 values of 30, 32, and 58 nM, respectively.  In the crystal 
structure of the CDK2/staurosporine complex (Figure 17), staurosporine binds to the 
ATP binding site93.  The N1 atom of staurosporine makes a hydrogen bond with the 
backbone carbonyl of Glu81 and the O5 atom with the backbone NH of Leu83, 
mimicking the hydrogen bonds by ATP to CDK2.  In addition, N4 of the glycosyl 
portion in staurosporine forms additional hydrogen bonds with the side chain oxygen 
of Asp86 and the backbone carbonyl of Gln131.  The fused aromatic ring in 
staurosporine makes significant hydrophobic interactions with CDK2.  The residues 
of CDK2 contributing to hydrophobic contacts with staurosporine include Ile10, 
 
 
Figure 17. A stereoview of staurosporine binding site of CDK2 
complex structure (1AQ1)93.  Green colored molecule is 
staurosporine. Blue dashed lines represent hydrogen bonds 
and orange dashed lines denote van der Waals interactions. 
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Gly11, Val18, Ala31, Lys33, Val64, Phe80, Phe82, Asp86, Gln131, Leu134, Ala144, 
and Asp145. 
2)  The second class of compounds extensively studied as inhibitors of CDKs are 
flavones.  Flavopiridol and 
deschloroflavopiridol are 
synthetic flavonoid analogs 
of a natural alkaloid, 
rohitukine, extracted from 
the stem-bark of the plant 
Dysoxylum binactariferum.  
Flavopiridol is the first 
CDK inhibitor to enter 
clinical trials for cancer 
treatment due to its 
antiproliferative properties115–117.  Flavopiridol is active against a number of protein 
kinases, but it is most active against CDK/cyclin complexes with IC50 values up to 
100 nM.  The X-ray crystal structure of CDK2/deschloroflavopiridol reveals the 
inhibition mode of action of deschloroflavopiridol (Figure 18)118.  Deschloro-
flavopiridol binds in the ATP binding site of CDK2 with the benzopyran ring of 
deschloroflavopiridol occupying the same position as the adenine of ATP.  The O5 
hydroxyl group and O4 of deschloroflavopiridol form hydrogen bonds with the 
backbone carbonyl of Glu81 and the backbone NH of Leu83, respectively.  The 
 
 
Figure 18.  A schematic diagram of deschloroflavopiridol 
binding in CDK2118.  Hydrogen bonds are shown 
as green dashed lines with distances.  Blue arches 
represent van der Waals interactions while red 
arches denote possible sterical clashes. 
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phenyl ring of deschloroflavopiridol points toward the outside of the ATP binding site, 
i.e. the solvent exposed space.  The piperidinyl ring occupies a part of the phosphate 
binding pocket of CDK2.  The flavopiridol molecule has an additional chlorine atom 
on the phenyl ring of deschloroflavopiridol, and this difference results in an increased 
inhibitory potency by a factor of 10.  This is probably due to the new interactions that 
the chloro group is able to make with Ile10, Phe82, and Leu83.  This area is 
conserved between CDKs, but not in protein kinase A, and thus protein kinase A is 
not potently inhibited by flavopiridol119.   
3) Indirubins are CDK inhibitors which belong to the oxindole class.  Oxindoles 
have been used in traditional Chinese medicine for the treatment of chronic 
myelocytic leukemia120.  Indirubin analogs such as indirubin-5-sulfate have shown 
good inhibitory potency for CDK1, CDK2, CDK4, and CDK5 compared to other 
protein kinases100.  The crystal structures of CDK2 complexed with indirubin-5-
sulfate (1E9H)121 and oxindole (7 in Figure 14, 1FVT)92 show that both derivatives 
bind to the ATP binding site in a similar fashion (Figure 19).  The amide nitrogen of 
lactam acts as a hydrogen bond donor to the backbone carbonyl of Glu81, and the 
amide oxygen of lactam forms a hydrogen bond with the backbone NH of Leu83.  In 
addition to these two hydrogen bonds, the indole NH of oxindole donates a hydrogen 
bond to the backbone carbonyl of Leu83.  In the structures, it is shown that oxindoles 
make an additional interaction with Phe80, which is not seen in the ATP binding to 
CDK2.  The sulfate group of indirubin-5-sulfate induces a conformational change of 
Asp145 and Phe146 to avoid possible steric hindrance.  This makes CDK2 adopt a 
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conformation 
similar to the 
one it adopts 
when bound to 
cyclin A.  Also, 
the sulfate 
group makes 
additional ionic 
interactions 
with Lys33 and 
Asp145, which 
may explain the 
increased 
potency of 
indirubin sulfate (IC50 = 35 nM for CDK2/cyclinA), compared to the indirubin 
without the sulfate group (IC50 = 2.2 μM for CDK2/cyclinA).  In the crystal structure 
of oxindole (compound 7 in Figure 14) bound to CDK2, one of the sulfonamide 
oxygens accepts a hydrogen bond from the backbone NH of Asp86 and the 
sulfonamide NH donates a hydrogen bond to the side chain of Asp86.  It is likely that 
these interactions of the sulfonamide contribute to the high inhibitory potency of 
oxindole (compound 7)119. 
 
 
 
Figure 19.  Stereoviews of indirubin-5-sulfate (upper, 1E9H)121 and 
oxindole (7) (bottom, 1FVT)92 in the binding sites of CDK2 
complex structures.  Green colored molecules are inhibitor 
molecules. Blue dashed lines represent hydrogen bonds and 
orange dashed lines denote van der Waals interactions. 
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4) The CDK inhibitors of purine derivatives have been identified by screening.  
The compound olomoucine represents the initial purine analogous inhibitor122.  
Olomoucine 
inhibits CDK1, 
CDK2, and 
CDK5 but does 
not inhibit 
CDK4 or 
CDK6123.  
Roscovitine is 
the most 
promising drug 
candidate in this 
group of CDK 
inhibitors.  
Roscovitine was 
identified 
through a series of structure-activity relationship (SAR) studies, and it is currently in 
clinical trials124, 125.  In the structure of the complexes of CDK2 with olomoucine 
(1WOX) and roscovitine (2A4L)126, there are no significant differences compared to 
the ATP bound CDK2 structure (Figure 20).  N6 of the purine ring makes a hydrogen 
bond with the backbone carbonyl oxygen of Leu83 and N7 with the backbone NH of 
 
 
 
Figure 20.  Stereoviews of olomoucine (up, 1W0X) and roscovitine 
(down, 2A4L)126 binding sites of CDK2 complex structures. 
Green colored molecules are purine analog inhibitors. Blue 
dashed lines represent hydrogen bonds and orange dashed lines 
denote van der Waals interactions. 
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Leu83.  The benzyl ring of olomoucine and roscovitine occupies space outside the 
ATP binding site forming hydrophobic interactions with Ile10, Phe82, and His84.  
The hydroxyl alkyl chain is located in the ribose binding pocket, and the alkyl group 
on N9 occupies the space near Lys33.  Combinatorial chemistry has assisted in the 
discovery of CDK inhibitors with purine scaffolds that possess excellent 
potency94, 127, 128.  Purvanalol B was identified from a pool of compounds prepared by 
combinatorial chemistry, and it inhibits CDK2/cyclin A with a 1000-fold better 
potency than olomoucine (IC50 = 6 nM)94.  
5) The pyrimidine class inhibitor, NU6027, was designed as an alternative to 
purine derivative inhibitors129, 130.  NU6027 maintains three hydrogen bonds with 
backbone Leu83 and Glu81.  The purpose of the 5-nitroso group was to provide an 
intramolecular interaction with NH2 on the 6-position, thus assisting the hydrogen 
atom of the NH2 to be located on the correct position for a hydrogen bond with the 
backbone oxygen of Glu81.  The concept of the design of NU6027 was supported by 
a study with compound 13 (Figure 15), which does not have the nitroso group and 
shows no inhibitory activity. 
6) Quinazoline compounds were found through screening to be CDK 
inhibitors95, 131.  In the crystal structure of compound 16 (Figure 15) (2B53)131, the 
inhibitor is found in the ATP binding site of the enzyme (Figure 21).  Interestingly, 
the hydrogen bonds between the inhibitor and the backbone of CDK2 are bridged 
with a water molecule, i.e. N1 of quinazoline has a hydrogen bond with a water 
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Figure 21.  A stereoview of quinazoline inhibitor bound to CDK2 (2B53)131. 
Green colored molecule is a quinazoline inhibitor. Blue dashed lines 
represent hydrogen bonds and orange dashed lines denote van der 
Waals interactions.  A water molecule is shown as a cyan sphere. 
molecule and the water molecule forms hydrogen bonds with the backbone carbonyl 
oxygen of Glu81 and the backbone nitrogen of Leu83. 
7) Hymenialdisine (compound 14 in Figure 15), the natural product isolated from 
a marine sponge, was found to have inhibitory potency against CDK1, CDK2, and 
CDK5, as well as glycogen synthase 3β (GSK3β)96.  In the crystal structure of 
hymenialdisine bound to CDK2 (1DM2)96, three hydrogen bonds between the 
inhibitor and backbone of CDK2 were observed (Figure 22). The nitrogen atom of the 
pyrrole ring makes a hydrogen bond with the backbone oxygen of Leu83, and the 
amide of azepine have hydrogen bonds with the backbone nitrogen of Leu83 and the 
backbone carbonyl of Glu81.  In addition, the guanidine ring makes direct hydrogen 
bonds to one of the side chain oxygen atoms of Asp145 and two more hydrogen 
bonds through water molecules to the backbone nitrogen of Asp145 and to the 
backbone carbonyl of Gln131.  
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Figure 22.   A stereoview of hymenialdisine bound to CDK2 (1DM2)96.  Green colored 
molecule is hymenialdisine. Blue dashed lines represent hydrogen bonds and orange 
dashed lines denote van der Waals interactions. Water molecules are shown as cyan 
spheres. 
8) The Paullone class of compounds were identified as CDK inhibitors from the 
analysis of the NCI compound collection132, 133.  The most potent inhibitor of this 
group is a nitro derivative, alsterpaullon, inhibiting CDK2/cyclin A with a 15 nM IC50 
value133.  Paullones show good potency for CDK1, CDK2, and CDK5, but show no 
inhibition against CDK4.  
Although the studies of CDK were initially directed towards anticancer therapies, 
CDK inhibitors are currently being evaluated in multiple therapeutic areas, such as 
nervous systems, viral infections, cardiovascular diseases, reproduction, and 
protozoan diseases, and it seems likely that other therapeutic indications may yet be 
discovered.  Thus, the discovery of novel CDK inhibitors with better selectivity 
would provide the next generation of CDK inhibitors that are effective on specific 
diseases as well as cancer.  
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2. Materials and Methods 
2.1. General Materials 
2.1.1. Competent Cells 
Competent cell strains used: BL21(DE3) (Stratagene, La Jolla, CA) and DH5α 
(Invitrogen, Carlsbad, CA). 
2.1.2. Chemicals 
A Labconco Water Pure Plus System (Kansas City, MO) was used to purify H2O 
used for all research.   All biochemical reagents were purchased from Sigma (St. 
Louis, MO) or Fisher (Springfield, NJ) unless otherwise noted. 
2.1.3. Solutions 
2.1.3.1.  Media 
All media was autoclaved and stored at 4 ˚C.  Antibiotic stocks were added to the 
media prior to use. 
Luria Bertani (LB): 
10 g tryptone 
5 g yeast extract 
10 g NaCl 
Fill to 1 L with H2O  
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2.1.3.2.  Antibiotics 
Ampicillin (Amp, Fisher) at 100 mg/mL and kanamycin (Kan, Fisher) at 
30 mg/mL were sterile filtered with a 0.45 μm filter and stored at -20 ˚C.  Antibiotics 
were used as a 1:1000 dilution unless otherwise mentioned. 
2.1.3.3.  DNA Electrophoresis 
A 50× concentrated stock solution of TAE was stored at room temperature and 
diluted before the use.  The protocol for DNA gel is following: 500 mg of agarose in 
50 mL of 1× TAE was heated with microwave until dissolved, 1 μL of ethidium 
bromide (5 mg/mL) was added to the solution and the gel was cast. 
 
50× TAE (1L): 
242 g Tris (pH 8.5) 
57.1 mL glacial acetic acid 
100 mL 0.5 M EDTA (pH 8.0) 
Fill to 1 L with H2O 
 
Molecular ladder (Cambrex Bio Science, Rockland, ME) was prepared by adding 
5 μL marker and 2 μL 10× Blue-juice (Invitrogen) to 3 μL H2O.  The DNA ladder 
corresponded to 10, 7, 5, 4, 3, 2.5, 2, 1.5, and 1 Kb markers. 
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2.1.3.4. SDS Electrophoresis 
SDS-PAGE running buffer was prepared as a 10× concentrated solution and 
diluted prior to use.  Coomassie stain was filtered with a Nalgene PES filter with 
75 μm membrane size and stored in a bottle wrapped with aluminum foil at room 
temperature.  30 % Acrylamide/bisacrylamide, 10 % APS (Biorad, Hercules CA), 
TEMED (Biorad) and Tris buffers were stored at 4 ˚C.  All other solutions were 
stored at room temperature.  SDS-PAGE gels were made according to the following 
protocol and stored at 4 ˚C for up to 2 weeks.  
 
Resolving SDS gel portion (1 gel):  
4 mL  30 % acrylamide/bisacrylamide 
100 μL 10% SDS 
2.5 mL 1.5 M Tris (pH 8.8) 
3.36 mL water 
80 μL 10 % APS  
10.0 μL TEMED  
 
30 % Acrylamide/bisacrylamide (500 mL): 
150 g acrylamide  
4 g bisacrylamide 
Fill to 500 mL with H2O 
 
Stacking SDS gel portion (1 gel):  
650 μL 30 % acrylamide/bisacrylamide 
50 μL 10 % SDS 
1.25 mL 0.5 M Tris (pH 6.8) 
3.05 mL water 
40 μL 10 % APS 
5 μL TEMED 
 
10× SDS Running buffer (1L): 
30 g Tris (pH 8.5) 
144 g glycine 
10 g SDS 
Fill to 1 L with H2O 
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Destaining solution (1L):  
500 mL ethanol 5× Treatment buffer: 
100 mL acetic acid  300 mM Tris (pH 8.5) 
400 mL H2O 10 % SDS  
 4 mL H2O 
Coomassie stain (1L): 25 % β-mercaptoethanol 
1.25 g Coomassie brilliant blue R-250 50 % glycerol 
500 mL 95 % ethanol 282 mM HCl 
450 mL H2O 0.05 % bromophenol blue 
50 mL 100 % acetic acid 
 
 
 
 
SDS low range marker (Biorad): 
Protein Molecular marker was prepared by adding 50 μL concentrated marker and 
100 μL 5× treatment buffer to 350 μL H2O and heating the solution at 100 ˚C for 
5 min.  Marker was stored at -20 ˚C.  The molecular weights in the marker 
corresponded to 97.4, 66.2, 45, 31, 21.5, and 14.4 kDa.   
2.1.3.5.  FPLC Buffers 
All buffers for protein purification were filtered with a 0.45 μm filter and stored at 
4 ˚C. 
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Buffer A: 
50 mM Tris (pH 7.8) 
1 mM DTT 
1 mM EDTA 
 
Buffer A + 1M (NH4)2SO4: 
50 mM Tris (pH 7.8) 
1 M (NH4)2SO4 
1 mM DTT 
1 mM EDTA 
 
Buffer A (CDK-GST 1) 
50 mM HEPES (pH 7.5) 
150 mM NaCl 
1 mM EGTA 
10 mM MgCl2 
2 mM DTT 
 
 
 
 
Buffer A + 0.4M NaCl: 
50 mM Tris (pH 7.8) 
0.4 M NaCl 
1 mM DTT 
1 mM EDTA 
 
 
 
 
 
 
Buffer A (CDK-GST 1) + glutathione 
50 mM HEPES (pH 7.5) 
150 mM NaCl 
1 mM EGTA 
10 mM MgCl2 
2 mM DTT 
10 mM glutathione, reduced 
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Buffer A (CDK-GST 2) + glutathione Buffer A (CDK-GST 2) 
50 mM HEPES (pH 7.5) 50 mM HEPES (pH 7.5) 
150 mM NaCl 150 mM NaCl 
1 mM EGTA 1 mM EGTA 
10 mM MgCl2 10 mM MgCl2 
2 mM DTT 2 mM DTT 
0.01 mM ADP 0.01 mM ADP 
 10 mM glutathione, reduced 
 
2.1.3.6. Lanzetta Reagent 
Lanzetta reagent was prepared by using plastic-ware to avoid phosphate 
contamination from glass.  The following protocol was used:  5.25 g ammonium 
molybdate was dissolved in 41 mL of 12 M HCl and added to a solution containing 
169 mg malachite green in 375 mL H2O.  This solution was stirred for 2 - 4 hrs, 
filtered using a Nalgene PES filter with 75 μm pore size and stored at room 
temperature wrapped in aluminium foil. 
2.1.3.7. Crystallization Solutions 
For crystallization screening, Hampton 1 and 2 (Tables 3 and 4, Hampton 
Research, Aliso Viejo, CA), and Wizard 1 and 2 (Tables 5 and 6, Emerald 
Biosciences, Cambridge, MA) screening solutions were purchased. 
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Table 3. Crystallization buffers for Hampton crystallization screen #1. 
 
 Salt Buffer Precipitant 
1 0.02 M CaCl2 ·2H2O 0.1 M NaOAc ·3H2O pH 4.6 30% v/v MPD 
2 None None 0.4 M K/Na tartrate ·2H2O 
3 None None 0.4 M (NH4)H2PO4 
4 None 0.1 M TRIS· HCl pH 8.5 2.0 M (NH4)2SO4 
5 0.2 M Na3citrate ·2H2O 0.1 M HEPES· Na pH 7.5 30% v/v MPD 
6 0.2 M MgCl2 ·6H2O 0.1 M TRIS· HCl pH 8.5 30% w/v PEG4,000 
7 None 0.1 M Na cacodylate  pH 6.5 1.4 M NaOAc ·3H2O 
8 0.2 M Na3citrate ·2H2O 0.1 M Na cacodylate pH 6.5 30% v/v 2-Propanol 
9 0.2 M NH4OAc 0.1 M Na3citrate· 2H2O pH 5.6 30% w/v PEG4,000 
10 0.2 M NH4OAc 0.1 M NaOAc· 3H2O pH 4.6 30% w/v PEG4,000 
11 None 0.1 M Na3citrate· 2H2O pH 5.6 1.0 M (NH4)H2PO4 
12 0.2 M MgCl2 ·6H2O 0.1 M HEPES· Na pH 7.5 30% v/v 2-Propanol 
13 0.2 M Na3citrate ·2H2O 0.1 M TRIS· HCl pH 8.5 30% v/v PEG400 
14 0.2 M CaCl2 ·2H2O 0.1 M HEPES· Na pH 7.5 28% v/v PEG400 
15 0.2 M (NH4)2SO4 0.1 M Na cacodylate pH 6.5 30% w/v PEG8,000 
16 None 0.1 M HEPES· Na pH 7.5 1.5 M Li2SO4 ·H2O 
17 0.2 M Li2SO4 ·H2O 0.1 M TRIS· HCl pH 8.5 30% w/v PEG4,000 
18 0.2 M Mg(OAc)2 ·4H2O 0.1 M Na cacodylate pH 6.5 20% w/v PEG8,000 
19 0.2 M NH4OAc 0.1 M TRIS· HCl pH 8.5 30% v/v 2-Propanol 
20 0.2 M (NH4)2SO4 0.1 M NaOAc· 3H2O pH 4.6 25% w/v PEG4,000 
21 0.2 M Mg(OAc)2 ·4H2O 0.1 M Na cacodylate pH 6.5 30% v/v MPD 
22 0.2 M NaOAc ·3H2O 0.1 M TRIS· HCl pH 8.5 30% w/v PEG4,000 
23 0.2 M MgCl2 ·6H2O 0.1 M HEPES· Na pH 7.5 30% v/v PEG400 
24 0.2 M CaCl2· 2H2O 0.1 M NaOAc· 3H2O pH 4.6 20% v/v 2-Propanol 
25 None 0.1 M Imidazole pH 6.5 1.0 M NaOAc ·3H2O 
26 0.2 M NH4OAc 0.1 M Na3citrate 2H2O pH 5.6 30% v/v MPD 
27 0.2 M Na3citrate ·2H2O 0.1 M HEPES· Na pH 7.5 20% v/v 2-Propanol 
28 0.2 M NaOAc ·3H2O 0.1 M Na cacodylate pH 6.5 30% w/v PEG8,000 
29 None 0.1 M HEPES· Na pH 7.5 0.8 M K/Na tartrate 2H2O 
30 0.2 M (NH4)2SO4 None 30% w/v PEG8,000 
31 0.2 M (NH4)2SO4 None 30% w/v PEG4,000 
32 None None 2.0 M (NH4)2SO4 
33 None None 4.0 M Na formate 
34 None 0.1 M NaOAc· 3H2O pH 4.6 2.0 M Na formate 
35 None 0.1 M HEPES· Na pH 7.5 0.8 M NaH2PO4 · H2O  0.8 M KH2PO4 
36 None 0.1 M TRIS· HCl pH 8.5 8% w/v PEG8,000 
37 None 0.1 M NaOAc· 3H2O pH 4.6 8% w/v PEG4,000 
38 None 0.1 M HEPES· Na pH 7.5 1.4 M Na3citrate· 2H2O 
39 None 0.1 M HEPES· Na pH 7.5 2% v/v PEG400 2.0 M (NH4)2SO4 
40 None 0.1 M Na3citrate· 2H2O pH 5.6 
20% v/v 2-Propanol 
20% w/v PEG4,000 
41 None 0.1 M HEPES· Na pH 7.5 10% v/v 2-Propanol 20% w/v PEG4,000 
42 0.05 M KH2PO4 None 20% w/v PEG8,000 
43 None None 30% w/v PEG1,500 
44 None None 0.2 M Mg formate 
45 0.2 M Zn(OAc)2 ·2H2O 0.1 M Na cacodylate pH 6.5 18% w/v PEG8,000 
46 0.2 M Ca(OAc)2 ·H2O 0.1 M Na cacodylate pH 6.5 18% w/v PEG8,000 
47 None 0.1 M NaOAc ·3H2O pH 4.6 2.0 M (NH4)2SO4 
48 None 0.1 M TRIS· HCl pH 8.5 2.0 M (NH4)H2PO4 
49 1.0 M Li2SO4 ·H2O None 2% w/v PEG8,000 
50 0.5 M Li2SO4 ·H2O None 15% w/v PEG8,000 
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Table 4. Crystallization buffers for Hampton crystallization screen #2. 
 
 Salt Buffer Precipitant 
1 2.0 M NaCl None 10% w/v PEG 6,000 
2 0.5 M NaCl 0.01 M MgCl2· 6(H2O) None 0.01 M CH3(CH2)15N(Br)(CH3)3 
3 None None 25% v/v Ethylene glycol 
4 None None 35% v/v 1,4-Dioxane 
5 2.0 M (NH4)2SO4 None 5% v/v 2-Propanol 
6 None None 1.0 M Imidazole pH 7.0 
7 None None 10% w/v PEG 1,000 10% w/v PEG 8,000 
8 1.5 M NaCl None 10% v/v Ethanol 
9 None 0.1 M NaOAc ·3H2O pH 4.6 2.0 M NaCl 
10 0.2 M NaCl 0.1 M NaOAc ·3H2O pH 4.6 30% v/v MPD 
11 0.01 M CoCl2 · 6H2O 0.1 M NaOAc ·3H2O pH 4.6 1.0 M 1,6-Hexanediol 
12 0.1 M CdCl2 ·H2O 0.1 M NaOAc ·3H2O pH 4.6 30% v/v PEG 400 
13 0.2 M (NH4)2SO4 0.1 M NaOAc ·3H2O pH 4.6 30% w/v PEG MME 2,000 
14 0.2 M K Na tartrate  · 4H2O 0.1 M Na3citrate· 2H2O pH 5.6 2.0 M (NH4)2SO4 
15 0.5 M (NH4)2SO4 0.1 M Na3citrate· 2H2O pH 5.6 1.0 M Li2SO4 ·H2O 
16 0.5 M NaCl 0.1 M Na3citrate· 2H2O pH 5.6 2% v/v Ethylene imine polymer 
17 None 0.1 M Na3citrate· 2H2O pH 5.6 35% v/v tert-Butanol 
18 0.01 M FeCl3 · 6H2O 0.1 M Na3citrate· 2H2O pH 5.6 10% v/v Jeffamine M-600 
19 None 0.1 M Na3citrate· 2H2O pH 5.6 2.5 M 1,6-Hexanediol 
20 None 0.1 M MES· H2O pH 6.5 1.6 M MgSO4· 6H2O 
21 0.1 M NaH2PO4 · H2O 0.1 M KH2PO4 0.1 M MES· H2O pH 6.5 2.0 M NaCl 
22 None 0.1 M MES· H2O pH 6.5 12% w/v PEG 20,000 
23 1.6 M (NH4)2SO4 0.1 M MES· H2O pH 6.5 10% v/v 1,4-Dioxane 
24 0.05 M CsCl 0.1 M MES· H2O pH 6.5 30% v/v Jeffamine M-600 
25 0.01 M CoCl2 · 6H2O 0.1 M MES· H2O pH 6.5 1.8 M (NH4)2SO4 
26 0.2 M (NH4)2SO4 0.1 M MES· H2O pH 6.5 30% w/v PEG MME 5,000 
27 0.01 M ZnSO4 · 7H2O 0.1 M MES· H2O pH 6.5 25% v/v PEG MME 550 
28 None None 1.6 M Na3citrate ·2H2O pH 6.5 
29 0.5 M (NH4)2SO4 0.1 M HEPES pH 7.5 30% v/v MPD 
30 None 0.1 M HEPES pH 7.5 10% w/v PEG 6,000 5% v/v MPD 
31 None 0.1 M HEPES pH 7.5 20% v/v Jeffamine M-600 
32 0.1 M NaCl 0.1 M HEPES pH 7.5 1.6 M (NH4)2SO4 
33 None 0.1 M HEPES pH 7.5 2.0 M NH4HCO2 
34 0.05 M CdSO4 · H2O 0.1 M HEPES pH 7.5 1.0 M NaOAc· 3H2O 
35 None 0.1 M HEPES pH 7.5 70% v/v MPD 
36 None 0.1 M HEPES pH 7.5 4.3 M NaCl 
37 None 0.1 M HEPES pH 7.5 10% w/v PEG 8,000 8% v/v Ethylene glycol 
38 None 0.1 M HEPES pH 7.5 20% w/v PEG 10,000 
39 0.2 M MgCl2· 6H2O 0.1 M Tris pH 8.5 3.4 M 1,6-Hexanediol 
40 None 0.1 M Tris pH 8.5 25% v/v tert-Butanol 
41 0.01 M NiCl2 · 6H2O 0.1 M Tris pH 8.5 1.0 M Li2SO4· H2O 
42 1.5 M (NH4)2SO4 0.1 M Tris pH 8.5 12% v/v Glycerol 
43 0.2 M NH4H2PO4 0.1 M Tris pH 8.5 50% v/v MPD 
44 None 0.1 M Tris pH 8.5 20% v/v Ethanol 
45 0.01 M NiCl2·6H2O 0.1 M Tris pH 8.5 20% w/v PEG MME 2,000 
46 0.1 M NaCl 0.1 M BICINE pH 9.0 20% v/v PEG MME 550 
47 None 0.1 M BICINE pH 9.0 2.0 M MgCl2· 6H2O 
48 None 0.1 M BICINE pH 9.0 2% v/v 1,4-Dioxane 10% w/v PEG 20,000 
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Table 5. Crystallization buffers for Wizard crystallization screen #1. 
 
  crystallant buffer (0.1 M) salt (0.2 M) 
1 20% (w/v) PEG-8000 CHES pH 9.5 none 
2 10% (v/v) 2-propanol HEPES pH 7.5 NaCl 
3 15% (v/v) ethanol CHES pH 9.5 none 
4 35% (v/v) 2-methyl-2,4-pentanediol imidazole pH 8.0 MgCl2 
5 30% (v/v) PEG-400 CAPS pH 10.5 none 
6 20% (w/v) PEG-3000 citrate pH 5.5 none 
7 10% (w/v) PEG-8000 MES pH 6.0 Zn(OAc)2 
8 2.0 M (NH4)2SO4 citrate pH 5.5 none 
9 1.0 M (NH4)2HPO4 acetate pH 4.5 none 
10 20% (w/v) PEG-2000 MME Tris pH 7.0 none 
11 20% (v/v) 1,4-butanediol MES pH 6.0 Li2SO4 
12 20% (w/v) PEG-1000 imidazole pH 8.0 Ca(OAc)2 
13 1.26 M (NH4)2SO4 cacodylate pH 6.5 none 
14 1.0 M sodium citrate cacodylate pH 6.5 none 
15 10% (w/v) PEG-3000 imidazole pH 8.0 Li2SO4 
16 2.5 M NaCl Na/K phosphate pH 6.2 none 
17 30% (w/v) PEG-8000 acetate pH 4.5 Li2SO4 
18 1.0 M K/Na tartrate imidazole pH 8.0 NaCl 
19 20% (w/v) PEG-1000 Tris pH 7.0 none 
20 0.4 M NaH2PO4/1.6 M K2HPO4 imidazole pH 8.0 NaCl 
21 20% (w/v) PEG-8000 HEPES pH 7.5 none 
22 10% (v/v) 2-propanol Tris pH 8.5 none 
23 15% (v/v) ethanol imidazole pH 8.0 MgCl2 
24 35% (v/v) 2-methyl-2,4-pentanediol Tris pH 7.0 NaCl 
25 30% (v/v) PEG-400 Tris pH 8.5 MgCl2 
26 10% (w/v) PEG-3000 CHES pH 9.5 none 
27 1.2 M NaH2PO4/0.8 M K2HPO4 CAPS pH 10.5 Li2SO4 
28 20% (w/v) PEG-3000 HEPES pH 7.5 NaCl 
29 10% (w/v) PEG-8000 CHES pH 9.5 NaCl 
30 1.26 M (NH4)2SO4 acetate pH 4.5 NaCl 
31 20% (w/v) PEG-8000 phosphate-citrate pH 4.2 NaCl 
32 10% (w/v) PEG-3000 Na/K phosphate pH 6.2 none 
33 2.0 M (NH4)2SO4 CAPS pH 10.5 Li2SO4 
34 1.0 M (NH4)2HPO4 imidazole pH 8.0 none 
35 20% (v/v) 1,4-butanediol acetate pH 4.5 none 
36 1.0 M sodium citrate imidazole pH 8.0 none 
37 2.5 M NaCl imidazole pH 8.0 none 
38 1.0 M K/Na tartrate CHES pH 9.5 Li2SO4 
39 20% (w/v) PEG-1000 phosphate-citrate pH 4.2 Li2SO4 
40 10% (v/v) 2-propanol MES pH 6.0 Ca(OAc)2 
41 30% (w/v) PEG-3000 CHES pH 9.5 none 
42 15% (v/v) ethanol Tris pH 7.0 none 
43 35% (v/v) 2-methyl-2,4-pentanediol Na/K phosphate pH 6.2 none 
44 30% (v/v) PEG-400 acetate pH 4.5 Ca(OAc)2 
45 20% (w/v) PEG-3000 acetate pH 4.5 none 
46 10% (w/v) PEG-8000 imidazole pH 8.0 Ca(OAc)2 
47 1.26 M (NH4)2SO4 Tris pH 8.5 Li2SO4 
48 20% (w/v) PEG-1000 acetate pH 4.5 Zn(OAc)2 
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Table 6. Crystallization buffers for Wizard crystallization screen #2. 
 
  crystallant buffer (0.1 M) salt (0.2 M) 
1 10% (w/v) PEG-3000 acetate pH 4.5 Zn(OAc)2 
2 35% (v/v) 2-methyl-2,4-pentanediol MES pH 6.0 Li2SO4 
3 20% (w/v) PEG-8000 Tris pH 8.5 MgCl2 
4 2.0 M (NH4)2SO4 cacodylate pH 6.5 NaCl 
5 20% (v/v) 1,4-butanediol HEPES pH 7.5 NaCl 
6 10% (v/v) 2-propanol phosphate-citrate pH 4.2 Li2SO4 
7 30% (w/v) PEG-3000 Tris pH 7.0 NaCl 
8 10% (w/v) PEG-8000 Na/K phosphate pH 6.2 NaCl 
9 2.0 M (NH4)2SO4 phosphate-citrate pH 4.2 none 
10 1.0 M (NH4)2HPO4 Tris pH 8.5 none 
11 10% (v/v) 2-propanol cacodylate pH 6.5 Zn(OAc)2 
12 30% (v/v) PEG-400 cacodylate pH 6.5 Li2SO4 
13 15% (v/v) ethanol citrate pH 5.5 Li2SO4 
14 20% (w/v) PEG-1000 Na/K phosphate pH 6.2 NaCl 
15 1.26 M (NH4)2SO4 HEPES pH 7.5 none 
16 1.0 M sodium citrate CHES pH 9.5 none 
17 2.5 M NaCl Tris pH 7.0 MgCl2 
18 20% (w/v) PEG-3000 Tris pH 7.0 Ca(OAc)2 
19 1.6 M NaH2PO4/0.4 M K2HPO4 phosphate-citrate pH 4.2 none 
20 15% (v/v) ethanol MES pH 6.0 Zn(OAc)2 
21 35% (v/v) 2-methyl-2,4-pentanediol acetate pH 4.5 none 
22 10% (v/v) 2-propanol imidazole pH 8.0 none 
23 15% (v/v) ethanol HEPES pH 7.5 MgCl2 
24 30% (w/v) PEG-8000 imidazole pH 8.0 NaCl 
25 35% (v/v) 2-methyl-2,4-pentanediol HEPES pH 7.5 NaCl 
26 30% (v/v) PEG-400 CHES pH 9.5 none 
27 10% (w/v) PEG-3000 cacodylate pH 6.5 MgCl2 
28 20% (w/v) PEG-8000 MES pH 6.0 Ca(OAc)2 
29 1.26 M (NH4)2SO4 CHES pH 9.5 NaCl 
30 20% (v/v) 1,4-butanediol imidazole pH 8.0 Zn(OAc)2 
31 1.0 M sodium citrate Tris pH 7.0 NaCl 
32 20% (w/v) PEG-1000 Tris pH 8.5 none 
33 1.0 M (NH4)2HPO4 citrate pH 5.5 NaCl 
34 10% (w/v) PEG-8000 imidazole pH 8.0 none 
35 0.8 M NaH2PO4/1.2 M K2HPO4 acetate pH 4.5 none 
36 10% (w/v) PEG-3000 phosphate-citrate pH 4.2 NaCl 
37 1.0 M K/Na tartrate Tris pH 7.0 Li2SO4 
38 2.5 M NaCl acetate pH 4.5 Li2SO4 
39 20% (w/v) PEG-8000 CAPS pH 10.5 NaCl 
40 20% (w/v) PEG-3000 imidazole pH 8.0 Zn(OAc)2 
41 2.0 M (NH4)2SO4 Tris pH 7.0 Li2SO4 
42 30% (v/v) PEG-400 HEPES pH 7.5 NaCl 
43 10% (w/v) PEG-8000 Tris pH 7.0 MgCl2 
44 20% (w/v) PEG-1000 cacodylate pH 6.5 MgCl2 
45 1.26 M (NH4)2SO4 MES pH 6.0 none 
46 1.0 M (NH4)2HPO4 imidazole pH 8.0 NaCl 
47 2.5 M NaCl imidazole pH 8.0 Zn(OAc)2 
48 1.0 M K/Na tartrate MES pH 6.0 none 
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The crystallization solutions in which crystals were present were optimized to 
obtain the best crystal by changing buffer pH and the concentrations of salt and 
precipitant (Tables 7-9).  Every stock solution used to make in-house crystallization 
solutions was filtered with a 45 μm membrane filter prior to mixing.  The components 
of crystallization solutions are shown below. 
 
 
Table 7.  Variations of crystallization condition H1-18.  Each row illustrates the variations 
attempted from the original condition, H1-18. 
 
H1-18 condition Mg(OAc)2 Na cacodylate PEG8000 
H1-18-1 0.1 M 0.1M, pH 6.0 20 % 
H1-18-2 (original) 0.1 M 0.1M, pH 6.5 20 % 
H1-18-3 0.1 M 0.1M, pH 7.0 20 % 
H1-18-4 0.2 M 0.05M, pH 6.0 20 % 
H1-18-5 0.2 M 0.05M, pH 6.5 20 % 
H1-18-6 0.2 M 0.05M, pH 7.0 20 % 
H1-18-7 0.2 M 0.2M, pH 6.0 20 % 
H1-18-8 0.2 M 0.2M, pH 6.5 20 % 
H1-18-9 0.2 M 0.2M, pH 7.0 20 % 
H1-18-10 0.4 M 0.1M, pH 6.0 20 % 
H1-18-11 0.4 M 0.1M, pH 6.5 20 % 
H1-18-12 0.4 M 0.1M, pH 7.0 20 % 
H1-18-13 0.1 M 0.1M, pH 6.0 15 % 
H1-18-14 0.1 M 0.1M, pH 6.5 15 % 
H1-18-15 0.1 M 0.1M, pH 7.0 15 % 
H1-18-16 0.2 M 0.05M, pH 6.0 15 % 
H1-18-17 0.2 M 0.05M, pH 6.5 15 % 
H1-18-18 0.2 M 0.05M, pH 7.0 15 % 
H1-18-19 0.2 M 0.2M, pH 6.0 15 % 
H1-18-20 0.2 M 0.2M, pH 6.5 15 % 
H1-18-21 0.2 M 0.2M, pH 7.0 15 % 
H1-18-22 0.4 M 0.1M, pH 6.0 15 % 
H1-18-23 0.4 M 0.1M, pH 6.5 15 % 
H1-18-24 0.4 M 0.1M, pH 7.0 15 % 
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Table 8. Variations of crystallization condition PEG20K.  Each row illustrates the variations 
attempted from the original condition, PEG20K. 
 
PEG20K condition MES PEG 20K 
PEG20K-1 25 mM 12.5 % 
PEG20K-2 25 mM 10 % 
PEG20K-3 25 mM 8 % 
PEG20K-4 50 mM 12.5 % 
PEG20K-5 50 mM 10 % 
PEG20K-6 50 mM 8 % 
PEG20K-7 100 mM 12.5 % 
PEG20K-8 100 mM 10 % 
PEG20K-9 150 mM 12.5 % 
PEG20K-10 150 mM 10 % 
PEG20K-11 200 mM 12.5 % 
PEG20K-12 200 mM 10 % 
PEG20K-13 200 mM 8 % 
PEG20K-14 200 mM 6 % 
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Table 9.  Variations of crystallization condition H1-41.  Each row illustrates the variations 
attempted from the original condition, H1-41. 
 
H1-41 conditions HEPES 2-propanol PEG4000 
H1-41-1 0.1 M, pH 7.5 10 % 20 % 
H1-41-2 0.1 M, pH 7.5 9 % 20 % 
H1-41-3 0.1 M, pH 7.5 8 % 20 % 
H1-41-4 0.1 M, pH 7.5 7 % 20 % 
H1-41-5 0.1 M, pH 7.5 6 % 20 % 
H1-41-6 0.1 M, pH 7.5 11 % 20 % 
H1-41-7 0.1 M, pH 7.5 12 % 20 % 
H1-41-8 0.1 M, pH 7.5 10 % 22 % 
H1-41-9 0.05 M, pH 7.5 10 % 20 % 
H1-41-10 0.15 M, pH 7.5 10 % 20 % 
H1-41-11 0.1 M, pH 7.5 10 % 18 % 
H1-41-12 0.1 M, pH 7.8 10 % 20 % 
H1-41-13 0.1 M, pH 8.2 10 % 20 % 
H1-41-14 0.1 M, pH 7.2 10 % 20 % 
H1-41-15 0.1 M, pH 6.8 10 % 20 % 
H1-41-16 0.1 M, pH 7.5 14 % 20 % 
H1-41-17 0.1 M, pH 7.5 16 % 20 % 
H1-41-18 0.1 M, pH 7.5 18 % 20 % 
H1-41-19 0.1 M, pH 7.5 10 % 25 % 
H1-41-20 0.1 M, pH 7.5 12 % 22 % 
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2.2. General Methods 
2.2.1.  Preparation of Competent Cells 
Commercially available competent cells were used to make stocks of new CaCl2 
competent cells.  Five milliliters of overnight cultures were grown in LB media with 
no antibiotic and transferred to 250 mL LB media.  When the OD550 reached to 0.5–
0.7, the cells were harvested by centrifugation at 4 ˚C for 10 min at 6,000 rpm using a 
Beckman J2-21 centrifuge.  The cell pellets were washed with 100 mL of sterile 
0.1 M MgCl2 and centrifuged at 4 ˚C for 10 min.  The supernatant was discarded and 
the pellets were resuspended in 100 mL of sterile 0.1 M CaCl2.  The resuspended 
solution was incubated on ice for 20 min prior to centrifugation at 4 ˚C for 10 min.  
The supernatant was decanted and the cells were resuspended with 50 mL of sterile 
0.1 M CaCl2.  Following the resuspension, the cells were incubated for 30 min on ice 
before 5 mL of sterile 50 % glycerol was added.  The cells were aliquoted into 1.5 
mL micro centrifuge tubes and stored at -80 ˚C.   
2.2.2.  Transformations 
Competent cells were transformed by adding 50 to 250 ng of plasmid to 100 μL 
of cells.  This mixture was incubated on ice for 30 min, then heat-shocked for 45 sec 
in 42 ˚C water bath and re-incubated on ice for 2 min.  After adding 900 μL of LB 
broth, the mixture was incubated at 37 °C for 1 h with shaking at 250 rpm.  The cells 
were then centrifuged for 1 min at 6,000 rpm using Eppendorf centrifuge 5417C and 
950 μL of supernatant was removed.  The pellet was resuspended in the remaining 
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solution and plated on LB agar plates, which contained the appropriate antibiotics, 
and incubated overnight at 37 ˚C.   
2.2.3.  Plasmid Preparations 
Plasmids were isolated and purified using the Mini-Prep kit (Qiagen, Valencia, 
CA), according to the user’s manual.  
2.2.4.  DNA Electrophoresis 
All DNA samples were prepared by adding 2 μL of 10× Blue-juice to 8 μL of 
DNA (50–250 ng).  DNA gels were performed at 120 volt for 30 min.  
2.2.5.  Sequencing 
DNA sequences were determined with commercially available T7 primer (GE 
Healthcare) or in-house primers at the biotech research support facility in the 
University of Kansas Medical Center using a PE Biosystems Prism 377XL sequencer 
(Applied Biosystems, Foster City, CA). 
2.2.6.  Glycerol Stocks 
An 800 μL aliquot of an overnight cell culture was mixed with 200 μL 50% 
glycerol and stored at -80 ˚C for future use. 
2.2.7.  SDS Electrophoresis 
All SDS-PAGE samples were prepared by adding the appropriate amount of 5× 
loading buffer to the sample, followed by heating the sample at 100 ˚C for 5 min.  
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SDS-PAGE was performed using a mini PROTEAN® 3 cell (Biorad) at 150 volt for 
1 hour.  
2.2.8.  Determination of Protein Concentration 
Protein concentration was determined using the Coomassie reagent (Pierce, 
Rockford IL) according to the Bradford method.  All protein concentrations were 
determined by comparison to a bovine serum albumin (BSA) standard curve at 
concentrations of 0.5, 1.0, 1.5 and 2.0 mg/mL.    
The protein concentrations of standards and unknowns were determined as 
follows: 5 μL of protein was added to 95 μL of water and 900 μL of Coomassie 
reagent and the absorbance was measured at 596 nm.  The UV absorption of each 
unknown was fit to the BSA standard curve to determine the protein concentration.  
All measurements were recorded in a cuvette using a Shimazdu UV-1650PC 
spectrophotometer (Shimadzu, Colombia, MD).  
2.2.9. PD-10 
PD-10 desalting columns (GE Healthcare) were used to buffer exchange a protein.  
The columns were equilibrated with 25 mL of buffer prior to loading a 2.5 mL aliquot 
of protein onto the column.  The protein was eluted with 3.5 mL of buffer according 
to the manual.  The column was re-equilibrated with 25 mL of buffer before the re-
use if more protein was to be used.   
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2.2.10. Centricon 
Protein was concentrated in YM-30 or YM-10 devices (Millipore, Bedford, MA).  
Approximately 2 mL of protein solution was added to the Centricon device and 
centrifuged for 20 min at 7,000 rpm and 4 °C using a Thermo Fisher IEC Multi RF 
centrifuge.  More protein was added and the centrifugation was repeated until all the 
protein had been added to the device, then the Centricon was inverted and centrifuged 
for 1 min to collect the concentrated protein at a desired volume.   
2.2.11. Crystallization 
For crystallization, proteins were concentrated to 150 mg/mL for MurA enzymes 
and to 10 mg/mL for CDK2.  All proteins were crystallized using the hanging-drop 
vapor-diffusion method.  The VDX 24 well plate (Hampton Research) and 22 mm 
siliconized glass coverslides (Hampton Research) were used for crystallization.  
Micro-seeding was performed on the droplets without crystal growth after overnight 
incubation at 19 °C.  The plates were checked at intervals of 1, 2, and 4 days and 1, 2, 
and 4 weeks.  After four weeks, the plates were moved to room temperature and 
checked monthly thereafter.   
2.2.11.1.  Hanging-Drop method 
In the reservoir, 500 μL of crystallization or equilibrium solution was placed.  A 
few microliters (2 μL unless otherwise mentioned) of protein solution was mixed 
with the same amount of crystallization solution on a glass coverslide.  The glass 
slide was placed on the top of the reservoir and the plate was incubated at 19 °C.  
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2.2.11.2.  Micro-Seeding method 
Crystal seeds were prepared by crushing a harvested crystal and diluting the 
pieces to harvesting buffers.  A micro-capillary tube was used to seed the drops, 
which crystal growth had not been observed.  The tube was soaked in the seeding 
solution and placed in the center of the crystallization drop briefly.  The coverslides 
were placed back on the reservoir and the plate was incubated at 19 °C. 
2.2.12. Data Collection 
The crystals with proper sizes were used for data collection, and soaked into cryo-
protectant solutions briefly.  A cryo-loop was used to take the crystal out from the 
solution and it was mounted on the goniometer to be flash-frozen in the cryo stream.  
The crystal was centered by adjusting the position of goniometer.  Data collections 
were performed in two places, the University of Kansas (Lawrence, KS) and H. Lee 
Moffitt Cancer Center (Tampa, FL).  The equipment at the University of Kansas is a 
Raxis IV++ imaging plate (MSC) with CuKα X-rays generated by a Rigaku rotating 
anode (RU300), and focused by Osmic mirror optics (MSC) with CrystalClear 
(Rigaku, The Woodlands, TX) software.  The facility in H. Lee Moffitt Cancer Center 
is a Raxis HTC imaging plate with CuKα X-rays generated by a Rigaku rotating 
anode with Collect (Rigaku) software.  General conditions for data collection were 
following: 0.5° frame width for 180° of phi axis rotation, 100–180 mm distance, and 
2 to 10 min of exposure time.     
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2.2.13. Data Reduction and Structure Refinement 
Collected data sets were indexed and scaled with XDS134 or HKL-2000135.  The 
structures have been solved by the molecular replacement method.  Molecular 
replacements and refinements were performed with the CNS136 program package.  
Diffraction data were limited to low resolution reflections 20.0 – 4.0 Å in the cross-
rotation and translation search.  Refinements were performed using data for the 
highest resolution with no σ cut-off applied.  Several rounds of minimization, 
simulated annealing and restrained individual B factor refinement were carried out.  
The resulting electron density maps (Fo-Fc, 2Fo-Fc) were evaluated with O137.  Solvent 
molecules were added to the model at chemically reasonable positions (2.0 Å ≤ d ≤ 
3.2 Å) from other oxygen or nitrogen atom where the difference density was observed 
clearly.   
Ligand molecules, if necessary, were drawn with Sybyl 7.1 (Tripos Association, 
St. Louis, MO) or Maestro 8.0 (Schrödinger, New York, NY) and saved as the PDB 
formats.  The texts of the PDB files were edited to have proper atom names and 
hydrogen atoms were eliminated.  The edited structures were run for xplo2d 138 to 
acquire parameter and topology files.  The numbers of hydrogen atoms in topology 
files were fixed before use.  The PDB files of ligands were called on O, moved to fit 
to electron densities, and the final coordinates were saved for further refinements.  
After the final cycle of refinements, figures were prepared with Molscript139 or 
PyMol (DeLano Scientific, Palo Alto, CA). 
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2.3. E. cloacae and mutant MurA enzymes  
2.3.1.  DNA 
E. cloacae MurA was in a pET9d derived vector, with a stop codon before the C-
terminal His-tag. 
2.3.2.  Primers 
Primers for site-directed mutagenesis were synthesized by MWG Biotech AG, 
and diluted to 100 pmol/μL with dd H2O and stored at -20 °C.  
 
Arg120Ala MurA #1 5’-gcc att ggc gcg gct cct gtt gac ctg-3’ 
Arg120Ala MurA #2 5’-cag gtc aac agg agc cgc gcc aat ggc-3’ 
Lys248Asp MurA #1 5'-gcc att tct ggc ggc aac att gtt tgc cgt aat gcg-3’ 
Lys248Asp MurA #2 5'-cgc att acg gca aac aat gtt gcc gcc aga aat ggc-3’ 
Trp71Val MurA #1   5'-cgt aat ggc tcc gtc gtg atc gat gcc agc aac-3’ 
Trp71Val MurA #2   5'-gtt gct ggc atc gat cac gac gga gcc att acg-3’ 
 
2.3.3.  Site-directed Mutagenesis of E. cloacae MurA 
Site-directed mutagenesis of WT E. cloacae MurA vector was performed using 
Quik change site-directed mutagenesis kit (Stratagene). 
The mutagenesis of Asp123Ala and Arg91Lys were performed by Dr. Andreas 
Becker. 
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2.3.4.  Over-expression of WT and Mutant E. cloacae MurA Enzymes 
Large-scale over-expression was carried out using the following protocol:  an 
overnight culture was prepared in which 50 μL of the glycerol stock was added to 50 
mL of LB-kan and incubated at 37 °C overnight.  A 5 mL aliquot of the overnight 
culture was added to each of 6 flasks containing 500 mL of LB-kan and 1 drop of 
antifoam.  When the optical density measured at 600 nm (OD600) of the cell culture 
reached 0.4 – 0.8, cells were induced by adding IPTG to a final concentration of 
0.5 μM.  After induction, the cells were allowed to grow at 37 °C for 4 – 6 h with 
shaking at 250 rpm.  The cells were then harvested by centrifugation at 6,000 rpm for 
10 min using a Beckman J2-21 centrifuge.  The supernatant was discarded, and the 
cell pellets were collected and stored at   -80 °C till future use.      
2.3.5.  Purification of WT and Mutant E. cloacae MurA Enzymes 
MurA was purified using an ÄKTA FPLC and pre-packed columns (GE 
Healthcare).  The cell pellets were suspended in 8–10 mL extraction buffer (50 mM 
Tris, 1 mM DTT, 1 mM EDTA, 0.1 M NaCl, 0.1% Triton X-100, pH 8.0) / 1 g of 
cells plus 1 mg lysozyme / 1 g of cells by stirring for 1 h at 4 °C.  The solution was 
sonicated on ice for 2×30 sec and centrifuged for 30 min at 14,000 rpm using a 
Beckman J2-21 centrifuge, and then the supernatant was collected.  The combined 
supernatants were subjected to a 25 % (NH4)2SO4 precipitation for 1 h.  The amount 
of (NH4)2SO4 added for this precipitation was calculated using the following 
equation: 
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X
X
27.0100
515 L 1for  SO)(NHg 424 −= , Equation 1 
where X is the desired percentage of (NH4)2SO4.     
After the (NH4)2SO4 precipitation, the solution was centrifuged at 4 °C for 1 h at 
18,000 rpm using a Beckman J2-21 centrifuge to remove the precipitates.  The 
supernatant from this centrifugation was purified using the phenyl sepharose (P-seph) 
26/10 column (GE healthcare), a hydrophobic interaction based column.  The column 
was pre-equilibrated with Buffer A + 1 M (NH4)2SO4, the supernatant was loaded 
onto the column and the protein was eluted from the column by decreasing the salt 
concentration in the mobile phase via a gradient of Buffer A + 1 M (NH4)2SO4  to 
Buffer A over 10 column volumes (CV).  Every third fraction was evaluated on SDS-
PAGE and the results were compared with the chromatograph.  Fractions containing 
MurA were combined, desalted, and concentrated to < 50 mL using an Amicon 
ultrafiltration device with a 30 kD Millipore filter (Fisher Scientific).  Desalting was 
accomplished by adding Buffer A until the conductivity readings were below 
5 μS / cm2 on a Corning Checkmate II conductivity meter (Fisher Scientific).  The 
desalted and concentrated MurA was then loaded onto a Q-seph 26/10 column (GE 
healthcare) and eluted from the column by increasing the salt concentration in the 
mobile phase via a gradient of Buffer A to Buffer A + 0.4 M NaCl over 10 CV.  
Fractions analyzed on SDS-PAGE were combined, desalted, and concentrated in the 
same manner as for the P-seph column. 
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After the concentration, the fractions were aliquoted into micro centrifuge tubes 
and stored at -80 °C.  
2.3.6.  Kinetic analysis of WT and Mutant E. cloacae MurA Enzymes 
2.3.6.1.   High-throughput Screening (HTS) of MurA 
High-throughput screening (HTS) with about 50,000 compounds had been 
performed by Dr. Melanie A. Priestman.  Since then, 50,000 more compounds were 
purchased through the HTS facility at the University of Kansas.  These newly 
purchased compounds included compounds selected from ChemDiv (San Diego, CA) 
and natural products from MicroSource (Gaylordville, CT). 
The condition for MurA screening on a 384-well plate was varied a little from the 
previous screening.  The first trial with previously used conditions did not work very 
well due to a low signal to noise ratio.  Thus, the enzymatic reaction condition for 
HTS was modified.  Originally, the assay was performed using 60 μL reaction 
volume: 20 μL compound, 20 μL MurA (0.1 μg final reaction concentration of 2.2 
nM) in buffer (50 mM HEPES pH 7.0, 2 mM DTT, and 50 mM KCl), and 20 μL of 
the solution containing 0.3 mM PEP and 0.3 mM UNAG in buffer (final reaction 
concentration of 0.1 mM for both substrates).  The reaction solution was incubated at 
room temperature for 5 to 30 min, followed by the addition of 40 μL of Lanzetta 
reagent.  This condition was tested for the reproducibility.  Although the reaction 
showed a linear correlation with time, the OD650 of the final solution was not more 
than 0.2 after the reading of negative control was fixed to zero.  To increase the OD 
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readings, higher concentrations of MurA and both substrates, UNAG and PEP, were 
used for this enzymatic reaction.  Thus, the final condition for HTS has been changed 
to 60 μL reaction volume: 20 μL compound, 20 μL MurA (0.2 μg final reaction 
concentration of 4.4 nM) in buffer (50 mM HEPES pH 7.0, 2 mM DTT, and 50 mM 
KCl), and 20 μL of the solution containing 0.45 mM PEP and 0.45 mM UNAG in 
buffer (final concentration of 0.15 mM).  At the same time, negative control reaction 
was set up without MurA addition.  Under this condition, the linearity of the reaction 
by time has also been tested over 30 minutes, and the graph of optical density (OD) 
vs. reaction time showed a linear correlation.  
The HTS assays were performed by the addition of the above solutions to a well 
in a 384-well plate by a Biomek FX Liquid Handling Workstation.  In the 384-well 
plates, the compounds in 2.5 % DMSO had been plated and stored at -20 °C.  After 
thawing the compound solutions in the plates, each plate was centrifuged at 2,000 
rpm for 1 min.  20 μL of MurA was then added to the wells, and the reaction started 
by the addition of 20 μL of PEP and UNAG mixture.  The plates were centrifuged 
one more time after the addition of MurA and substrates, to make sure that none of 
the reaction components remained on the walls of the well.  The reaction was allowed 
to proceed for 30 min before 40 μL of the Lanzetta reagent was added.  The optical 
density was then promptly measured at 650 nm using a SpectraMax 340PC 384 
Absorbance.  Each plate had one column that had no compounds (positive control 
with no inhibition), as well as one column containing no MurA (negative control with 
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no reaction).  The reproducibility of the screening was ensured by checking negative 
and positive controls on each plate.  
IC50 determination was carried out for the compounds that initially showed 
greater than 40 % inhibition of MurA.  The compounds were picked up from mother 
plates, aliquoted to new 384 well plates. After serial dilution to vary their 
concentration, assays were carried out at the HTS facilities using procedure described 
above.  Data were fit to the equation 2 to derive IC50 values. 
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where v is the initial velocity, Vmax is the maximum velocity, Vmin is the minimum 
velocity, [I] is the concentration of inhibitor and n is the hill slope. 
2.3.6.2.  Inhibition Study of HTS Leads 
Thorough studies of HTS hits were performed by testing the activity of MurA 
with two different methods: determination of Pi concentration with Lanzetta reagent 
and by measurement of the amount of EP-UNAG using MurA–MurB coupled assay.   
HTS1-1, HTS3-1, and HTS4-1 were studied by Dr. Melanie A. Priestman.  
The modes of action of HTS2-2, HTS7-1, and HTS8-1 were thoroughly 
determined by MurA–MurB coupled assay.  The ANS fluorescence assay was 
performed for HTS2-2.  Ki values of inhibitors were determined by detecting the 
amount of product, EP-UNAG, using MurA–MurB coupled assay.   The enzyme 
reaction was performed in the following condition: 1 mL of 50 mM HEPES (pH 7.5), 
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50 mM KCl, 20 mM glucose, 20 U glucose oxidase, 1 mM PEP, 0.1 – 4 mM UNAG, 
0–20 μM inhibitor, 0.2 mM NADPH, 20 μg MurB, and 10 μg MurA.  Before the 
addition of NADPH, MurB, and MurA, the absorbance of the mixture was auto-
zeroed at 340 nm. The absorbance was fixed to between 1.1 and 1.2 OD by the 
addition of 0.2 mM NADPH.  20 μg of MurB was then added to the reaction mixture, 
and the absorbance reading was performed.  After about 30 seconds time course 
reading, the reaction was initiated by the addition of MurA.  The decrease in NADPH 
absorbance was recorded at 340 nm, and the control reaction was conducted without 
MurA at each inhibitor concentration.  Specific activity was calculated from the slope 
of the time-course curve of each reaction.  The data were fit to equation 3 (the 
Michaelis-Menten equation): 
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where v is the initial velocity, Vmax(obs) is the observed maximum velocity, Km(obs) is 
the observed Michaelis constant, and [S] is the substrate concentration.   
The Ki values were determined by linear regression of the replot of the Km(obs) 
values versus the concentration of the inhibitor and the data were fit to equation 4.  
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Then, the K'i values were determined by linear regression of the replot of the 
1/Vmax(obs) values versus the concentration of the inhibitor and the data were fit to 
equation 5. 
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where Vmax(obs) is the observed maximum velocity, K'i is the inhibitor constant with 
respect to Vmax, Vmax is the true maximum velocity, and [I] is the inhibitor 
concentration. 
The dissociation constant of HTS2-2 was measured by fluorescence experiments 
with ANS.  Fluorescence was detected with Varian Cary Eclipse fluorescence 
spectrometer.  The buffer used for all measurements was 50 mM sodium/potassium 
phosphate (pH 6.9) with 2 mM DTT with a final concentration of 125 μg/mL MurA.  
Fluorescence of ANS was excited at 366 nm, and emission spectra were recorded 
between 400 and 600 nm.  The buffer in the quartz cuvette was used for auto-zero, 
then 100 μM ANS was added and scanned.  After the addition of MurA into the 
solution, the emission spectrum was read again.  Various concentrations of HTS2-2 
(2.5 – 100 μM) were then mixed in the solution and the fluorescence recorded.  For 
the data evaluation, ANS emission spectra in buffer were subtracted from the 
corresponding ANS/MurA or ANS/MurA/HTS2-2 spectra, thereby giving the 
fluorescence intensities as a function of the UNAG concentrations.  The highest 
points of the emission spectra were selected in between 470 and 480 nm and the 
intensities were read.  Then, 1–FL/FO (where FL is the intensity when a ligand is 
added and FO is the intensity without the ligand) was calculated and the graph, 1–
FL/FO vs. [HTS2-2], was fitted to the Michaelis-Menten equation to derive Kd value 
for HTS2-2. 
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2.3.6.3.  Structure-Activity Relationships (SAR) of HTS 1 and HTS 2 on WT 
MurA 
Compounds with HTS 1 and HTS 2 scaffolds were purchased from IBS 
(InterBioScreen, Moscow, Russia), ChemBridge, and ChemDiv to study structure-
activity relationships (SAR) for WT E. cloacae MurA.  Purchased compounds were 
dissolved in 100 % DMSO at 100 mM concentration.  Inhibitory activity of the 
compounds was tested by detecting the amount of Pi produced by MurA enzyme 
reaction.  Assays were performed in 100 μL of 50 mM HEPES, 2mM DTT, 1mM 
PEP, 1 mM UNAG, and 1 mM final concentration of each compound.  By the 
addition of 22nM of WT MurA, the enzyme reactions were started.  Reactions were 
incubated for 3 min at room temperature and stopped by the addition of 800 μL of 
Lanzetta reagent.  After an additional 5 min for color development, 100 μL of 34 % 
(w/v) sodium citrate was added to stop the color change.  The absorbance was then 
measured at 660 nm with Shimazu UV-1650PC spectrometer.  A negative control 
reaction was performed without MurA to eliminate the auto-hydrolysis effect of PEP, 
and a positive control reaction was carried out without inhibitor.  The inhibition 
activity was recorded as relative activity against the positive control.  For the HTS 2 
scaffold compounds, the activity was measured daily until the inhibition was 
observed up to 2 weeks. 
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2.3.6.4.  Inhibition study of known inhibitors  
Peptide inhibitor, HESFWYLPHQSY, was synthesized at the University of 
Kansas Structural Biology Center.  The activity of this peptide was tested by 
detecting the amount of Pi produced by MurA enzyme reaction.  Assays were 
performed in 100 μL of 50 mM HEPES, 2mM DTT, 1mM PEP, 1 mM UNAG, and 1 
mM final concentration of the peptide.  The reaction condition was the same as the 
reactions of HTS 1 and 2 compounds, described in the section 2.3.6.3. 
   The inhibition activity of cnicin was determined by MurA–MurB coupled assay.  
The inhibitor was incubated with MurA and with or without UNAG (0, 0.01, and 
1 mM) for various times (0–10 min).  In the incubation mixture, 10 μg of MurA was 
used at various concentration of cnicin (0–10 mM) in a volume of 25 μL at room 
temperature.  The reaction mixture contained 50 mM HEPES (pH 7.5), 50 mM KCl, 
20 mM glucose, 20 U glucose oxidase, 1 mM PEP, and 1, 0.99, or 0 mM UNAG in 
945 μL of total volume.  Before the addition of NADPH, MurB, and the incubation 
mixture, the absorbance of the mixture was auto-zeroed at 340 nm.  The absorbance 
was fixed to between 1.1 and 1.2 OD by the addition of 0.2 mM NADPH (10 μL of 
20 mM stock solution).  20 μg of MurB (a volume of 20 μL) was then added to the 
reaction mixture, and the absorbance reading was performed.  After about 30 seconds 
time course reading, the reaction was initiated by the addition of the incubated 
solution (MurA + cnicin ± UNAG).  The decrease in NADPH absorbance was 
recorded at 340 nm.  Specific activity was calculated from the slope on time-course 
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curve of each reaction.  The graph of specific activity vs. incubation time (sec) were 
plotted at various inhibitor concentrations and fitted to equation 6, 
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where A is enzyme activity, k' is the rate constant at equilibrium, and F1 and F2 are 
the fractions of activity at zero time (F1=1) and infinite time (after equilibrium has 
been established, F2).   
Determined k' values at various inhibition concentrations were used to determine 
Ki of cnicin.  The graph of k' vs. [inhibitor] were plotted and fitted to the equation 7, 
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The Ki value was calculated using the values of k1 and k–1 fitted to the equation 8, 
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2.3.6.5.  WT, Asp123Ala, and Arg91Lys E. cloacae MurA  
The activity of MurA was measured using an end-point assay in 100 μL of 
50 mM HEPES (pH 7.5) and 2 mM DTT at room temperature by determining the 
amount of Pi produced in the reaction for primary test.  The final concentrations of 
WT, Asp123Ala, and Arg91Lys MurA were 0.025, 0.025, and 1.7 mg/mL, 
respectively.  Assays were performed with a final concentration of 1 mM PEP and 
varied concentrations of UNAG (0.010–10 mM).  Every reaction was started with the 
addition of MurA.  The reactions were allowed for 3 min prior to the addition of 
800 μL of Lanzetta reagent to stop the reactions and develop the color change by Pi.  
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After additional 5 min, 100 μL of 34 % (w/v) sodium citrate was added to stop the 
color change.  The absorbance was measured at 660 nm with Shimazu UV-1650PC 
spectrometer and the amount of Pi was determined in comparison with phosphate 
standards, and the enzyme activity was expressed as U/mg.  Control reactions were 
used without MurA as blanks to eliminate the auto-hydrolysis effect of PEP.  The 
approximate values of Km and Vmax were determined by fitting the kinetic data to the 
Michaelis-Menten equation (equation 3).  The Km and Vmax values from Lanzetta 
assay were used to determine the range of the concentrations of substrates for MurA–
MurB coupled assays. 
For thorough characterizations, MurA–MurB coupled assays were performed for 
WT, Asp123Ala, and Arg91Lys MurA.  The activities of these MurAs were tested in 
950 μL of 50 mM HEPES (pH 7.5) + 2 mM DTT + 50 mM KCl with 20 mM glucose 
and 20 U GOX at room temperature.  The final concentration of one substrate was 
varied from 0.01 to 5 mM when the other was fixed to 1 mM.  After the addition of 
PEP and UNAG, the absorbance of the mixture was auto-zeroed at 340 nm.  The 
absorbance was fixed to between 1.1 and 1.2 OD by the addition of 0.2 mM NADPH.  
Then, the final concentration of 0.02 mg/mL of MurB was added to the reaction 
mixture, and the absorbance reading was started.  After about 30 seconds time course 
reading, the reaction was started by the addition of MurA.  The final MurA 
concentrations were 0.01 mg/mL for both WT and Asp123Ala MurA, and 
0.68 mg/mL for Arg91Lys.  The absorbance was recorded until no more NADPH 
consumption was detected.  Specific activities of each of the reactions were 
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determined, based on initial slopes of each time course curve.  The graph of specific 
activity vs. [substrate] was plotted and fitted to equation 3 to derive Km values of each 
substrate. 
The inhibition study by fosfomycin was performed for WT and Asp123Ala MurA 
using Lanzetta assay.  The assay was performed in 100 μL of 50 mM HEPES 
(pH 7.5) + 2 mM DTT.  Concentrations of fosfomycin varied from 20 nM to 200 μM 
were incubated in buffer with 0.025 mg/mL WT or Asp123Ala MurA and 1 mM 
UNAG at room temperature for 5 min.  The reaction was initiated by the addition of 
1 mM PEP to the mixture and was allowed to proceed for 3 min at room temperature 
before 800 μL Lanzetta reagent was added to the solution.  After 5 min of color 
development, 100 μL of 34 % (w/v) sodium citrate solution was added and the 
absorbance was measured at 660 nm.  Negative and positive controls were carried out 
without enzyme and without fosfomycin, respectively.  IC50 values were derived from 
equation 2.  
Before the ANS fluorescence assay, WT, Asp123Ala and Arg91Lys MurA 
enzymes in the HEPES buffer (50 mM HEPES (pH 7.5) + 2 mM DTT) were 
incubated with 0.5 mM UNAG for 1 hour at room temperature.  The UNAG in the 
solution was then removed by PD-10 with 50 mM HEPES (pH 7.5) + 2 mM DTT.   
Each enzyme concentration was measured with Bradford assay. 
Fluorescence experiments were performed using Varian Cary Eclipse 
fluorescence spectrometer.  The buffer used for all measurements was 50 mM 
sodium/potassium phosphate (pH 6.9) with 2 mM DTT.  The final concentration of 
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MurA enzymes was 125 μg/mL.  Fluorescence of ANS was excited at 366 nm, and 
emission spectra were recorded between 400 and 600 nm.  The buffer in the quartz 
cuvette was used for auto-zero, then 100 μM ANS was added and scanned.  After the 
addition of MurA into the solution, the emission spectrum was scanned. Various 
concentrations of UNAG (5 – 500 μM) were added to the solution and the emission 
spectra were measured once again.  For the data evaluation, ANS emission spectra in 
buffer were subtracted from the corresponding ANS/MurA or ANS/MurA/UNAG 
spectra, thereby giving the fluorescence intensities as a function of the UNAG 
concentrations.  The highest points of the emission spectra were selected in between 
470 and 480 nm and the intensities were read.  Then, the 1–FL/FO was calculated and 
the graph, 1–FL/FO vs. [UNAG], was fitted to the Michaelis-Menten equation to 
derive UNAG Kd values.   
2.3.6.6.  Arg120Ala E. cloacae MurA 
The activity test of Arg120Ala MurA was performed with His-tagged enzyme to 
eliminate the effect of genomic E. coli MurA.  His-tagged Arg120Ala MurA was 
prepared by Martha L. Healy-Fried.  
To determine if Arg120Ala MurA is capable of catalyzing the conversion of 
UNAG and PEP to EP-UNAG and Pi, but is unable to release the products (i.e. a 
single-turnover), urea was used to establish if the trapped products could be detected 
after denaturation of the enzyme•ligand complex.  This was performed by incubating 
a reaction mixture containing 50 mM Tris (pH 8.0), 50 mM KCl, 2 mM DTT, 5 mM 
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UNAG, 5mM PEP, and 40 mg/mL His-tagged Arg120Ala MurA (0.9 mM), in a final 
volume of 400 μL at room temperature for 5 min.  To stop the reaction and denature 
Arg120Ala MurA, a final concentration of 6.0 M urea was added and incubated at 
4 ˚C for 16 hr.  To measure the product EP-UNAG, the coupled assays with 50 mM 
Tris (pH 8.0), 50 mM KCl, 2 mM DTT, 20 mM glucose, 20 U glucose oxidase, 
0.20 mM NADPH, and various concentrations of the denaturation mixture (0.4–
2.9 mg / 0.01–0.07 mM), were employed.  An OD340 reading was stabilized prior to 
the start of the reaction by the addition of 40 μg of MurB, and the decrease in 
NADPH absorbance was recorded.  Control experiments were conducted throughout 
with Arg120Ala MurA treated in the same way, but omitting PEP during the assay. 
2.3.6.7.  Cys115Asp E. cloacae MurA 
MurA–MurB coupled assays were performed to determine PEP Km for 
Cys115Asp MurA.  The activity of Cys115Asp MurA was tested in 950 μL of 50 mM 
HEPES (pH 7.5) + 2 mM DTT + 50 mM KCl with 20 mM glucose and 20 U GOX at 
room temperature.  The final concentration of UNAG was 1 mM and PEP was varied 
from 1 to 500 μM.  After the addition of PEP and UNAG, the absorbance of the 
mixture was auto-zeroed at 340 nm.  The absorbance was then fixed to between 1.1 
and 1.2 OD340 by the addition of 0.2 mM NADPH.  The final concentration of 
0.02 mg/mL of MurB was added to the reaction mixture, and the absorbance reading 
was started.  After about 30 seconds time course reading, the reaction was started by 
the addition of Cys115Asp MurA.  The final concentration of Cys115Asp MurA was 
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0.01 mg/mL.  The reading was recorded until time course curve was observed to be 
flat.  Specific activities of each reaction were calculated from the slope of respective 
time course curve.  The graph of specific activity vs. [PEP] was plotted and fitted to 
Michaelis-Menten equation to determine PEP Km value of Cys115Asp MurA. 
Fluorescence assay with ANS was applied to determine Kd value of UNAG for 
Cys115Asp MurA.  The buffer used for this assay was 50 mM sodium/potassium 
phosphate (pH 6.9) with 2 mM DTT.  The final concentration of Cys115Asp MurA 
enzyme was 125 μg/mL.  The excitation wavelength of ANS was 366 nm, and 
emission spectra were recorded between 400 and 600 nm.  Buffer in the quartz 
cuvette was used for auto-zero, and 100 μM ANS was added and scanned.  After the 
addition of MurA into the solution, the scanning was done again, then various 
concentrations of UNAG (5 – 1000 μM) were added to the solution and the 
fluorescence measured.  For the data evaluation, ANS emission spectra in buffer were 
subtracted from the corresponding ANS/MurA or ANS/MurA/UNAG spectra, 
thereby giving the fluorescence intensities as a function of the UNAG concentrations.  
The highest points of the emission spectra were selected in between 470 and 480 nm 
and the intensities were read.  Then, the 1–FL/FO was calculated and the graph, 1–
FL/FO vs. [UNAG], was fitted to Michaelis-Menten equation to derive UNAG Kd 
values.   
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2.3.7. Crystallization of E. cloacae MurA Enzymes 
2.3.7.1.   Asp123Ala and Arg91Lys MurA 
The crystallization of open forms of Asp123Ala MurA was attempted with 
PEG20K conditions (Table 8).  Three microliters of Asp123Ala MurA (3.5 mg/mL) 
in HEPES buffer (50 mM HEPES (pH 7.5) + 2 mM DTT) was mixed to 3 μL of 
crystallization solutions.  500 μL of 0.5 M MES (pH 6.1) was added to the reservoir.  
Crystals were obtained after overnight incubation at 19 °C.  Crystals from PEG20K-
11 condition were harvested in 200 mM MES (pH 6.1) + 12.5 % PEG20K.  The 
harvested crystal was soaked into the cyro-protectant solution (200 mM MES (pH 
6.1) + 12.5 % PEG20K + 25 % glycerol) prior to data collection.  Data collection was 
accomplished at the Structural Biology Center of the University of Kansas. 
The open form crystal of Arg91Lys MurA was setup with PEG20K conditions.  
Three microliters of Arg91Lys MurA (75 mg/mL) in HEPES buffer (50 mM HEPES 
(pH 7.5) + 2 mM DTT) was mixed with 3 μL of crystallization solutions.  In the 
reservoir, 500 μL of 0.5 M MES (pH 6.1) was added.  The crystal growth was not 
detected after 24 hour incubation at 19 °C.  Thus, microseeding method with a 
harvested Asp123Ala MurA crystal from the previous experiment was applied to the 
drops.  The crystals in PEG20K-1 condition were formed after seeding and harvested 
on the next day.  Harvesting buffer was composed with 50 mM MES (pH 6.1) and 
12.5 % PEG20K.  The harvested crystal was transferred to the cryo-protectant 
solution (50 mM MES (pH 6.1) + 12.5 % PEG20K + 25 % glycerol).  After a brief 
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soaking, the crystal was mounted on goniometer for data collection.  This crystal was 
measured at the Structural Biology Center of the University of Kansas.  
2.3.7.2.   Arg120Ala MurA 
The crystallization of the closed form of Arg120Ala MurA was attempted with 
the variations of Hampton 1-41 condition (Table 9).  Two microliters of the mixture 
of 84 mg/mL of Arg120Ala MurA in Tris buffer (50 mM Tris, pH 8.5, 2mM DTT, 
and 1 mM EDTA) with 10 mM UNAG and 10 mM PEP was added to 2 μL of 
reservoir solution (H4-41-8 in Table 9). The crystal grew to a good size after the 
incubation for 3 days.  
The harvesting conditions for this crystal could not be optimized due to the 
fragility of the crystal.  Thus, the crystal was directly soaked into the cryo-protectant 
solution (20 % ethylene glycol, 0.1 M HEPES (pH 7.5), 25 % PEG4000, 1 mM 
UNAG, and 1 mM PEP).  After the brief soaking in the cryo-protectant solution, the 
crystal was flash-frozen in the cryo stream.  Data collection was performed at the 
University of Kansas Structural Biology Center.   
2.3.7.3.   Cys115Asp MurA 
The crystallization of the open form Cys115Asp MurA was attempted with the 
variations of PEG20K condition (Table 8).  Three microliters of 33 mg/mL of 
Cys115Asp MurA in phosphate buffer (50 mM Na/K phosphate (pH 6.9), 2mM DTT) 
was mixed with 2 μL of crystallization solution (PEG20K-3).  500 μL of 0.5 M MES 
(pH 6.1) was placed in the reservoir.  Crystal growth was observed instantly, and 
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reached to a proper size in one hour.  The crystal was soaked into the cryo protectant 
solution (25 mM MES (pH 6.1), 8% PEG20K, and 25 % glycerol).  The crystal on a 
cryo-loop was then transferred to the goniometer and flash-frozen in the cryo stream.  
Data collection was performed at H. Lee Moffitt Cancer Center. 
2.3.7.4.   MurA with HTS2-2 
Initial crystallization screening of MurA with HTS2-2 was performed with 
Hampton 1 and 2 and Wizard 1 and 2 screens.  Highly concentrated WT MurA was 
prepared in 50 mM HEPES (pH 7.5) + 2 mM DTT.  MurA was diluted to 25 mg/mL 
and 50 mg/mL and prepared for crystallization by mixing with 10 mM of HTS2-2 
(from a 100 mM stock solution in DMSO).  Small crystals were found in H1-18 
(0.1 M Na cacodylate (pH 6.5), 0.1 M magnesium acetate, and 20 % PEG8000) 
condition at 50 mg/mL MurA concentration.  To get an optimized crystal for the data 
collection, H1-18 condition was varied on pH and the concentration of buffer, salt, 
and precipitant as well as the concentration of MurA (Table 7).  The Na cacodylate 
(buffer) was varied from 0.05 to 0.2 M with pH from 6.0 to 7.0, the concentration of 
Mg(OAc)2 was increased up to 0.4 M, and PEG8000 was changed from 20 % to 
15 %.  New drops were setup with varied H1-18 conditions at 60 mg/mL and 
100 mg/mL MurA concentration.  The largest crystals were formed at H1-18-15 
(0.1 M Na cacodylate (pH 7.0), 0.1 M magnesium acetate, 15 % PEG8000), and 
harvested in the solution of 0.05 M Mg(OAc)2, 0.05 M Na cacodylate (pH 7.0), and 
15 % PEG8000.  The data collection was performed at the Structural Biology Center 
of the University of Kansas. 
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2.3.7.5.   MurA with HTS1-1 
HTS1-1 (1 mM of final concentration) was incubated with WT MurA (10 mg/mL 
in 50 mM HEPES and 2 mM DTT) at room temperature for 2 hours.  Incubated 
solution with the inhibitor was applied to PD-10 for buffer exchange into 50 mM 
HEPES, 2 mM DTT for the removal of DMSO.  The eluted protein solution still had 
orange color from HTS1-1, indicating that the inhibitor bound to protein even after 
the buffer exchange, and it was concentrated up to 65 mg/mL with a Centricon YM-
30 device.  
The crystallization of WT MurA with HTS1-1 in 50 mM HEPES and 2 mM DTT 
was screened with Hampton 1 and 2, and Wizard 1 and 2 screening solutions.  Plate 
shaped crystals were found in H1-41 condition (0.1 M HEPES (pH 7.5), 10 % 
2-propanol, and 20 % PEG4000) after the incubation at 19 °C for a month.  The 
crystal setup with the same protein was performed with the various H1-41 conditions 
(Table 9).  The best crystals were detected in the H1-41-8 and H1-41-19 conditions.  
Since these crystals were very unstable, no harvesting condition could be identified.  
The crystals were transferred to cryo-protectant solutions including glycerol, ethylene 
glycol, MPD, PEG200, PEG400, sucrose, or xylitol.  Most of the crystals dissolved in 
these cryo-protectant solutions, hense no harvesting conditions could be identified.  
Although some crystals survived in the cryo-protectant solutions for a short time, 
none of them diffracted well. 
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2.3.8. Further Studies with HTS2-2 
2.3.8.1.  Kinetic Study of Trp71Val and Lys248Asp MurA 
Mutation and purification of Trp71Val and Lys248Asp were accomplished to 
investigate the effects of HTS2-2 on WT MurA.  
The Km value of UNAG was measured in 100 μL of 50 mM HEPES (pH 8.0) + 
2 mM DTT at room temperature using the Lanzetta assay.  The final concentration of 
both Trp71Val and Lys248Asp MurA was 220 nM.  Assays were performed with a 
final concentration of 1 mM PEP and various concentrations of UNAG (0.025–
5 mM).  All assays were started with the addition of MurA.  The enzyme and 
substrates were allowed to react for 3 min prior to the quenching of the reaction with 
800 μL of the Lanzetta reagent.  After an additional 5 min, 100 μL of 34 % (w/v) 
sodium citrate was added to stop the color development by inorganic phosphate.  The 
absorbance was then measured at 660 nm and the amount of Pi was determined by 
comparison with phosphate standards.  Enzyme activity was expressed as U/mg.  
Control samples without MurA were used as an auto-zero to eliminate an increase in 
the absorbance due to hydrolysis of Pi from PEP.  The Km values were determined by 
fitting the kinetic data to the Michaelis-Menten equation.  
Inhibitory activities of HTS2-2 against Trp71Val and Lys248Asp mutant MurAs 
were measured using the same way of UNAG Km determination.  The final 
concentrations of PEP and UNAG were 0.5 mM each, and the concentration of 
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HTS2-2 was varied from 5 to 500 μM.  The IC50 values were determined by fitting 
the data to equation 2. 
2.3.8.2.  MurA Oligomerization by HTS2-2 
Superdex 75 column (GE Healthcare) on ÄKTA FPLC was used to identify the 
oligomerization effect of HTS2-2 on WT MurA.  Prior to the experiment, the column 
was calibrated with standards.  Blue Dextran 200 (GE Healthcare) was diluted to 1 
mg/mL in 50 mM HEPES and 2 mM DTT, and loaded to measure the void volume of 
the column, then the mixture of ribonuclease A (MW: 13700), chymotrypsinogen A 
(MW: 25000), ovalbumin (MW: 43000), and albumin (MW: 67000) was loaded.  Kav 
(gel-phase distribution coefficient, equation 9) values for each protein were calculated 
and Kav vs. log MW graph was plotted.  
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where V0, Ve, and Vc represent void volume, elution volume, and geometric column 
volume, respectively. 
One milliliter of WT MurA (15 mg/mL) in 50 mM HEPES + 2 mM DTT with 
10 mM HTS2-2 in DMSO was loaded to the column at flow rate of 0.5 mL/min.  One 
CV of 50 mM HEPES + 2 mM DTT solution was eluted with the same flow rate.  
The molecular weight that each peak represents was calculated from the calibration 
curves. 
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2.4. Cyclin-Dependent Kinase 2 
2.4.1. DNA 
Recombinant GST fusion human CDK2 (GST-hCDK2) plasmid in pGEX6p1 
vector was prepared by Katinka Bahr. 
2.4.2. Over-expression of CDK2 
The GST-hCDK2 plasmid was transformed to RIL E. coli competent cell and 
glycerol stock was prepared.  An overnight culture was prepared in which 50 μL of 
the glycerol stock was added to 50 mL LB with 0.1 mg/mL ampilcillin (amp) and 
incubated at 37 °C overnight.  A 5 mL aliquot of the overnight culture was added to 
each of 6 flasks containing 500 mL each of LB-amp and 1 drop of antifoam.  When 
the OD600 reached 0.4–0.6, the temperature of the incubator was lowered to 16 °C.  
When the temperature was stabilized, cells were induced with 0.01mM IPTG.  After 
24 hr culture at 16 °C, cells were centrifuged at 6,000 rpm for 10 min using a 
Beckman J2-21 centrifuge.  The supernatant was discarded, and the cell pellets 
collected, combined, and frozen at   -80 °C.    
2.4.3. Purification of CDK2 
CDK2 was purified at 4 °C using an ÄKTA FPLC (GE Healthcare).  The cell 
pellets were resuspended with lysis buffer: 50 mM HEPES (pH 7.5), 150 mM NaCl, 
1 mM EGTA, 10 mM MgCl2, 2mM DTT, and 1 mg lysozyme/1 g of cell.  After 
2×30s sonications, the lysate was clarified by centrifugation.  The GST-affinity 
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column was pre-equilibrated with Buffer A (CDK2-GST 1), the supernatant was 
loaded onto the column and the protein was eluted from the column by increasing the 
glutathione (reduced) concentration from Buffer A (CDK2-GST 1) to Buffer A 
(CDK2-GST 1) + glutathione (10 mM glutathione included).  Fractions 
corresponding to the peak were run for SDS-PAGE and the results were compared 
with the chromatograph.  Fractions containing GST-hCDK2 were combined, and 
GST-prescission protease (20:1 ratio) was added to the solution to cleave GST.  
During the GST cleavage reaction, the buffer was exchanged to Buffer A (CDK2-
GST 2) and total volume was decreased to 150 mL.  The sample was loaded to the 
second GST column eluting from Buffer A (CDK2-GST 2) to Buffer A (CDK2-
GST 2) + glutathione to remove cleaved GST-tag and GST-prescission.  The fractions 
corresponding to flow-through were run for SDS-PAGE and combined.  The 
combined CDK2 was concentrated until the total volume was less than 15 mL.  The 
solution was further purified with Superdex 200 column to eliminate aggregated 
CDK2.  The size exclusion column was eluted with Buffer A (CDK2-GST 2) for 
1 CV.  The fractions corresponding to the peak of monomeric CDK2 (Ve ~ 240 mL) 
were run for SDS-PAGE, then combined and concentrated.  The buffer of highly 
purified CDK2 was exchanged to 100 mM sodium/potassium phosphate (pH 6.2) 
with 2 mM DTT using a PD-10 column, and concentrated to about 10 mg/mL with a 
Centricon YM-10 device.  
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2.4.4. Crystallization of CDK2 with inhibitors 
The co-crystals of CDK2-inhibitor were grown by vapor diffusion using the 
hanging drop method.  Two microliters of 10 mg/mL CDK2 in phosphate buffer (100 
mM Na/K phosphate (pH 6.2) + 2 mM DTT) was added to 2 μL of reservoir solution 
(0.1 M HEPES (pH 7.5) and 10 % PEG3350).  The final concentration of inhibitors 
was 1.5 mM in the drops.  Crystals were formed after 1–2 days at 19 °C.  
The crystals were immersed briefly in the cryo protectant solution, 50 mM 
HEPES (pH 7.5), 50 mM Na/K phosphate (pH 6.2), 15 % PEG3350, 0.5 mM 
inhibitor, and 22 % ethylene glycol, and then flash-frozen in the cryo stream.  
Complete diffraction data were collected at the Structural Biology Center of the 
University of Kansas or at H. Lee Moffitt Cancer Center.  Data reduction and scaling 
were performed with XDS or HKL-2000.  Molecular replacement and refinement 
were performed with the CNS program package.  1HCK (PDB ID) was used as the 
model structure for the molecular replacement.   
2.4.5. Molecular docking of CDK2 
Glide 4.5140, which is a part of Maestro 8.0, was used in molecular docking 
studies. The PDB files of co-crystallized CDK2 structures were used for molecular 
docking after inhibitor molecules and alternative conformations had been removed.  
All water molecules were removed and hydrogen atoms were generated by the 
Protein Preparation Wizard.  The structures of ligands were built and their ionization 
states, tautomers and ring conformations were varied with LigPrep in Maestro.  The 
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receptor grid box with 8.0 Å on each side was generated at the ATP binding site of 
CDK2, and the constraints of the key hydrogen bonds, i.e. the carbonyl oxygen of 
Glu81 and Leu83 as hydrogen bond acceptors, and the backbone nitrogen of Leu83 as 
a hydrogen bond donor, were included in the grid file.  The prepared ligands were 
docked into CDK2 using the prepared grid file with the extra precision (XP) mode.  
The default values for energy-minimization, scaling of van der Waals radii, and 
output settings were maintained.  The outputs were saved as the Maestro-format pose 
viewer files (.mae).  The pose viewer files were opened with the Glide Pose Viewer 
panel.  The CDK2 structure was displayed with docked structures, and the ligand files 
with good contacts were saved for figures.  The figures were prepared with PyMol. 
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3. Results and Discussion 
3.1. Structure and Mechanism of MurA 
MurA catalyzes the transfer of the enolpyruvyl moiety of phosphoenolpyruvate 
(PEP) to the 3'-OH group of UDP-N-acetyl-glucosamine (UNAG), producing 
enolpyruvyl-UDP-N-acetyl-glucosamine (EP-UNAG) and inorganic phosphate (Pi).  
In this enzymatic reaction, the C-O bond of PEP is cleaved rather than the P-O bond, 
which is normally favored in most chemical reactions ofo PEP and in other PEP-
utilizing enzyme reactions.  Due to this chemically unfavorable enzyme reaction by 
MurA, there have been many studies of the enzymatic mechanism of MurA.  
The enzyme undergoes a large conformational change upon UNAG binding in the 
active site before PEP binds to its binding site.  The structures of both conformational 
states, open and closed, were revealed by crystallography.  This induced-fit 
mechanism is the structural proof to the ordered substrate binding mode assessed for 
the enolpyruvyl transfer reaction in which UNAG interacts with the free enzyme prior 
to the binding of PEP. 
3.1.1. The Role of Arg91 and Asp123 in E. cloacae MurA 
Site-directed mutagenesis and protein purification were performed by Dr. Andreas 
Becker.  Kinetic analysis and crystallization were accomplished by Huijong Han.  
Structure refinement was done by Prof. Ernst Schönbrunn and Huijong Han.  
Arg91 is located close to the loop of MurA and conserved through most species of 
MurA30.  Thus, it was thought that Arg91 is one of the crucial residues in the 
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regulating the loop conformational change of the MurA reaction.  The structural and 
kinetic studies of Arg91Lys MurA were performed to evaluate the function of Arg91 
in the conformational change and the enzymatic activity of MurA.   
The mutation of Arg91 to Lys resulted in complete loss of the enzymatic activity 
(data not shown).  The fluorescence study with ANS suggested that the inactivity of 
this mutant is due to the loss of 
the conformational changes 
required for catalysis.  Even at 
high concentrations of UNAG 
(up to 2.5 mM) almost no 
change in the emission spectra 
of ANS was observed, 
implying that the open form 
state of the mutant MurA with 
ANS was not affected by the 
presence of UNAG (Figure 23).  This infers that Arg91 is an essential residue for the 
open-closed conformational changes.   
Further studies of the mutant enzyme were performed by crystallography.  The 
un-liganded structure, the open form, of Arg91Lys E. cloacae MurA was solved to 
2.0 Å resolution.  The conformation of the mutant enzyme was the same as WT 
MurA including the conformation of the flexible large loop (Figure 24A).  The only 
 
 
Figure 23. Emission spectra of ANS study with 
Arg91Lys mutant MurA.  The spectra were 
measured at various UNAG concentration 
but almost no change was observed even at 
very high concentration of UNAG (2.5 mM). 
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       (A)                                                                     (B) 
 
       (C)                                                                     (D) 
 
Figure 24.  (A) Overlap figure of overall structures of WT (dark blue) and Arg91Lys (light 
blue) MurAs. The loops (Pro112 – Pro121) are represented with red (WT) and green 
(Arg91Lys) colors.   
(B) Overlap figure of position 91 of WT (dark blue) and Arg91Lys (light blue) 
MurAs. Arg91 of WT is shown as a pink colored residue, and Lys 91 of mutant 
enzyme is a green colored residue. 
(C) Interactions of Arg91 in the open form WT MurA. Arg91 is shown as pink 
colored sticks. Arg91 has hydrogen bonds (red dashed lines) with Gly113 directly 
and with Val87, Lys88 and Gly114 through water molecules (cyan colored spheres) 
in the open form of WT MurA. 
(D) Interactions of Lys91 in the open form Arg91Lys MurA. Lys91 is shown as 
green colored sticks. Lys91 has hydrogen bonds (red dashed lines) with Gly114 
directly and with Gly113 through a water molecule (cyan colored sphere) in the open 
status of Arg91Lys mutant MurA. 
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difference between the mutant and WT MurA was the side chains of arginine and 
lysine at the 91 position (Figure 24B):  The guanidinium group of Arg91 in WT 
MurA has hydrogen bonds with the backbone carbonyl oxygen atom of Gly113 and 
three water molecules, and the water molecules form hydrogen bonds with backbone 
carbonyls of Val87, Lys88 and Gly114 (Figure 24C).  The side chain of Lys91 has 
hydrogen bonds with the backbone carbonyl of Gly114 and a water molecule 
interacting with the backbone carbonyl oxygen of Gly113 (Figure 24D).  Except for 
the difference in the conformation and hydrogen bond interactions of side chains 
between Arg91 and Lys91, the backbone conformations of each structure are the 
same.  This suggests that the mutation of Arg91 to Lys does not affect the open status 
of MurA. 
The role of Arg91 was analyzed based on the binary structure, the closed form, of 
WT MurA because the closed form of the Arg91Lys mutant enzyme does not form..  
It was shown 
that the multiple 
hydrogen bond 
donors of the 
guanidinium 
group of 
arginine are 
required to hold 
the loop in the 
 
Figure 25.  A stereoview of the loop region of the binary structure of 
WT MurA.  The side chain of Arg91 has hydrogen bonds (red 
dashed lines) with Gly113 and Arg120 located on the flexible 
loop (purple color) in the closed form of WT MurA with 
UNAG (yellow).  
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closed status (Figure 25):  The side chain of Arg91 has hydrogen bonds with the 
backbone carbonyl oxygen atoms of Gly113 and Arg129.  Although Lys91 of the 
mutant enzyme has a hydrogen bond donor, one amine group is not enough to keep 
the hydrogen bonds with two residues as strong as a guanidinium group.  Also, the 
side chain of Lys is shorter than of Arg and cannot reach to the acceptor residues.  
These hydrogen bonds are possibly key interactions at abilizing the closed form of the 
loop. 
 The location of Asp123 on MurA is close to the loop, and Asp123 is found in 
87.1 % of 163 known MurA forms30.  The only observed variation of this residue is 
Gln.  In order to evaluate the function of Asp123 in MurA, kinetic and structural 
studies of the mutant MurA, Asp123Ala, were performed.   
Compared to E. cloacae WT MurA, the Asp123Ala mutant enzyme has similar 
(A)             (B) 
 
 
Figure 26.  (A) Determination of Km and Vmax of UNAG for WT (○) and Asp123Ala (●) 
MurAs.  
Vmax was measured to 2.04±0.03 U/mg and Km was 64.94±4.23 μM for WT MurA.  
Vmax was 1.98±0.08 U/mg and Km was 871.41±92.65 μM for Asp123Ala MurA. 
 (B) Determination of Kd of UNAG for WT (○) and Asp123Ala (●) MurAs. 
Kd values were measured to 72.9±6.7 μM for WT, and 517.8±53.4 μM for 
Asp123Ala MurA. 
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full enzymatic activity but lower UNAG affinity, showing similar Vmax and higher Km 
values for UNAG.  The values are 1.98 U/mg of Vmax(UNAG) and 0.87 mM of 
Km(UNAG) (Figure 26A).  The ANS study of Asp123Ala mutant enzyme also 
indicates the binding affinity of UNAG is significantly lower than WT (Figure 26B), 
i.e. the derived dissociation constant (Kd) of UNAG for Asp123Ala mutant is 7 times 
higher than for WT.  Thus, it is assumed that Asp123 is involved in the enzymatic 
activity by alternating the binding affinity of UNAG to MurA.  
The un-liganded structure, the open status of Asp123Ala mutant MurA was 
solved to 2.35 Å resolution with two monomers in one unit cell.  The two monomers 
show different 
conformations of 
the loop structure, 
i.e. the loop struc-
ture of the mono-
mer A adopts a 
partial α-helix 
while the loop of 
monomer B does 
not have any 
distinct secondary 
structure.  The 
variation of the 
(A)                                                    (B) 
 
Figure 27. (A) Overlapped structures of WT (dark blue) and 
monomer A of Asp123Ala (light blue) MurA.  
  (B) Overlapped structures  of WT (dark blue) and 
monomer B of Asp123Ala (light blue) MurA.  
The loop conformations of the two monomers are different. 
See the text for details. The purple-colored structure denotes 
the loop of WT, and the pink-colored structure is the loop of 
Asp123Ala.  Green-colored residue represents Asp123 while 
yellow-colored residue shows Ala123 of the mutant enzyme. 
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conformation of the loop is possibly due to differenct crystal lattice contacts because 
the loop of both monomers contacts the neighboring monomeric structure.  Not only 
are the loop conformations of these two monomers different, they also show the 
conformational change compared to the structure of WT (Figure 27).  This difference 
and variation of the loop conformation is probably due to the lack of the carboxylate 
group on Ala123, which acts as a hydrogen bond acceptor. 
In the open form structure of WT MurA, Asp123 has several hydrogen bonds, 
which may define the conformation of the loop, i.e. the carboxylate has hydrogen 
bonds with the backbone nitrogen atoms of Gly118, His125, and Ile126 as well as 
hydrogen bonds with water molecules bridging the side chain and backbone atoms of 
Arg120 (Figure 28A).  In particular, hydrogen bonds of Asp123 with Gly118 and 
Arg120 are likely to induce more rigidity in the loop.  The mutation of Asp123 to 
alanine eliminates these hydrogen bonds, thus allowing the loop to move to a new 
position.   
The weak binding affinity of UNAG to Asp123Ala mutant MurA is explained by 
the interaction of Asp123 with UNAG in WT MurA (Figure 28B).  In the binary 
structure of WT MurA, a couple of hydrogen bonds between Asp123 and UNAG 
were observed.  The carboxylate of Asp123 has a hydrogen bond with N3 of the 
uracil moiety of UNAG, and the backbone nitrogen of Asp123 interacts with O4 of 
the uracil through a hydrogen bond.  However, Ala123 in the mutant enzyme cannot 
maintain the hydrogen bond with N3 of the uracil due to the lack of a hydrogen bond 
acceptor.   
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As expected from the structures of the open and closed forms of WT MurA, 
Arg91 is involved in the open-closed conformational changes, and the Asp123 
residue affects the binding affinity for UNAG, confirmed by kinetic and structural 
studies.  Specifically, Arg91 showed a very strong effect on the loop conformational 
change resulting in loss of enzymatic activity.  Based on this, it was concluded that 
Arg91 is an essential residue for the open-closed transition of MurA.  Although 
(A) 
 
(B) 
 
 
Figure 28.  (A) A stereoview of the loop region of the open form WT MurA structure. 
Asp123 (green) has hydrogen bonds with Gly118, Arg120, His125, and Ile126. 
Some of the hydrogen bonds (red dashed lines) are via water molecules (cyan-
colored spheres).  
   (B) A stereoview of UNAG binding site of the closed form WT MurA structure. 
Asp123 (green) interacts with UNAG (yellow) by hydrogen bonds (red dashed 
lines). Purple-colored structure is the loop (Pro112 – Pro121). 
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Asp123 is not a critical residue for the enzymatic activity, it affects the UNAG 
binding on MurA:  It was observed that the loss of the hydrogen bonds of Asp123 
with UNAG in the closed form lowered the UNAG affinity to the enzyme.  Mutation 
studies of other highly conserved residues (Table 1) on the loop such as Pro112, 
Gly113, Gly114, Ala116, Ile117, Gly118, and Pro121 would help to further 
understand the induced-fit mechanism of MurA. 
3.1.2. Arg120 in E. cloacae MurA and Enzymatic Mechanism 
Site-directed mutagenesis, protein purification, and kinetic analysis of his-tagged 
Arg120Ala MurA were performed by Martha L. Healy-Fried.  Protein purification, 
crystallization and structure refinement of native Arg120Ala MurA were done by 
Huijong Han.  
The active site of WT E. cloacae MurA contains several charged residues: Lys22, 
Arg91, Arg120, Arg331, Arg371, and Arg397, which are thought to be involved in 
proton transfers during the enzyme reaction of MurA23.  Thus, mutational studies of 
these residues could potentially provide details of the enzymatic mechanism of MurA. 
Mutagenesis of Arg120 in E. cloacae MurA to an alanine residue results in an 
inactive enzyme (data not shown).  The inactivity of Arg120Ala mutant MurA was 
also proved by the co-crystal structure of Arg120Ala MurA with UNAG and PEP, 
solved to 1.90 Å resolution (Figure 29).  Both substrates were bound in the active site 
in a closed conformation of the mutant MurA.  The active site of the mutant enzyme 
has more space available because of the smaller amino acid alanine compared to 
arginine.  This creates a conformational change of the loop in addition to a stretching 
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of the side chain of Arg91 into 
the active site.  As described in 
section 3.1.1, Arg91 in WT 
MurA is involved in the open-
closed conformational changes 
by keeping the loop position in 
the closed form through several 
hydrogen bonds with the 
backbone carbonyl oxygen atoms 
of Gly113 and Arg120 (Figure 
25).  It is observed that Arg91 is 
still involved in maintaining the 
loop conformation in the closed 
form of Arg120Ala mutant MurA.  However, the interactions of Arg91 have changed, 
i.e. the guanidinium group of Arg91 now forms hydrogen bonds with the backbone 
carbonyls of Cys115, Gly118, and Ala119 instead of Gly113 and Arg120, due to the 
positional change of the side chain of Arg91 in the mutant enzyme (Figure 30A).  It 
was also found that Arg91 establishes hydrogen bonds with the phosphate group of 
PEP covalently bound to Cys115.  The Arg120 residue forms a couple of hydrogen 
bonds with UNAG in the binary structure of MurA, while it is the side chain of Arg91 
interacting with the UNAG molecule through a bridging water molecule in 
Arg120Ala MurA.  In WT MurA, the side chains of Arg91 and Arg120 interacts each 
 
Figure 29.  Overall structure of Arg120Ala MurA 
complexed with UNAG and PEP.   
Orange color represents the loop region, 
cyan-colored residue is Cys115, yellow 
colored molecule denotes UNAG, and 
green colored molecule is PEP. 
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(A) 
 
(B) 
 
 
 
Figure 30.  (A) A stereoview of the interactions of Arg91 in Arg120Ala MurA.  
Arg91 is a green-colored residue while Cys115, Gly118, Ala119, and Ala120 are 
colored with light grey on the purple-colored loop. Arg91 has hydrogen bonds (red 
dashed lines) with Cys115, Gly118, Ala119, phosphate of Cys115-PEP adduct, and 
UNAG through a water molecule.  
(B) Stereoviews of the active sites of Arg120Ala (up) and WT (bottom) MurA.  
In each figure, grey colored residue is Arg91, and yellow colored molecule denotes 
UNAG.  It is clearly shown that PEP (green) in Arg120Ala MurA (up) forms 
covalent bonding with Cys115 (cyan) supporting the thio-ketal intermediate in the 
MurA enzyme reaction mechanism. 
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other via hydrophobic interactions.  The disruption of this hydrophobic interaction in 
the mutant enzyme induces the conformational change of the side chain of Arg91, 
thus Arg91 undertakes   the functions of Arg120 seen in WT, i.e. filling the space of 
Arg120 and interacting with UNAG.  
The most interesting feature of the structure of Arg120Ala MurA is the covalent 
bonding between PEP and Cys115 (Figure 30B).  Although earlier studies had 
suggested the existence of a hemi thio-ketal intermediate between PEP and Cys115 
during the MurA enzyme reaction, it has been visualized for the first time in this 
study.  These findings indicate that the enzymatic mechanism may occur via the 
formation of the thio-ketal tetrahedral intermediate (Figure 31).  In this mechanism, 
the stronger nucleophile, i.e. the thiol group of Cys115, in comparison to the 3'-OH of 
UNAG, attacks the C-2 of PEP and the PEP-Cys115 hemi thio-ketal intermediate is 
Enz-B-H
Enz-A:
Cys115
A2-1
Enz-B or C:
Cys115
U
N
AG
A2-2
Arg120
 
 
Figure 31.  The first step reaction of the proposed enzymatic mechanism of MurA based on 
the studies of Arg120Ala mutant.  A proton is added to phosphoenol pyruvate 
yielding PEP oxocarbenium ion and sulfhydryl of Cys115 is deprotonated by an 
amino acid (A2-1), followed by a nucleophilic attack of the sulfanion on the C2 atom 
of the PEP oxocarbenium ion leading to a thio-ketal intermediate (A2-2).  The target 
hydroxyl group of UNAG attacks C2 of PEP in thio-ketal intermediate aided by a 
base residue (Enz-B or C), and sulfur atom is re-protonated by Arg120 and Cys115 is 
released. The next step is consistent with the original mechanism shown in Figure 3. 
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formed.  The 3'-OH of UNAG then attacks the reaction center, C-2 of the PEP-
Cys115 tetrahedral intermediate, and Cys115 is released.  In this reaction step, the 
sulfur atom of Cys115 needs to receive a proton because the pKa value of a thiol 
group is around 8.7.  The proton required in this step can be supplied from the 
positively charged guanidinium group of the Arg120 residue.  From the binary 
structure of WT E. cloacae MurA, the distance between the sulfur atom of Cys115 
and NH1 of Arg120 is 3.6 Å.  Considering that the van der Waals radius of a sulfur 
atom is 1.85 Å compared to 1.4 and 1.45 Å of oxygen and nitrogen, respectively, and 
also arginine being a flexible residue, 3.6 Å is within the distance range that the 
proton transfer can occur between Arg120 and Cys115.   
In this proposed mechanism, one of the roles of Cys115 in WT MurA is the 
formation of the first tetrahedral intermediate (PEP–Cys115), and the benefit of this 
mechanism is lowering the activation energy (Ea).  In general, a thiol group is a better 
nucleophile than a hydroxyl group, and the PEP-Cys115 tetrahedral intermediate is 
less sterically hindered because the Cβ of cystein is a secondary carbon while the 
3'-OH of UNAG is attached to the tertiary carbon.  Thus, MurA can lower the 
activation energy by the formation of a thio-ketal intermediate at the first step of the 
mechanism, thereby accelerating the reaction.   
The thio-ketal intermediate was stabilized and hence observed in the co-crystal 
structure of Arg120Ala mutant MurA with UNAG and PEP.  We suggest that this 
trapped thio-ketal intermediate is due to the lack of a proton source, the guanidinium 
group of Arg120.  To further confirm this proposed mechanism, the retaining of 
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enzymatic activity of Cys115Asp MurA, which does not have a thiol functional group 
in the active site, is explained in the next section (3.1.3).  The study of the double 
mutant Cys115Asp/Arg120Ala of MurA is also currently underway in Prof. 
Schönbrunn’s laboratory. 
3.1.3.  The Role of Cys115 in the Enzymatic Mechanism of MurA  
Cys115 is the most studied residue in MurA to date, because the mutation of 
Cys115 to an Asp residue is known as one of the fosfomycin resistance mechanisms.  
This mutation has been found in some pathogenic species, such as Mycobacterium 
tuberculosis and Chlamydia.  Previously, several studies with Cys115Asp E. cloacae 
MurA have been performed in Prof. Schönbrunn’s research group.  The IC50 value of 
fosfomycin for the Cys115Asp mutant enzyme was measured to be 2.5 mM while it is 
less than 1 μM for WT141.  
Since the complex structure of Arg120Ala MurA with UNAG and PEP showed 
the evidence of the thio-ketal tetrahedral intermediate, the mechanistic role of the 
Cys115 residue has received more attention.  Although the new mechanism can lower 
the activation energy of the enzyme reaction, the same mechanism is not likely to 
happen in Cys115Asp MurA because the carboxylate in the Asp residue is much 
weaker nucleophile compared to the Cys residue.  Therefore, the enzymatic 
mechanism of Cys115Asp MurA cannot include the thio-ketal intermediate, but the 
3'-OH of UNAG directly attacks PEP creating a PEP-UNAG tetrahedral intermediate.  
It is considered that the activation energy of Cys115Asp MurA is higher than WT as a 
result of the direct attack of the 3'-OH of UNAG.  To test this hypothesis, the 
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activities of both WT and 
Cys115Asp MurAs were 
measured at 5, 15, and 
25 °C, and the activity 
ratios at different 
temperatures were 
calculated to derive 
activation energy values (Table 10).  Although the values of Ea differ at various 
temperatures in one enzyme, the data clearly demonstrate that the activation energy of 
Cys115Asp MurA is higher than WT.  
Cys115 in E. cloacae MurA is located in a flexible loop that undergoes a large 
conformational change upon UNAG binding.  Thus it was thought that the mutation 
of Cys115 to other amino acid residues would affect the conformation of the loop.  
The un-liganded structure of Cys115Asp MurA was solved to 1.95 Å resolution 
(Figure 32).  Although this crystal was formed under the same conditions as the WT 
crystal, it had a different crystal lattice.  The loop conformation of the open form of 
Cys115Asp MurA is different from WT, however this does not affect UNAG binding.  
From a previous kinetic study by Dr. Melanie Priestman141, the Km value of UNAG 
for the mutant enzyme is similar to WT at pH 6, and the values are even lower than 
WT at pH 7 and 8, implying that UNAG binds to the mutant enzyme with better 
affinity at physiological pH.  This was also confirmed by the determination of the 
dissociation constant (Kd) of UNAG (Figure 33A).  The Kd value of UNAG for 
Table 10.  Activity ratio and calculated activation energy of 
WT and Cys115Asp MurAs. 
 
Activity Ratio 25 °C/5 °C 25 °C/15 °C 15 °C/5 °C 
WT 3.6 1.5 2.4 
Cys115Asp 9.1 2.0 4.6 
Ea (Kcal/mol) 25 °C/5 °C 25 °C/15 °C 15 °C/5 °C 
WT 11.0 7.2 14.4 
Cys115Asp 18.7 12.0 25.1 
 112
Cys115Asp is 70.8 μM, and 72.9 μM for WT, indicating that the Cys115 mutation 
does not influence UNAG binding.   
However, the mutation of Cys115 to Asp alters the binding of PEP.  For WT 
MurA, the Km value of PEP is too low to measure (less than 0.1 μM), whereas it was 
measured for Cys115Asp MurA to be 30 μM (Figure 33B).  Although Cys115Asp 
MurA needs a higher concentration of PEP to obtain the full velocity of the enzyme 
reaction (Vmax), it is still in the range of the physiological concentration of PEP, 
0.2 mM142.  Thus, MurA in those species that have aspartate instead of cysteine at the 
(A)          (B) 
 
 
Figure 32.  (A) Overlapped structures of the open form WT (dark blue) and Cys115Asp 
(light blue) MurAs.  The loop structures are shown as purple and pink colors in WT 
and Cys115Asp, respectively. 
  (B) Differences of the loop conformation between WT (purple) and Cys115Asp 
(pink) MurAs.  The orange-colored residue is Cys115 in WT and the green-colored 
residue denotes Asp115 in Cys115Asp MurA.  
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115 position is still as active as the other species that contain cysteine, but they are 
not inhibited by fosfomycin. 
The ideal molecular mode of action of MurA inhibitor is binding in the UNAG 
binding site and preventing the conformational changes.  This mechanistic-based 
inhibitor would also inhibit Cys115Asp mutant MurA, which is resistant to 
fosfomycin.  To design this kind of inhibitor, the detailed information of enzymatic 
mechanism of MurA is required.  Thus, the mechanistic studies of MurA described in 
this thesis will be used as critical information to design the inhibitors deriving the 
open-closed conformational changes.  
(A)          (B) 
 
Figure 33.  Kinetic analysis of Cys115Asp MurA. 
(A) Kd determination of UNAG for WT (○) and Cys115Asp (●) MurAs.  
Kd (UNAG) is 70.8 μM for Cys115Asp while it is 72.9 μM for WT.  
(B) Km determination of PEP for Cys115Asp MurA. 
Km (PEP) for Cys115Asp was measured to 30 μM.  
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3.2. Identification and Characterization of MurA Inhibitors 
Although MurA is a proven antibiotic drug target, very few inhibitors have been 
identified.  To date, fosfomycin, the active ingredient of Monurol®, is the only 
marketed drug targeting MurA. Several resistant mechanisms against fosfomycin 
were revealed, thus, there is a need for the discovery of new inhibitors of MurA.  
3.2.1.  Study of Known MurA Inhibitors  
0B3.2.1.1.  Peptide Inhibitors 
Kinetic evaluations of known inhibitors from the literatures have been performed.  
The peptide inhibitor, HESFWYLPHQSY, identified from phage display libraries63 
was synthesized at the University of Kansas.  No inhibitory activity of the peptide on 
WT E. cloacae MurA was found at 1 mM concentration even though the peptide was 
reported to inhibit Pseudomonas aeruginosa MurA with an IC50 value of 200 μM.  
Notably, a protein of viral origin, A2 maturation factor (420 amino acids), was 
recently reported as a potent MurA inhibitor, inducing bacterial lysis64.  The A2 
maturation factor was cloned and the studies to produce the protein in a large-scale 
are currently underway in Prof. Schönbrunn’s laboratory. 
1B3.2.1.2.  Cnicin 
A natural product, cnicin was recently reported as an irreversible inhibitor by 
preliminary kinetic studies60 and the co-crystal structure with E. coli MurA was 
solved by the same research group143 (Figure 34A).  Cnicin is a sesquiterpene lactone, 
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Figure 34.  (A) The co-crystal structure of cnicin with MurA and UNAG.  A covalent adduct 
of cnicin and UNAG is bound in the MurA active site. 
  (B) A proposed mechanism of action of cnicin in the literature.  UNAG attacks 
Cα of the carbonyl, then the ring portion of cnicin is removed by hydrolysis. The 
vicinal diol group of cnicin mimicks the phosphate group of PEP. 
  (C) A newly proposed mechanism of action of cnicin.  The mechanism step of the 
green colored box in B) is revised. The fused ring of cnicin induces the 
conformational changes of MurA, and then Cys115 makes a covalent bond with 
cnicin. The hydrolysis occurs, and the conformation of MurA changes back to the 
open state.  UNAG binds to MurA and induces the conformational changes and the 
3'-OH of UNAG attacks the carbon center of cnicin with releasing Cys115. 
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and its α,β-unsaturated carbonyl  group is thought to be electrophilic.  The solved 
structure revealed the formation of a covalent adduct between cnicin and UNAG.  It 
shows that cnicin acts as a non-covalent suicide inhibitor (Figure 34B).   
We purchased cnicin and tested its inhibitory potential on E. cloacae MurA.  The 
measured inhibitory potency was much lower (Ki value of 3.4 mM) than the reported 
value (IC50 value of ~10 μM).  The mode of action found in our kinetic study of 
A)             B) 
   
 
   C) 
 
Figure 35. Ki determination of cnicin on E. cloacae MurA.  
A) Plots of 3 component exponential decrease curves (equation 6) at various cnicin 
concentrations of 10 (●), 4 (○), 2 (▼) and 1 (Δ) mM.  Cnicin is identified as one-step 
slow-binding inhibitor to MurA. 
B) Plots of relative activity at various UNAG concentrations (0(●), 0.01(○), and 1.0(▼) 
mM). The MurA inhibition by cnicin shows a competitive pattern against UNAG.  
C) Replot of inhibitor concentration vs. k (obtained from exponential decrease curves).  
The determined Ki value is 3.4 mM.
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cnicin indicated a one-step slow-binding inhibition (Figure 35A).  In addition, the 
inhibition of cnicin was competitive to UNAG (Figure 35B), contrary to the mode of 
action reported in the literature.  Although Cys115Asp mutant MurA is reportedly not 
inhibited by cnicin, the authors proposed the molecular mode of action of cnicin did 
not involve Cys115 (Figure 34B).  However, based on our preliminary studies and 
findings that Cys115 covalently attaches to PEP, we propose a different mode of 
action of cnicin (Figure 34C):  First, cnicin binds to the UNAG binding site of MurA 
and induces the conformational changes.  In the closed form, Cys115 make a covalent 
bond with cnicin, and then the hydrolysis of cnicin occurs, releasing the fused ring 
system.  Once the conformation of MurA goes back to the open state, UNAG binds to 
its binding site and induces the conformational changes again.  The 3'-OH group of 
UNAG then attacks the Cys115-cnicin adduct and replaces Cys115, producing the 
UNAG-cnicin complex, found in the structure.  This newly proposed mechanism 
seems more rational because it includes the role of Cys115, and the mechanism of 
action proposed in the literature indicates that cnicin is a non-specific group-specific 
inhibitor.  To provide further confirmation, thorough kinetic and structural studies are 
currently ongoing. 
3.2.2.  Identification and Characterization of Novel MurA Inhibitors  
From a previous high-throughput screening (HTS) campaign with 50,000 
compounds from ChemBridge, four new chemical scaffolds of MurA inhibitors were 
identified141.  Representative compounds from each scaffold were studied thoroughly 
(Figure 36).  Initial kinetic studies indicated that freshly dissolved HTS 2 compounds 
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in DMSO did not display inhibitory potential to MurA, while the ‘aged’ (incubated in 
DMSO or MeOH at room temperature) solutions showed inhibition.  Color changes 
of DMSO and MeOH solutions, from light to dark, were detected as well.  These 
results imply that there is an unidentified reaction of HTS 2 compounds in DMSO or 
MeOH, and the product of this reaction is the active component as the MurA 
inhibitor.  Black-colored solid precipitated out from HTS2-2 solution in MeOH with 
time. Although the product was identified as the active ingredient, the attempt to 
identify the chemical structure of this compound by NMR and mass spectra was not 
successful (data not shown).  
Inhibition kinetics were performed with HTS2-2 to understand its molecular 
mode of action on MurA.  HTS2-2 was identified as a mixed inhibitor with respect to 
UNAG (Figure 37).  The Ki for HTS2-2, with respect to alteration of the affinity for 
UNAG, is 6.8 μM, whereas the Ki', with respect to changes in maximal velocity of 
MurA, is 42 μM.  The dissociation constant of HTS2-2 was measured by the ANS  
 
 
Figure 36.  Representative compounds from 1st HTS of MurA.  The Ki values of each 
compound are shown.   
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Figure 37. Ki determination of HTS2-2.  
A) Michaelis-Menton curves of MurA activity as a function of UNAG concentration for 
various HTS2-2concentrations. 
B) Lineweaver-Burk presentation of MurA activity as a function of reciprocal UNAG 
concentration for HTS2-2 concentrations. 
C) Replot of the observed Km from B) as a function of HTS2-2 concentration yielding Ki of 
6.83 ± 0.89 μM. 
D) Replot of the observed Vmax from B) as a function of HTS2-2 concentration yielding Ki' 
of 42.07 ± 3.90 μM.  
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fluorescence assay, and the Kd value for HTS2-2 is 51 μM (Figure 38) indicating that 
this inhibitor binds in the loop region of MurA.  These results of the kinetic and 
fluorescence studies suggest that HTS2-2 binds in the vicinity of the UNAG binding 
site, but cannot cause the conformational change from the open to the closed state.  
Therefore, we propose that HTS2-2 inhibits MurA in a similar way to T6362, the 
Aventis inhibitor (compound 9 in Figure 9), i.e. bind in the loop region of the open 
state MurA and inhibit the conformational changes. 
Intense efforts were made to obtain co-crystal structures of MurA with the HTS 
inhibitors.  HTS2-2 was co-crystallized with MurA, and the structure was refined to 
2.3 Å resolution.  Although clear electron density of HTS2-2 was visible in the 
solved structure, the binding site was opposite to the active site of MurA 
(Figure 39A).  A close look of the binding site demonstrates that the binding of 
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Figure 38.  (A) Fluorescence scans from 400-600 nm with excitation at 366 nm.  
ANS spectra show a decremental change with increasing concentrations of HTS2-2, 
as labeled on the graph. 
(B) Replot of HTS2-2 ANS fluorescence data as a function of HTS2-2 
concentration.  
The Kd value of HTS2-2 was determined to 50.9 ± 1.7μM. 
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HTS2-2 with MurA is mostly from hydrophobic interactions (Figure 39B), i.e. 
cyclopentene ring of HTS2-2 interacts with Lys248 and Val250, and the aromatic 
ring is in a range of a π-π stacking interaction with Trp71.  Only the nitro group of 
HTS2-2 has a hydrogen bond with the backbone nitrogen of Asp15.  The structural 
(A) 
 
(B) 
 
 
Figure 39.  (A) The co-crystal structure of HTS2-2 with WT E. cloacae MurA.  Grey color 
represents MurA and red-colored residues are Trp71 and Asp248 interacting with 
HTS2-2, which is a green-colored molecule. 
(B) A stereoview of the HTS2-2 binding site on MurA.  Orange-colored residue is 
Trp71, and Asp15, Lys248, and Val250 are shown as cyan-colored sticks. A yellow-
colored molecule is HTS2-2. 
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data do not corroborate with the inhibition kinetics, the latter suggesting that HTS2-2 
binds to the loop containing Cys115 in the open form of MurA. 
Because of the unexpected binding of HTS2-2 observed in the crystal structure, 
further studies with HTS2-2 were performed.  A mixed solution of MurA containing 
HTS2-2 was subjected to a size exclusion chromatography to investigate possible 
oligomerization of MurA induced by the inhibition..  The elution profile of the 
mixture of MurA with HTS2-2 is consistent with mixture of monomer, dimer and 
tetramer, whereas un-liganded MurA under the same experimental condition is 
clearly monomeric.  These results confirmed that HTS2-2 indeed induces 
oligomerization of MurA (Figure 40A). 
The hydrophobic interactions of HTS2-2 with Trp71 and Lys248 were eliminated 
by mutations to Val and Asp, respectively.  Val and Asp were chosen because they 
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Figure 40.  (A) Elution profile of size exclusion column with MurA + HTS2-2 (blue) and 
MurA only (black).   
The elution profile for MurA shows monomeric state, while the one with HTS2-2 
represents tetramer and dimer as well as monomer. 
(B) IC50 determination of WT(●, black), Lys248Asp(○, blue), and Trp71Val(▼, 
red) MurAs.  The IC50 values are 19.1, 19.5 and 13.6 μM, respectively.  The graph 
of WT is almost overlapped with the one of Lys248Asp. 
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are found in the equivalent position in other MurAs.  The enzymatic activities of 
these mutant enzymes were similar to WT, and the inhibitions by HTS2-2 were also 
retained (Figure 40B).  If the dimerization of MurA by HTS2-2, found in the co-
crystal structure, is the inhibitory mechanism, HTS2-2 should be ineffective against 
these mutant enzymes.  Thus, the inhibitory activity of HTS2-2 against Trp71Val and 
Lys248Asp MurA infers that the co-crystal structure is an artifact of crystallization, 
and the MurA dimerization via hydrophobic interactions with Trp71 and Lys248 is 
not the inhibitory mechanism by HTS2-2.  Crystallization trials of these mutant 
enzymes with HTS2-2 using the same condition as with WT enzyme failed to 
produce crystals, suggesting that HTS2-2 promotes crystallization of only the WT 
enzyme in this particular crystal lattice.  In other words, HTS2-2 can be considered as 
a mere crystallization additive under this condition. 
Co-crystallization of HTS1-1 with WT MurA was attempted and crystals were 
formed in the presence of iso-propanol (H1-41 conditions in Table 9).  The crystals 
are not X-ray graded yet, and refining the crystallization conditions is currently 
underway.   
To study structure-activity relationships (SAR) of scaffolds HTS 1 and 2, 35 and 
51 analogs of each scaffold were tested with WT E. cloacae MurA (Tables 11 and 
12).  For the HTS 1 scaffold, the carboxylic acid functional group at the R2 position 
was essential as well as a chloride or hydroxyl group at R3 for inhibitory activity.  
When the pyrrole ring was changed to a pyrrolidine ring or succinimide, the 
inhibitory activity was significantly decreased while the variation of the 5-membered 
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ring to maleimide retained the inhibitory activity.  For the HTS 2 scaffold, the 
carboxylic acid group at the R1 or R2 position was essential for their inhibitory 
activity.  Notably, when R2 was a carboxylic acid, aromaticity was required at the R1 
position.  Freshly made solutions of HTS 2 compounds in DMSO were not active on 
MurA.  However, the compounds became active after the incubation at room 
temperature, although the incubation time varied for different compounds.  Thus, the 
activity of the compounds in this scaffold was measured until they showed inhibition, 
up to two weeks.  As shown on the Table 12, most compounds inhibited MurA after 
the incubation.  Thus, the SAR evaluation of the HTS 2 scaffold was not possible 
although it was clear that the carboxylic acid group is required at the R1 or R2 
position.  It is probably due to the fact that unknown reaction of the compounds 
occurs in the solution and the product is the active component.  Thereafter, it is 
proposed that the unknown reaction depends on the existence of the carboxylic acid 
group at the R1 or R2 position. 
 
Table 11. SAR table of the HTS 1 scaffold. 
 
        
        
        
        
        
        
                
ID R1 R2 R3 R4 R5 R6 
Remaining activity 
at 500 μM (%) IC50 (μM) 
H1-1 H CO2H Cl H H H  27.2 ± 2.7 
H1-2 H CO2H OH H H H 10 ~190 
H1-3 H CO2H OH H Me Me 14 82.6 ± 2.1 
H1-4 H CO2H Cl H Ph Me 129  
N
R3
R2
R1
R4
R6 R5
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H1-5 H CO2H Cl H Me Me 100   
H1-6 Cl CO2H H H H H 102   
H1-7 H CO2H H H Ph Me 147  
H1-8 H CO2H H H Me Me 106   
H1-9 H CO2H H CO2H Me Me 95   
H1-10 Me CO2H H H Me Me 110  
H1-11 H CO2H CO2H H Me Me 95   
H1-12 H CO2H H H Ph CH2CH2CO2H 129  
H1-13 H CO2H H H 
 
CH2CH2CO2H 158   
H1-14 H CO2H H H 
 
CH2CH2CO2H 139  
H1-15 H CO2H H H 
 
CH2CH2CO2H 137   
H1-16 H CO2H H H 
 
CH2CH2CO2H 171  
H1-17 H CO2H H H 
 
CH2CH2CO2H 169   
H1-18 H CO2H H H 
 
CH2CH2CO2H 140   
H1-19 Me H H CO2H H H 100   
H1-20 OH H H CO2H Me Me 97  
H1-21 Me H H CO2H Me Me 91   
H1-22 Cl H H CO2H Me Me 93  
H1-23 H  CO2Me Cl H H H 104   
H1-24 H NO2 Cl H H H 116  
H1-25 H CONMe2 Cl H H H 101   
H1-26 H CH2CO2H H H H H 106  
H1-27 H Cl CO2H H H H 107   
H1-28 H Cl CO2H H Me Me 108   
H1-29 H OH CO2H H H H 101  
H1-30 NO2 H CO2H H H H 70   
H1-31 OH H CO2H H H H 103   
H1-32 H H OH H H H 93   
H1-33   
 
   56  
H1-34     
 
      97   
H1-35     
 
      13 30.1 ± 1.7 
 
Me
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Table 12. SAR table of the HTS 2 scaffold. 
 
 
       
       
       
       
       
              
ID R1 R2 R3 R4 R5 
Remaining 
activity at 500 μM 
(%) IC50 (μM) 
H2-1 CO2H OH H Cl NO2 5  
H2-2 CO2H H Me H Me 7   
H2-3 CO2H H H NO2 H 8 46.8 ± 2.0 
H2-4 CO2H H H Br H 8 28.9 ± 1.9 
H2-5 CO2H CF3 H H H 8 39.7 ± 2.0 
H2-6 CO2H I H Me H 8 41.8 ± 0.4 
H2-7 CO2H H H COO(CH2)3CH3 H 9   
H2-8 CO2H CONH2 H H H 9   
H2-9 CO2H H H 
 
H 11  
H2-10 CO2H Me Cl H H 12   
H2-11 CO2H CO2H H H H 12 13.5 ± 0.4 
H2-12 CO2H H H SO2NH2 H 14   
H2-13 CO2H H H acetyl H 14  
H2-14 CO2H OMe  H H H 15   
H2-15 CO2H H H CO2H H 15 8.5 ± 0.7 
H2-16 CO2H H H CO2Et H 17 58.0 ± 4.0 
H2-17 CO2H H H COOCH2CH(CH3)2 H 16  
H2-18 CO2H H H Me H 19   
H2-19 CO2H OH H H H 21  
H2-20 CO2H 
 
H H H 24   
H2-21 CO2H H H 
 
H 24  
H2-22 CO2H CF3 H H Cl 28   
H2-23 CO2H Me H I H 32  
H2-24 CO2H H H 
 
H 40   
H2-25 CO2H H H 
 
H 44  
H2-26 CO2H H H 
 
H 44   
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H2-27 CO2H 
 
H H H 66  
H2-28 CO2H CO2H H H NO2 78   
H2-29 CO2H Me H NO2 H 90  
H2-30 CO2Et H H NO2 H 90   
H2-31 CO2Et Me CO2H H H 112  
H2-32 H CO2H H H NO2 102   
H2-33 propyl CO2H H H NO2 117  
H2-34 
 
CO2H H H NO2 106   
H2-35 Ph CO2H H H NO2 47   
H2-36 
 
CO2H H H H 16  
H2-37 
 
CO2H H H H 16   
H2-38 
 
CO2H H H H 17  
H2-39 
 
CO2H H H H 20   
H2-40 
 
CO2H H H H 22  
H2-41 
 
CO2H H H H 25   
H2-42 
 
CO2H H H H 25  
H2-43 
 
CO2H H H H 26   
H2-44 
 
CO2H H H NO2 28  
H2-45 
 
CO2H H H H 52   
H2-46 
 
CO2H H H NO2 54  
H2-47 
 
CO2H H H H 109   
H2-48 
 
CO2H H H H 120   
H2-49 
 
H H SO2NH2 H 95   
N
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O
Br
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NO2
F
Cl
Cl
Cl
Cl
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Br
NO2
Cl
O
O
O
O
O
O O
O
NO2
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H2-50 
  
H H H 98  
H2-51 
 
CO2Me H H H 105   
 
In addition to the previous high-throughput screening of 50,000 compounds, 
50,000 more compounds from ChemDiv and MicroSource were screened.  The IC50 
values were determined for the compounds showing less than 40 % remaining activity 
against WT E. cloacae MurA.  As a result, 49 new compounds were found with IC50 
values in a range of 5 μM to 50 μM.  11 compounds belong to scaffolds HTS 2, 3, 4, 
or 5, and the others were categorized into 3 new scaffolds and natural products (NP). 
(Figure 41)  Representative compounds of each group (HTS6-1, HTS7-1, HTS8-1, 
and NP-1, -2, and -3) were purchased and tested to confirm their inhibitory activity.  
Inhibitory activity of HTS6-1 was not observed while the other compounds also 
showed less inhibitory potency compared to the values from HTS under the same 
condition.  None of the compound showed time-dependent inhibition characteristics. 
To understand the modes of action on MurA, inhibition kinetics of HTS7-1 and 
HTS8-1 were conducted.  HTS7-1 showed non-competitive inhibition regarding 
UNAG.  The Ki' was determined to 56.9 μM (Figure 42A1-C1).  HTS8-1 is a mixed 
inhibitor with respect to UNAG.  The Ki for HTS8-1, regarding alteration of the 
affinity for UNAG, is 19.6 μM, whereas the Ki', with respect to changes in maximal 
velocity of MurA, is 40.1 μM (Figure 42A2-C2).  The efforts to obtain co-crystal 
structures of HTS7-1 or HTS8-1 with MurA have not succeeded to date.   
Br N
O
O
Cl
Cl
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The verifications of the HTS hits were not successful with commercially obtained 
compounds.  One possible explanation for this is that the compounds in the HTS 
library did undergo chemical modifications, e.g. oxidation, radical reactions.  We 
conclude that the best strategy for now is to repeat the HTS campaign with newer and 
possibly more diverse compound libraries. 
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Figure 41.  Chemical structures and IC50 values of HTS hit compounds. 
Blue colored structures in the first row are the common structure of each scaffold.  
The values in parentheses were measured in HTS facility and the values outside the 
parentheses were measured in the laboratory. HTS6-1 did not show inhibitory 
activity, and other inhibitors exhibited less potency than measured in HTS facility.  A 
few natural products showed inhibition to MurA (NP-1 to -3).
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A1)    B1)         C1) 
 
 
 
A2)    B2)         C2) 
 
 
Figure 42. Ki determinations of HTS7-1 (A1, B1, and C1) and HTS8-1 (A2, B2, and C2). 
A1) MurA activities as a function of UNAG concentration for various HTS7-1 concentrations. 
B1) Double-reciprocal plot of data from A1). 
C1) Replot of the observed Vmax from B1) as a function of HTS7-1 concentration yielding Ki ' 
of 56.9 μM. 
A2) MurA activities as a function of UNAG concentration for various HTS8-1 concentrations. 
B2) Double-reciprocal plot of data from A2). 
C2) Replot of the observed Km from B2) as a function of HTS8-1 concentration yielding Ki of 
19.6 μM. 
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3.3. Inhibitors of Cyclin-dependent Kinase 2 
High-throughput screening (HTS) was performed by Dr. Rawle Francis in the 
HTS facility of the University of Kansas, and kinetic analysis of CDK2 was 
performed by Dr. Andreas Becker.  The synthesized analogs were provided by the 
laboratory of Dr. Gunda Georg at the University of Minnesota. 
Cyclin-dependent kinases (CDKs) are key enzymes in the regulation of the cell 
cycle, and abnormal over-expression of CDKs is often observed in human cancer 
cells.  Thus, intense efforts to discover anti-cancer drugs that inhibit CDKs have been 
made for the last two decades.  Although a number of small molecule CDK inhibitors 
have been identified, assisted by expanded structural information about CDK2, they 
frequently lack adequate potency and/or specificity.  It is clear that improved 
selectivity will be required for the next generation of CDK inhibitors. 
HTS was conducted with about 100,000 compounds resulting in the identification 
of 62 compounds demonstrating more than 60 % inhibition of CDK2 at 8.3 μg/mL 
concentration.  These hits were categorized into six different scaffolds and the 
representatives of each scaffold are shown in Figure 43 with their Ki values.  Four of 
the representative compounds were co-crystallized with CDK2 and they were all seen 
to occupy the ATP binding pocket of CDK2.  The co-crystallized compounds were 
named Lead 1 (L1) to Lead 4 (L4).  More compounds with scaffolds L1 – L4 were 
purchased or synthesized, and inhibitory potencies were measured for structure 
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activity relationship (SAR) studies.  The detailed molecular modes of action of 
several analogs were analyzed by crystallographic studies. 
Prior to the study with the lead compounds, efforts to understand the ATP binding 
site of CDK were performed with the co-crystal structure of ADP on CDK2 
(Figure 44). The interactions of ADP with CDK2 were almost the same as with the 
ATP binding although the electron density of the β-phosphate group of ADP was too 
weak to refine its conformation of the phosphate group.  In addition, the co-crystal 
structures of CDK2 with two known inhibitors, aloisine A and NU6027 (chemical 
structures are shown in Figure 15), were solved to 1.75 and 1.85 Å resolution, 
respectively.  Aloisine A bound to the ATP binding site has two hydrogen bonds with 
the backbone carbonyl oxygen and nitrogen atoms of Leu83.  The phenyl ring 
 
 
Figure 43.  Six scaffolds of CDK2 inhibitors identified by HTS. 
Ki values of each scaffold are shown.  
The molecular modes of action of L1-L4 were identified by structural and SAR 
studies while investigations of H9 and H10 are currently undergoing.  
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ADP 
 
Aloisine A 
 
NU6027 
 
Figure 44.  Stereoviews of the co-crystal structures of ADP, aloisine A, and NU6027 with 
CDK2.  Light grey-colored structures are active site residues of CDK2 and green 
molecules are ligand structures.  A water molecule is shown as a cyan-colored sphere.  
Blue dashed lines denote hydrogen bonds while orange dashed lines represent van der 
Waals interactions. 
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maintains hydrophobic forces with Ile10 and Gln85.  NU6027 forms three hydrogen 
bonds between the pyrimidine ring and the backbone atoms of Glu81 and Leu83.  The 
5-nitroso group of NU6027 has hydrogen bonds with the backbone nitrogen of 
Asp145 and a water molecule, which interacts with the backbone carbonyl of Gln131.   
From these preliminary structural studies, it was confirmed that the hydrogen 
bonds with the backbone atoms of Glu81 and Leu83 are propably important for the 
binding because they are present in every ligand bound CDK2 structures including 
ADP, aloisine A and NU6027.  In addition to these hydrogen bonds, the hydrophobic 
interactions with Ala31 and Leu134 were consistently observed in the structures.   
3.3.1. Lead 1 and its analogs 
Lead 1 (L1, 5-nitro-2-(pyridine-3-ylmethylamino)benzamide), identified by HTS, 
showed a Ki value of 2.3 μM for CDK2/cyclinA.  The crystal structure of L1 with 
CDK2 was solved to 1.85 Å (Figure 45A).  L1 was bound in the ATP binding pocket 
containing three key hydrogen bonds with the backbone carbonyl oxygen atoms of 
Glu81 and Leu83 and the backbone nitrogen of Leu83: the amide group on C1 forms 
hydrogen bonds with the backbone carbonyl oxygen atom of Glu81 and the backbone 
amide nitrogen of Leu83, and the amino group on C2 interacts with the backbone 
carbonyl of Leu83.  The nitro group on C5 forms a salt bridge with the side chain 
amine of Lys33.  The benzene ring of L1 has hydrophobic interactions with Ile10, 
Val18, Ala31, and Leu134.  Ile10 is also close enough to the pyridine ring of L1 to 
make hydrophobic interactions (Figure 45B).  
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(A) 
 L1 
 
(B)      (C) 
 
 
Figure 45.  (A) A stereoview of the co-crystal structure of L1 with CDK2.  Light grey-colored 
structures are active site residues of CDK2 and the green molecule is L1. Blue dashed 
lines denote hydrogen bonds while orange dashed lines represent van der Waals 
interactions. 
(B) A schematic diagram of L1 binding in the CDK2 active site.  Residues in the 
active site interacting with L1 are shown. Van der Waals interactions are shown as 
blue colored arches and green dashed lines represent hydrogen bonds with their 
distances. 
(C) SAR strategy for the L1 scaffold.  The pharmacophore of the L1 scaffold is 
shown as red colored structure. Green colored structures are part of the molecule, 
which need to be modified for better inhibitory potency.  The blue colored circle 
indicates a space available in the active site.  The atoms of the pharmacophore, 2-
aminobenzamide, are numbered.  
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The pharmacophore of L1 was proposed as the aminobenzamide moiety from 
structural information obtained from the co-crystal structure of L1 bound to CDK2.  
Spaces for elongations from the core structure were available on the 3 and 4 positions 
of the aminobenzamide ring (Figure 45C), thus the investigations of the derivatives 
with various groups on those sites were needed.  The variation of the pyridine ring to 
other aromatic ring systems or aliphatic chains and the modification of the nitro group 
to other hydrogen bond acceptor groups, e.g. carboxylate, were proposed.  Several 
compounds satisfying the above conditions were commercially obtained as well as 
synthesized, and tested against CDK2/cyclinA (Tables 13 and 14).   
The amide group of the L1 scaffold was confirmed to be critical by kinetic 
analysis of several L1 derivatives.  Compounds with a carboxylate group instead of 
an amide on the C1 position of the benzene ring, L1-KVR-1-38, -42, -43, -46, 
and -52, lost their inhibitory activity. 
The IC50 values of L1 analogs also indicated that the inhibitory potency of L1 
depended on the presence of a methylene-aromatic ring moiety connected to the 
amino nitrogen of aminobenzamide (R1 group): all the compounds without the 
methylene-aromatic ring were inactive against CDK2/cyclinA.  Inhibition was not 
observed for the compounds without the ring system, L1-3, L1-4, and L1-13.  The 
compounds with saturated rings, L1-9, L1-11, and L1-KVR-1-25, did not show 
inhibitory activity.  Although the R1 substituents include aromatic rings, it was 
observed when the length of the carbon linker between the 2-amino group and the 
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ring was not one carbon, the inhibitory activities significantly decreased (e.g. L1-5 
(two-carbon linker), L1-KVR-1-22 (no carbon)).   
L1 analogs with variations at the position of the nitrogen atom on the pyridine 
ring of R1 group, 2-position (L1-KVR-1-9), 4-position (L1-KVR-1-45), and 2, 5-
positions (L1-KVR-1-67) have been tested and their activities did not differ from the 
parent compound, L1 (3-position).  Even the compound without the nitrogen atom on 
the aromatic ring (L1-10) had an IC50 that was not much different than the value of 
the pyridine ring system (L1).  This result was consistent with the information from 
structural data, where no specific interaction of the pyridyl nitrogen and CDK2 
residues existed.  The co-crystal structure of L1-KVR-1-9 with CDK2 was also 
solved to 1.95 Å (Figure 46).  The interaction of the pharmacophore of the inhibitor 
with the receptor was the same as L1.  The orientation of the pyridine ring was 
rotated a little compared to L1.  However, the electron density of this part of the 
molecule was poor, showing high temperature factors (B-factors).  This implied that 
L1-KVR-1-9 
 
Figure 46.  A stereoview of the co-crystal structure of L1-KVR-1-9 with CDK2. Light grey-
colored structures are active site residues of CDK2 and green molecule is L1-KVR-
1-9. Blue dashed lines denote hydrogen bonds while orange dashed lines represent 
van der Waals interactions. 
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Table 13.  SAR table of the L1 scaffold (1).  Blue shaded compounds were co-crystallized with 
CDK2. 
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 the R1 group of L1 analogs was flexible and did not have critical interactions with 
CDK2, thus it needs to be modified to have specific binding in the active site.  One 
suggestion is a substitution on the phenyl ring with hydrogen bond acceptors and/or 
donor groups because Lys, Asp and Glu residues are located near the phenyl group 
binds.  The R1 group is also open to solvent exposed space, thus it possibly stabilizes 
the binding of the ligand on CDK2. 
The attempt to increase inhibitory potency was carried out by varying the 
electronic character of the aromatic ring of R1.  Analogs with the substitutions on the 
phenyl ring with p-methoxy (L1-KVR-1-5), p-methyl (L1-KVR-1-6), p-chloride 
(L1-KVR-1-7), p-fluoride (L1-KVR-1-8), 2,3-difluoro (L1-KVR-1-12), 3,4-difluoro 
Table 14. SAR tables of the L1 scaffold (2). 
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(L1-KVR-1-13), p-trifluoromethyl (L1-KVR-1-15), and 3,4-dichloro (L1-KVR-1-
32) were synthesized and their inhibitory activities were tested.  As a result, none of 
the analog compounds with substituents on the aromatic ring had significantly better 
potencies.  Compounds, L1-KVR-1-12, -15, and -32, showed even considerably less 
activities than L1-10 (no substitution on the phenyl ring).  Thus, it was assumed that 
the electronic properties of the aromatic ring did not affect the interaction of the L1 
analogs with CDK2.  In addition to the hydrophobic substitutions on the phenyl ring, 
a couple of hydrophilic derivatives, p-carboxylic acid (L1-KVR-1-74), p-
aminomethyl (L1-KVR-1-75) were synthesized to enhance solvent contacts as well 
as possible hydrogen bonds.  However, both analogs exhibited similar potency 
compared to L1-10, suggesting that neither p-carboxylate nor p-aminomethyl groups 
involve the binding to CDK2.  Thus may result because the substitutions are not on 
the right position or they are too small groups to have interactions with CDK2.  Thus, 
future studies should probably include substitution on different positions of the 
phenyl ring with large hydrophilic functional groups such as sulfonamides. 
The variation of the R2 group with chloride, L1-KVR-1-55, L1-KVR-1-56, and 
L1-KVR-1-78, showed 3-fold increased inhibitory potency compared to the analogs 
without chloride, L1-KVR-1-9, L1-KVR-1-45, and L1.  From the structures of L1 
and L1-KVR-1-9, it was not possible to explain the increased inhibition because the 
space for R2 substitution is widely open and the chloride atom does not seem to have 
interactions with any residues.  Thus, the attempt to obtain the structures of the R2-
chloride substituted analogs with CDK2 is currently ongoing.  L1-KVR-1-55-2 (R2: 
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pyridinyl-2-methylamino group) was not active against CDK2/cyclinA, possibly 
because R2 is too large, thus causing steric clash.  Further investigation with various 
substituents of R2 needs to be performed as well as the modification of the nitro 
group on R3. 
3.3.2. Lead 2 and its analogs 
Lead compound 2 (L2, 2-(4,6-diamino-1,3,5-triazin-2-yl)phenol) inhibits CDK2 
reversibly and competitively with respect to ATP with a Ki value of 7.8 μM.  The 
crystal structure of human CDK2 liganded with L2 was determined at 2.0 Å 
resolution (Figure 47A).  L2 has hydrogen bonds with the backbone carbonyl oxygen 
and the backbone nitrogen of Leu83 in the adenine binding pocket.  In addition to the 
key hydrogen bonds, the amine on C4′ of the triazine ring interacts with the backbone 
carbonyl of Ile10 via a hydrogen bond.  The side chain of Ile10 is within a distance of 
van der Waals interaction (3.3 Å < d < 3.8 Å) with the triazine ring of L2.  The 
phenol ring is located in the hydrophobic pocket of Ala31, Leu134, and Val18 
(Figure 47B).   
The analysis of the co-crystal structure of L2 with CDK2 suggested that the 
pharmacophore of L2 is L2 itself (Figure 47C), although the 3′-positioned nitrogen 
atom of the triazine ring might be replaced by a carbon atom since the nitrogen atom 
does not have any specific interactions with CDK2.  A substitution on C6 of the 
phenol ring with a functional group containing a hydrogen bond donor is able to 
increase the inhibitory potency through an additional hydrogen bond with the 
backbone carbonyl of Glu81.  However, modifications on the R1 group are almost not 
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(A) 
 L2 
 
(B)      (C) 
 
 
Figure 47.  (A) A stereoview of the co-crystal structure of L2 with CDK2. Light grey-colored 
structures are active site residues of CDK2 and the green molecule is L2.  Blue 
dashed lines denote hydrogen bonds while orange dashed lines represent van der 
Waals interactions. 
(B) A schematic diagram of L2 binding in the CDK2 active site. Residues in the 
active site are shown. Van der Waals interactions are shown as blue colored arches 
and hydrogen bonds are denoted with green dashed lines with the distances between 
the atoms. 
(C) SAR strategy for the L2 scaffold. The pharmacophore of the L2 scaffold is 
shown as red colored structure.  The blue colored circles indicate spaces available in 
the active site.  The atoms of the pharmacophore are numbered.  
 
 143
possible due to the limited space: the distance between C6 of the phenol ring and the 
backbone oxygen atom of Glu81 is 3.3 Å.  The space available for substituents on C5 
of the phenol ring is not large, thus the variations on the R2 group were proposed 
with small substituents either to increase hydrophobic forces with neighboring Phe80 
and Val64 or to have interactions with π-electrons of the side chain of Phe80.  The 
distances from C4 of the phenol ring to Lys33 and Asp145 are 4.3 and 4.8 Å, 
respectively.  The addition of a functional group for the ionic interaction with either 
Lys33 or Asp145 was suggested.  Substitutions of R4, R5, and R6 with large groups 
seem to be possible based on the structural information obtained from L2 bound 
CDK2. 
Commercially available or synthesized derivatives of L2 were tested for the 
CDK2/cylinA inhibition using steady-state kinetics (Tables 15 and 16).  It was 
suggested that the 2-OH group of the phenol ring was critical for the inhibitory 
activity of the L2 analog by the co-crystal structure of L2 with CDK2, and this idea 
was supported by activity tests of L2 derivatives once again.  The elimination of the 
hydroxyl group of the phenol ring, L2-JWS-6-1, L2-JWS-6-14, L2-JWS-6-16, L2-
JWS-6-22, L2-JWS-6-24, L2-JWS-6-38, L2-JWS-6-44, and L2-JWS-6-46, resulted 
in significant decreases of the inhibitory activity.  The role of the 4′ amine group of 
the triazine ring was confirmed to be essential from the results that the compounds, 
L2-10 and L2-11, without the amine group on the 4′-position of the triazine ring 
show no inhibitory potency up to 140 μM.   
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Table 15.  SAR tables of the L2 scaffold (1).  Blue shaded compounds were co-crystallized with 
CDK2. 
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L2 analogs with variations of the R2 group, L2-JWS-6-50 (methoxy) and L2-
JWS-6-106 (chloride), were tested.  The methoxy group on C5 of the phenol ring was 
still tolerable, but decreased the inhibitory potency by more than 10-fold, implying 
the methoxy group was too large a substituent on R2.  The chloride derivative, L2-
JWS-6-106, exhibited even lower inhibitory potency (IC50 = 350 μM) than the 
methoxy derivative (IC50 = 83 μM).  The electronic character of methoxy and chloride 
groups might be the explanation for the difference on their inhibitory potencies 
despite their similar sizes.  The methoxy group, an electron-donating group, is 
partially positive-charged on the phenol ring, while the chloride group has an 
electron-withdrawing character, and it is thus partially negative-charged.  The side 
chain of Phe80 is located in the binding pocket of R2 group.  Thereafter, the methoxy 
Table 16. SAR table of the L2 scaffold (2). 
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group is able to involve a π-cation interaction with Phe80, while the chloride group 
cannot.  A protonated or partially positive-charged small group (e.g. amine or 
hydroxyl) is expected to participate in a π-cation interaction with the benzene ring of 
Phe80, and thus enhance the binding affinity of the L2 analogs to CDK2. 
Several different modifications of R3 were made.  The substitution of R3 to a 
chlorine atom, L2-5, demonstrated a two to three-fold increase of inhibitory potency, 
while the modifications with methoxy (L2-JWS-6-48), hydroxyl (L2-JWS-6-52), 
fluoride (L2-JWS-6-76), and methyl (L2-JWS-6-78) did not show a gain in potency.  
Several variations of the compound L2-5 were carried out on the 4′-amino group of 
the triazine ring to various aliphatic and aromatic groups.  Most of them showed up to 
2-fold increased activity, e.g. L2-7 with a Ki value of 1.0 μM, than L2-5.  However, 
when it was changed to a p-halophenyl group, L2-20 and L2-21, the inhibitory 
activity was considerably decreased.  It is considered that the para-substituted phenyl 
ring as the R5 group with an electron-withdrawing group loses the inhibitory potency.  
The co-crystallization studies of L2-20 and L2-21 are ongoing.  
The crystal structure of CDK2 liganded with L2-3 was determined to 2.1 Å 
resolution (Figure 48).  The chlorine atom on C4 of the phenol ring is close to 
Asp145 (d = 3.5 Å) and induces conformational changes of residues “above” the 
inhibitor binding site, Thr14, Tyr15, Lys129, and Asp127.  It appears that these 
structural changes provide space for the binding of a phosphate ion that is present in 
the crystallization buffer.  The repulsive forces between the chlorine atom of L2-3 
and Asp145 slightly shift the inhibitor molecule towards the backbone of residues 
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Leu83 and His84, resulting in shorter and presumably stronger hydrogen bonding 
interactions.  The bulky methoxy phenyl group on the C4′ position of the triazine ring 
is relatively loosely bound to the enzyme.  The co-crystal structures with L2-6 and 
L2-3 
 
L2-6 
 
Figure 48.   Stereoviews of the co-crystal structures of L2 analogs: L2-3 and L2-6 with 
CDK2.  Light grey-colored structures are active site residues of CDK2 and green 
molecules are inhibitor structures.  Blue dashed lines denote hydrogen bonds while 
orange dashed lines represent van der Waals interactions. 
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L2-JWS6-52 
 
L2-JWS6-76 
 
L2-JWS6-48 
 
Figure 49.  Stereoviews of the co-crystal structures of L2 analogs: L2-JWS6-52, L2-JWS6-
76, and L2-JWS6-48 with CDK2.  Light grey-colored structures are active site 
residues of CDK2 and green molecules are inhibitor structures. Blue dashed lines 
denote hydrogen bonds while orange dashed lines represent van der Waals 
interactions. 
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L2-8 with CDK2 were solved (Figures 48 and 50).  The binding modes of L2-6 and 
L2-8 were very similar to L2-3.  The conformations of the substituents on C4′ of the 
triazine ring could not be well refined because of the poor electron densities.  The co-
crystal structures of L2-JWS-6-48 and L2-JWS-6-52 were determined to 1.80 Å 
resolutions (Figure 49).  The methoxy group of L2-JWS-6-48 establishes 
hydrophobic interactions with the Cβ of Asp145 and the side chain of Phe80, and a 
phosphate ion is found at the same binding site of L2-3, L2-6, and L2-8.  The 
hydroxyl group of L2-JWS-6-52 does not establish interactions with the enzyme, and 
this explains the similar potency.  In the co-crystal structure of L2-JWS-6-76 with 
CDK2, the fluoride group interacts with the side chain of Asp145 in the same way as 
it does with the chloride group in L2-3, L2-6, and L2-8 (Figure 48).  This extra 
L2-8 
 
Figure 50.  A stereoview of the co-crystal structure L2-8 with CDK2.  Light grey-colored 
structures are active site residues of CDK2 and green molecule is L2-8.  Blue dashed 
lines denote hydrogen bonds while orange dashed lines represent van der Waals 
interactions.  A phosphate molecule is bound in the structure. 
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interaction explains the somewhat better activity of L2-JWS-6-76 than L2.  However, 
it is not as active as chloride-substituted L2 analogs.  This is probably due to the 
smaller atomic size of fluoride than chloride, thus the interaction with Asp145 is not 
strong with the fluoride as with the chloride.  
Future studies of L2 analogs will include variations on the R4 group.  The 
exchanges of the 3′- and 5′-nitrogen atoms on the triazine ring to carbon atoms will 
also be attempted for a SAR study.  The substituents of 4′-amine group tested thus far 
did not show any specific interactions with CDK2 based on the crystal structures, thus 
further modifications are ongoing.  Along with these variations, substitutions on 6′-
amine group will be added to enhance the inhibitory potencies.  The 6′-amine group 
will be elongated with large hydrophilic groups because the direction of the 6′-amine 
group is toward solvent exposure space.  The improved hydrophilicity is expected to 
increase solvent contacts and to interact with hydrophilic residues, and thereafter 
enhance the inhibitory potency of the compounds. 
3.3.3. Lead 3 and its analogs 
The compound, Lead 3 (L3, 5-tert-pentyl-4,5,6,7-tetrahydro-1H-indazole-3-
carbohydrazide), was identified as a reversible competitive inhibitor with respect to 
ATP, with a Ki value of 8.0 μM.  The crystal structure of L3 bound to human CDK2 
was determined at 1.85 Å resolution.  As expected from the kinetic data, L3 bound to 
the ATP binding site of CDK2 (Figure 51A).  L3 also made three key hydrogen 
bonds with the Glu81 backbone carbonyl, the Leu83 backbone carbonyl and nitrogen.  
Due to the large hydrophobic substituent, tert-pentyl, on the cyclohexene ring, 
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(B)      (C) 
 
 
Figure 51.  (A) A stereoview of the co-crystal structure of L3 with CDK2. Light grey-colored 
structures are active site residues of CDK2 and green molecule is L3.  Blue dashed 
lines denote hydrogen bonds while orange dashed lines represent van der Waals 
interactions. 
(B) A schematic diagram of L3 binding in the CDK2 active site.  Residues in the 
active site are shown. Van der Waals forces are shown as blue colored arches and 
repulsive forces are represented with red colored arches. Hydrogen bonds are denoted 
with green dashed lines with the distances between the atoms. 
(C) SAR strategy for the L3 scaffold. The pharmacophore of the L3 scaffold is 
shown as red colored structure. Green colored structures are part of molecule, which 
need to be modified for better inhibitory potency.  The blue colored circles indicate 
spaces available in the active site.  The atoms of the pharmacophore are numbered.  
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L3 interacted with the side chains of Ile10, Val18, Ala31, Leu134, and Ala144 
through hydrophobic forces (Figure 51B).  L3 has a chiral center at C5 of the 
cyclohexenyl ring.  However, both enantiomers could fit the electron density map 
(Figure 52).  Thus, it was not possible to determine which enantiomer was the active 
isomer in the structure with a 1.85 Å resolution, or whether both stereoisomers 
possibly inhibited CDK2.   
 
The pharmacophore of L3 was proposed as a 1H-pyrazole-3-carboxamide moiety 
from the structural information of L3 bound CDK2 (Figure 51C).  The terminal 
amine group of the carbohydrazide has been modified to various groups.  The 
cyclohexene ring and tert-pentyl group have also been investigated by using other 
ring systems and various substituents.  
A number of L3 analogs were obtained and tested for inhibitory activity against 
CDK2/cyclinA (Tables 17 and 18).  Replacing the carbohydrazide moiety of the 
parent compound with a carboxyl group eliminated inhibitory activity, evident from 
 
 
Figure 52.  A stereoview of both L3 enantiomers bound in the CDK2 active site. Both R- 
(magenta) and S- (light blue) enantiomers fit into the electron density. 
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Table 17.  SAR table of the L3 scaffold (1).  Blue shaded compounds were co-crystallized with 
CDK2. 
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Table 18.  SAR tables of the L3 scaffold (2).  Blue shaded compounds were co-crystallized with 
CDK2. 
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the results for L3-NSK-MC1-3.  Only L3-NSK-MC1-7 displayed measurable 
activity albeit considerably less than the parent compound.  Notably, replacement of 
the carbohydrazide group by amide derivatives influenced the affinity depending on 
the nature or the size of the R1 group.  L3-NSK-MC1-12 (R1: methyl) and L3-NSK-
MC1-15 (R1: ethyl) were 4-5 times more active than L3 while L3-NSK-MC1-277 
(R1: n-propyl) showed similar activity with L3.  It was suggested that two carbon 
chains extended from the amide group had interactions with the enzyme while one 
additional carbon abolished the positive effect by repulsive forces.  In addition to the 
length of the carbon chains, bulkiness of the aliphatic substituents exhibited a 
negative effect on the inhibitory potency.  Cyclohexyl (L3-NSK-MC1-14) and 
cyclopentyl (L3-NSK-MC1-13) substitutions resulted in loss of the activity and L3-
NSK-MC1-241 (R1: i-propyl) had 10 times lower activity than L3-NSK-MC1-15 
(R1: ethyl) and 2 times lower than L3-NSK-MC1-277 (R1: n-propyl).  Several 
different para-substituted benzyl groups at the R1 position were tested.  Interestingly, 
the sulfonamide group (L3-NSK-MC1-55) demonstrated the best inhibitory potency 
(IC50 = 3.7 μM) among all L3 analogs tested so far.  However, the other substituents, 
p-chloro (L3-NSK-MC1-13), p-trifluoromethyl (L3-NSK-MC1-27), and p-methoxy 
(L3-NSK-MC1-285), did not show any activity against CDK2/cyclinA.  The co-
crystallization of L3-NSK-MC1-55 with CDK2 in an attempt to visualize the effect 
of the sulfonamide on its binding, is currently underway.   
Variations on the tert-pentyl group did not show better inhibitory potency than L3. 
For example, although L3-4 differs in only one methyl group from L3, it 
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demonstrated 15-fold lower potency, implying that the additional methyl group in L3 
contributes to the proper binding of L3 to CDK2.  In addition to the replacement of 
the R2 group from tert-pentyl to tert-butyl, it has been modified to hydrogen (L3-1), 
n-propyl (L3-NSK-MC1-6), n-butyl (L3-NSK-MC1-11), phenyl (L3-NSK-MC1-5), 
and cyclohexyl (L3-NSK-MC1-9).  These analogs showed significantly reduced 
inhibitory activity against CDK2/cyclinA.  The L3 analogs with different ring 
systems, cyclopentenyl (L3-2), benzene (L3-3), and cycloheptenyl (L3-NSK-MC1-1) 
rings, as a replacement of the cyclohexenyl ring (L3-1) were evaluated.  Although 
only the benzene ring had a better potency than the compound L3-1 among these 
analogs, it exhibited an IC50 value of 130 μM.  The low inhibitory activity of the 
analog L3-3 is possibly due to its lack of a large hydrophobic group such as tert-
pentyl in L3, resulting in the loss of hydrophobic forces for binding on CDK2. 
In the current compound library of L3 scaffolds, hydrophilic functional groups as 
the R2 substituents are absent.  Since there are several hydrophilic residues, Lys33, 
Asn132, and Asp134, at the R2 binding site of CDK2, the application of hydrogen 
bond donors or acceptor groups might improve the binding affinity.  For future 
investigation, it is proposed to eliminate the stereo-center of L3 by replacing it with 
nitrogen or amide in the cyclohexenyl ring.  This variation would provide better 
solubility of the compounds as well as possible hydrogen bonds. 
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L3-3 
 
L3-4 
 
L3-NSK-MC1-6 
 
Figure 53.  Stereoviews of the co-crystal structures of L3 analogs: L3-3, L3-4, and L3-NSK-
MC1-6 with CDK2. Light grey-colored structures are active site residues of CDK2 
and green molecules are inhibitor structures. Blue dashed lines denote hydrogen 
bonds while orange dashed lines represent van der Waals interactions.  
 158
In addition to the crystal structure of L3 on CDK2, the co-crystal structures of 
L3-3, L3-4, and L3-NSK-MC1-6 were obtained (Figure 53).  As with the structure of 
L3, the active enantiomers of L3-4 and L3-NSK-MC1-6 were not clearly shown on 
the co-crystal structures.  Although the difference in chemical structure between L3 
and L3-4 or L3-NSK-MC1-6 is only one or two carbon atoms, the activities of these 
compounds differ by more than 6-fold.  This enourmous change of the inhibitory 
potency could not be explained even with the co-crystal structures.  The structure of 
L3-3 with CDK2 was solved to 1.80 Å.  The benzene (L3-3) as a replacement of the 
cyclohexenyl ring (L3) increased the hydrophobic interaction, specifically the π-π 
interaction with the side chain of Phe80.  It was evident that L3-3 bound in the active 
site more deeply, i.e. closer to Phe80, than L3.  Although the hydrophobic forces 
from the R2 alkyl group do not exist on L3-3, the compound maintains its binding 
affinity to the CDK2 active site due to the extra interactions with Phe80.  Thus, it is 
suggested that the substitution on the benzene ring of L3-3 would increase the 
inhibitory potency. 
3.3.4. Lead 4 and its analogs 
The lead compound 4 (L4, (2-(allylamino)-4-aminothiazol-5-yl)(phenyl) 
methanone) was identified as a competitive CDK2 inhibitor with respect to ATP, 
exhibiting a Ki value of 7.6 μM.  The co-crystal structure of CDK2 with L4, solved to 
1.95 Å resolution, confirmed the kinetic data: L4 was bound in the ATP binding 
pocket in CDK2 (Figure 54A).  The 4-amino group forms a hydrogen bond with the 
backbone carbonyl of Glu81.  The 3-nitrogen atom of the thiazole ring has a  
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Figure 54.  (A) A stereoview of the co-crystal structure of L4 with CDK2.  Light grey-colored 
structures are active site residues of CDK2 and green molecule is L4.  A water 
molecule is shown as a cyan sphere.  Blue dashed lines denote hydrogen bonds while 
orange dashed lines represent van der Waals interactions. 
(B) A schematic diagram of L4 binding in the CDK2 active site.  Residues in the 
active site are shown. Van der Waals forces are shown as blue colored arches and 
repulsive forces are represented with red colored arches. Hydrogen bonds are denoted 
with green dashed lines with the distances between the atoms. 
(C) SAR strategy for the L4 scaffold.  The pharmacophore of the L4 scaffold is 
shown as red colored structure. Green colored structures are part of molecule, which 
need to be modified for better inhibitory potency.  The blue colored circles indicate 
spaces available in the active site.  The atoms of the pharmacophore are numbered.  
 160
hydrogen bond with the backbone nitrogen of Leu83 and the 2-amino group interacts 
with backbone carbonyl of Leu83.  In addition, the 5-carbonyl group of L4 interacts 
with the backbone nitrogen atom of Asp145 through a water molecule.  The thiazole 
ring interacts with the side chain of Ile10, Ala31, and Leu134, the phenyl ring with 
Gly13, Val18, and Asp145, and the allyl moiety with Ile10 (Figure 54B).  However, 
the electron density of the allyl group, as well as that of the side chain of Ile10, is 
weak; thus the interaction between those two groups does not seem to be strong.  
The pharmacophore of L4 was recognized as a 2,4-diamino thiazole group, and 
the 2-amino group can be elongated with hydrocarbon substituents, such as allyl or 
phenyl groups (Figure 54C).  The space that the 4-amino group occupies is not large 
enough to accept any substitution.  This is consistent with the lack of CDK2 
inhibition by L4-RC2-31.  The 5-carbonyl has a hydrogen bond with the backbone 
nitrogen of Asp145 via a water molecule.  However, it is necessary to examine 
whether this interaction is essential for the binding affinity.   
L4 is the most studied scaffold among the four groups to date.  Over fifty L4 
analogs with various R1 and R2 groups purchased or synthesized were tested against 
CDK2/cyclinA (Tables 19-22).  It is shown on the SAR tables of the L4 scaffold that 
the inhibitory potency of compounds generally depends on the combination of R1 and 
R2, not on any one single side substitution.  For example, L4-RC1-148 (R1: phenyl, 
R2: phenyl) showed better activity than L4 (R1: allyl, R2: phenyl), suggesting phenyl 
is a better group for the R1 position.  However, the opposite result was 
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Table 19.  SAR table of the L4 scaffold (1).  Blue shaded compounds were co-crystallized with 
CDK2. 
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Table 20.  SAR table of the L4 scaffold (2).  Blue shaded compounds were co-crystallized with 
CDK2. 
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Table 21. SAR table of the L4 scaffold (3).  
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Table 22.  SAR table of the L4 scaffold (4).  Blue shaded compounds were co-crystallized with 
CDK2. 
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demonstrated when R2 is naphthyl (L4-RC1-132 and L4-RC2-14): L4-RC1-132 
(R1: allyl, R2: naphthyl) had an IC50 value of 5 μM while L4-RC2-14 (R1: phenyl,  
R2: naphthyl) did not show any inhibitory activity up to 1 mM against CDK2/cyclinA.  
Thus, it is suggested that the flexibility of the R1 substituent allows for a larger group 
on the R2 position.   
Fourteen different R1 groups 
have been applied when R2 is 
substituted with a phenyl group.  
From the activity test of those 
compounds, phenyl (L4-RC1-
148), cyclohexyl (L4-RC1-151), 
and i-propyl (L4-RC2-26) groups 
at the R1 position increased the 
inhibitory potency of the analogs, while tert-butyl (L4-RC2-27), p-trifluoromethyl 
phenyl (L4-RC2-30), and p-nitro phenyl (L4-RC2-31) groups had adverse effects.  
Remarkably, L4-RC2-32 (R1: p-sulfonamide phenyl group) exhibited the best 
inhibition, and the same results were found throughout all different R2 variations.  
This result is consistent for oxindole with the sulfonamide (compound 7 in Figure 14) 
which is more potent than the compound without the sulfonamide, reported 
previously119.  It was also found in a SAR study of the L3 scaffold, in which the 
sulfonamide derivative at the similar position exhibited the best inhibitory potency.  
Thus, future attempts to achieve higher inhibitory potency of L4 analogs would 
Table 23. Compounds belonging to the L4 scaffold. 
 166
contain the p-sulfonamide or a p-N-substituted sulfonamide phenyl group at the R1 
position. 
The inhibitions of the L4 analogs with the allyl group at the R1 position were 
compared.  Among 15 of those compounds, 3-pyridyl (L4-RC1-137) and m-nitro 
phenyl (L4-RC1-135) substitutions at the R2 position enhanced the activities 
compared to L4 (phenyl), while the others had similar or lower potencies.  Moreover, 
those two substitutions had consistently exhibited good inhibitions regardless of the 
R1 groups. 
The efforts to verify SAR of the L4 analogs were conducted by the co-crystal 
structures of the compounds with CDK2.  More than 10 structures of the L4 analogs 
have been solved (Figures 55–59).  Three different R1 groups, allyl, m-fluoro phenyl, 
and p-sulfonamide phenyl, were included in those structures.  The electron densities 
for the allyl groups were very weak in the structures.  Thus it is thought that the allyl 
group at the R1 position is flexible and does not have specific interactions.  In the co-
crystal structure of L4-12, the electron density of the R1 substituent, m-fluoro phenyl, 
was found to be clearer than the allyl, and had hydrophobic interactions with the side 
chain of Phe82.  The excellent activities of the p-sulfonamide phenyl substituted L4 
analogs were explained from the co-crystal structures of those compounds with 
CDK2.  The electron densities of the p-sulfonamide phenyl groups were clearly 
defined.  In the structures, the sulfonamide group has extra interactions with CDK2 
by forming hydrogen bonds with the backbone nitrogen and the side chain 
carboxylate of Asp86.  In addition to better solubility of the sulfonamide derivatives, 
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L4-4 
 
L4-12 
 
L4-14 
 
 
Figure 55.  Stereoviews of the co-crystal structures of L4 analogs: L4-4, L4-12, and L4-14 
with CDK2.  Light grey-colored structures are active site residues of CDK2 and 
green molecules are inhibitor structures. Water molecules are shown as cyan spheres. 
Blue dashed lines denote hydrogen bonds while orange dashed lines represent van der 
Waals interactions.  
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L4-RC1-34 
 
L4-RC1-35 
 
 
Figure 56.  Stereoviews of the co-crystal structures of L4 analogs: L4-RC1-34 and L4-RC1-
35 with CDK2.  Light grey-colored structures are active site residues of CDK2 and 
green molecules are inhibitor structures. A water molecule is shown as a cyan sphere. 
Blue dashed lines denote hydrogen bonds while orange dashed lines represent van der 
Waals interactions.  
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L4-RC1-36 
 
L4-RC1-37 
 
L4-RC1-38 
 
 
Figure 57.  Stereoviews of the co-crystal structures of L4 analogs: L4-RC1-36, L4-RC1-37, 
and L4-RC1-38 with CDK2.  Light grey-colored structures are active site residues 
of CDK2 and green molecules are inhibitor structures. Water molecules are shown as 
cyan spheres. Blue dashed lines denote hydrogen bonds while orange dashed lines 
represent van der Waals interactions.  
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L4-RC2-35 
 
L4-RC2-36 
 
L4-RC2-37 
 
 
Figure 58.  Stereoviews of the co-crystal structures of L4 analogs: L4-RC2-35, L4-RC2-36, 
and L4-RC2-37 with CDK2.  Light grey-colored structures are active site residues 
of CDK2 and green molecules are inhibitor structures. Water molecules are shown as 
cyan spheres. Blue dashed lines denote hydrogen bonds while orange dashed lines 
represent van der Waals interactions.  
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these extra hydrogen bonds found in the crystal structures induce better binding 
affinity of the molecules to CDK2 thus increase the inhibitory potency.  The 
5-carbonyl group in all solved structures has a hydrogen bond, although two different 
ways are shown.  One is a direct interaction with the side chain of Lys33, found in the 
structures of L4-14 and L4-RC1-35, and the other is a hydrogen bond with the 
backbone nitrogen of Asp145 through a water molecule.  From the SAR studies, it 
was found that small variations of the R2 group, e.g. different positions (2-, 3- or 4- 
position of nitrogen atom (L4-RC1-38, L4-RC1-37, and L4-RC1-36)) of the same 
functional groups (pyridine ring), induced large changes in the binding affinities of 
the L4 analogs.  The co-crystal structures of L4-RC1-36, L4-RC1-37, and L4-RC1-
38 were solved to identify which structural differences induce the activity changes.  
Although all three inhibitors were found in the ATP binding site, it was impossible to 
recognize the factor that determines the inhibitory potency.  It is considered that the 
L4-RC2-38 
 
 
Figure 59.  A stereoview of the co-crystal structure of L4-RC2-38 with CDK2.  Light grey-
colored structures are active site residues of CDK2 and green molecule is L4-RC2-
38. A water molecule is shown as a cyan sphere.  Blue dashed lines denote hydrogen 
bonds while orange dashed lines represent van der Waals interactions.  
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SAR study of the R2 position needs to be performed by the structural study with 
CDK2/cyclin complex instead of CDK2 only because the residues in the space that 
R2 group binds undergoes conformational change upon cyclin binding.  Thus, the 
efforts to crystallize the CDK2/cyclinA complex are currently ongoing in Prof. 
Schönbrunn’s laboratory. 
The inhibitory activity of the L4 scaffold has increased 100-fold from the lead 
compound, L4.  The sulfonamide group provided the most enhancement of the 
inhibitory potency.  Therefore, future investigation of the L4 analogs will be 
conducted where the sulfonamide will be maintained and the elongation from the 
nitrogen of the sulfonamide will be modified with various substituents. 
3.3.5. Design of New Inhibitors and Docking Study 
Although the analysis of the kinetic and structural data is an ongoing process and 
should result in the design of substantially improved analogs of the respective parent 
compounds, it has been found that the current 4 scaffolds were reported as CDK 
inhibitors144–149.  Thus, there is a need to discover CDK inhibitors with novel 
scaffolds.   
The thorough comparison of the binding patterns of the inhibitors may allow for 
the design of novel scaffolds with CDK2-inhibitory potential.  Superposition of the 
individual binding sites of the ligands co-crystallized with CDK2 indicates that 
certain molecule sites may be combined such that new scaffolds emerge: The 
superposition of structures, CDK2-L1 and CDK2-L2-6, indicates that the free amide 
group of L1 may be well confined in a ring system (Figure 60A) and that the phenyl 
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Figure 60.  (A) Orientation of inhibitors L1 (yellow) and L2-6 (cyan) after superposition of 
the respective CDK2 ligand structures. Superposition was performed using the Cα 
atoms of all CDK2 residues (1-298) of both inhibitor complexes. 
(B) New scaffolds with potential as inhibitors as a result of recombining the 
essential features and spatial orientation of both inhibitor molecules. 
(C) Designed molecules containing 2 or 3 hydrogen bond acceptors and donors. 
These molecules were designed to have hydrogen bonds with the backbone oxygen or 
nitrogen atoms of Glu81 and Leu83. R denotes any groups. 
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ring of L1 may be combined with the triazine ring of L2.  Even three and four fused 
ring systems are conceivable as new CDK2 inhibitors resulting from the combination 
of essential features of L1 and L2 (Figure 60B).   
More molecules were designed based on the key hydrogen bonds between ligands 
and CDK2 (Figure 60C).  The designed molecules include at least two hydrogen 
bonding donors or acceptors with similar patterns as known inhibitors, thus they are 
proposed to bind in the adenine binding site of CDK2.  
The molecules of new scaffolds were docked into the ATP binding site of CDK2 
using GLIDE140.  Among these compounds, ES4, ES5, ES6, HH2, HH4, HH5, and 
ES4          ES5     ES6 
 
HH2              HH4          HH5       HH6 
 
Figure 61.  The docking results of the designed inhibitors.  Light grey-colored structures are 
active site residues of CDK2 and green molecules are docked ligand structures. Blue 
dotted lines denote hydrogen bonds while orange colored lines represent van der 
Waals interactions.   
 175
HH6 (Figure 61) displayed proper interactions in the ATP binding site of CDK2 by 
docking.  As proposed, the docked molecules maintain at least two hydrogen bonds as 
well as some hydrophobic interactions.  The molecules that docked into CDK2 may 
represent possible alternatives to current lead structures.  Moreover, none of the 
newly designed molecules have been identified as a CDK inhibitor, thus it is 
considered that further studies with these compounds would provide a better 
opportunity to have novel scaffolds of CDK2 inhibitors.  Efforts to produce the 
designed compounds by synthetic methods are currently ongoing at Dr. Georg’s 
laboratory at the University of Minnesota.  
3.3.6. Selectivity of CDK2 inhibitors 
Selectivity has been a key issue of CDK inhibitors due to the high similarity of 
the ATP binding sites of all kinases.  There is no CDK inhibitor that is selective for a 
single CDK.  Thus, it is expected that the difficulty in selectivity of the CDK2 
inhibitors in previous sections would also occur in the near future.   
The studies to pre-screen the selectivity of the inhibitors were attempted by 
docking studies.  Prior to the structural studies, the sequences of all CDKs were 
aligned using ClustalW2150 (Figure 62 and Table 24).  Although they are highly 
conserved, differences are still found.  Thus, it is considered that the selectivity of the 
inhibitors for a specific CDK can be achieved by changing certain functional groups 
that respectively interact with different residues from other CDKs.  Among these 
CDKs, 5 different CDK structures are known including the one of CDK2, i.e. 
CDK286, CDK5 (PDB ID: 1UNL)151, CDK6 (1BLX)152, CDK7 (1UA2)153, and 
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Figure 62.  Sequence alignments of all 11 CDKs.  The aligned sequences of 1-222 (CDK2 
numbering) residues are shown.  The yellow box corresponds to the residues involved 
in the key hydrogen bonds and the blue boxes correspond to the residues in the active 
site.  * CD2L1 is another name of CDK11. 
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CDK9 (3BLR)154.  The CDK structures were aligned to the CDK2 structure by 
superimposing secondary structures using the CCP4 program suite155.  The Cα-
RMSD values of each superimposition were 1.45, 1.83, 1.48 and 2.00 Å, respectively.  
Four lead compounds, L1–L4, docked into the CDK structures.  Several inhibitors 
were found in the ATP binding sites of other CDK structures with the same binding 
pattern  as in the co-crystal structures with CDK2, e.g. L1 in CDK7 and CDK9, L2 in 
CDK5 and CDK9, and L4 in CDK9 (Figure 64).   
 
In addition, several other kinase structures were investigated in the same way as 
CDK structures.  First, the sequence alignments of AuroraA, mitogen-activated 
protein kinase (MAPK), glycogen synthase kinase-3β (GSK3β), protein kinase A 
(PKA), and protein kinase C (PKC) were carried out using ClustalW2150 (Figure 63 
and Table 25).  The structures of AuroraA (PDB ID: 2NP8)156, MAPK (1KV1)157, 
GSK3β (1R0E), PKA (2VO3)158, and PKC (1XJD)159 were aligned and the Cα-
RMSD values were 1.97, 2.27, 2.20, 2.00 and 2.01 Å, respectively.  The docking 
studies of these kinase structures were performed with the compounds L1–L4.  
Table 24. Sequence alignment scores (in percentage) for CDKs.  The sequences of CDK1–
CDK11 were aligned with ClustalW2 
 
 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK10 CDK11 
CDK1 65 64 43 56 46 42 38 40 40 41 
CDK2  75 44 59 48 44 37 39 43 44 
CDK3   45 61 46 44 39 38 42 44 
CDK4    44 68 36 36 34 40 39 
CDK5     46 45 36 41 43 41 
CDK6      33 30 32 35 36 
CDK7       34 35 36 35 
CDK8        29 32 33 
CDK9         34 32 
CDK10          46 
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Figure 63.  Sequence alignments of several protein kinases (Aurora A, MAPK, GSK3β, 
PKA, and PKC) with CDK2.  The yellow box corresponds to the residues involved 
in the key hydrogen bonds and the blue boxes correspond to the residues in the active 
site.  The bovine PKA sequence was used, to be consistent with the structural data.  
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L2-CDK5        L1-CDK7             L1-CDK9 
   
L2-CDK9        L4-CDK9             L2-AuroraA 
 
L3-AuroraA        L2-PKC             L3-PKC 
 
L3-GSK3β          L4-GSK3β 
 
Figure 64.  Docking results of the Lead compounds into various kinase structures. 
Light grey-colored structures are active site residues of kinases and green molecules 
are docked ligand structures. Blue dotted lines denote hydrogen bonds while orange 
colored lines represent van der Waals interactions. 
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Inhibitors, L2 and L3 were adequately docked into the AuroraA and PKC structures, 
and L3 and L4 were found in the GSK3β structure (Figure 64). 
 
The results of the docking studies with other kinase structures imply that the 
current CDK2 inhibitors might not be selective and they need to be modified to 
contain specific interactions only with CDK2 to gain the selectivity.     
From intensive SAR and structural studies, excellent inhibitory potencies, in the 
sub-micromolar range were achieved.  The selectivities of the current inhibitors are 
now known yet.  Future investigation will include the studies of the selectivity of the 
inhibitors.  
 
Table 25. Sequence alignment scores (in percentage) for protein 
kinases.  Sequences of CDK2, Aurora A, MAPK, GSK3b, 
PKA, and PKC were aligned with ClustalW2.  
 
 Aurora A MAPK GSK3b PKA PKC 
CDK2 27 37 31 23 25 
Aurora A  18 19 23 23 
MAPK   24 17 18 
GSK3b    15 15 
PKA     33 
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4. Conclusion 
 
The kinetic and structural characterizations of Arg91Lys and Asp123Ala MurA 
mutants revealed the roles of two residues in the enzymatic mechanism of MurA.  
Arg91 is a critical residue in the open-closed transition of MurA.  Asp123 is involved 
in the binding of UNAG to MurA.   
The crystallographic studies of Arg120Ala MurA provided evidence for the 
existence of a thio-ketal intermediate between Cys115 and PEP during the reaction.  
Arg120 presumably functions as a key residue in transferring PEP from Cys115 to the 
target hydroxyl of UNAG.  
The kinetic studies of cnicin, a recently reported MurA inhibitor, indicated slow 
binding inhibition.  In addition, several new inhibitors of MurA were identified by 
HTS and characterized by enzyme kinetics.  It appeared that HTS2-2 inhibits the 
enzyme by inducing oligomerization of MurA.  From the kinetic and crystallographic 
studies of the new inhibitors, we conclude that all of these compounds bind in the 
open form of the enzyme.  Future studies will focus on the identification of novel 
inhibitors, inducing the open-closed conformational changes of MurA, similar to 
UNAG.   
Six different CDK2 inhibitor scaffolds were identified by HTS.  The molecular 
modes of action of four of the representative compounds were revealed by kinetic and 
crystallographic studies.  All inhibitors are competitive with respect to ATP.  SAR 
analysis of each scaffold was conducted with various analogs.  Structural information 
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obtained from crystallographic studies provided the detailed binding modes of the 
derivatives, and allowed for the design of new analogs with improved binding 
affinities.  Excellent inhibitory potencies to CDK2 in the sub-micromolar ranges of 
IC50 values were achieved.  In addition, several new inhibitor scaffolds were designed.  
The syntheses of the new compounds are currently underway.  Selectivities of the 
inhibitors over other protein kinases are not known yet, and will be a focus in future 
investigation. 
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